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1. ABSTRACT 
 
1.1. Summary 
In the first part of the thesis a new Triple RNA interference (RNAi) vector system was 
established. We developed an RNAi technique to simultaneously target up to three genes. For 
stable silencing, the MultiSite-GatewayTM system was used to shuttle up to three different 
cassettes, each consisting of a human U6 promoter and an oligonucleotide encoding a short 
hairpin RNA (shRNA), into one destination vector. The system was shown to work efficiently 
on three ectopically expressed proteins. Thus, this tool is applicable for analyzing proteins 
with redundant functions and protein hierarchies within signal transduction pathways. 
 
In the second part of the thesis, we further analyzed the in vivo function of lamina-associated 
polypeptide 2 alpha (LAP2α) and related proteins by RNAi. For transient and/or stable RNAi, 
we designed hairpin constructs targeting LAP2α, LAP2ß, all LAP2 isoforms, A-type lamins, 
emerin and BAF. We were able to transiently reduce the expression of LAP2α and all LAP2 
isoforms, and created pools of cells stably expressing these functional shRNAs. Single cell 
clones, strongly down regulating LAP2α, were selected and their phenotype analyzed. 
LAP2α deficient HeLa cells showed increased cell proliferation rates and did not respond to 
serum starvation, like cells transfected with control plasmids. In contrast, HEK cells, which 
do not correctly process pre-lamin A, did not show any proliferation effect, underscoring the 
necessity of lamin A for the cell cycle control pathway. Co-localization studies by 
immunofluorescence indicate, that lamin A and LAP2ß localization as well as the overall 
integrity of the nuclear envelope was not compromised upon downregulation of LAP2α. 
In summary, RNAi mediated downregulation of LAP2α revealed a role of LAP2α on cell 
proliferation. 
1.2. Zusammenfassung 
Im ersten Teil der vorliegenden Diplomarbeit wird die Entwicklung einer neuen RNA 
Interferenz (RNAi) Anwendung, dem Triple-RNAi-Vector, beschrieben. Diese Technik 
erlaubt uns, zeitgleich bis zu drei Proteinexpressionen mittels RNAi zu verringern. Wir 
benutzten das MultiSite-GatewayTM System, um bis zu drei Kassetten, bestehend aus je einem 
humanen U6 Promoter und einem RNAi vermittelndem Oligonucleotid, in einem 
Expressionsvektor zu rekombinieren. Erste Test zeigten die effiziente Funktion des Triple-
RNAi-Vektors an drei ektopisch exprimierten Reporter Enzymen in HEK 293 Zellen. Diese 
Technik ist konzipiert für funktionelle Proteinanalyse, speziell für funktionell redundante 
Proteine und für Proteine in parallelen Signalkaskaden. 
 
Der zweite Teil der Arbeit befasst sich mit der weiterführenden Charakterisierung des 
Kernproteins Lamina-assoziertes-Polypeptid 2 alpha (LAP2α). RNAi-Konstrukte gegen 
LAP2α, LAP2β, alle LAP2 Isoformen, A-Typ Lamine, Emerin und BAF wurden in 
transienten Transfektionsexperimenten getestet. Funktionelle RNAi-Konstrukte gegen LAP2α 
und alle LAP2 Isoformen nutzten wir um stabil transfektierte Zellpools herzustellen. Zur 
Charakterisierung wurden Einzelzellklone mit stark reduzierten LAP2α Proteinniveaus in 
HEK und HeLa Zellen selektiert. Die HeLa Einzelzellklone zeigten stark erhöhte 
Zellteilungsraten verglichen mit den Kontrollzellinien, dieser Effekt war unter 
Serumreduktion noch stärker ausgeprägt. Im Gegensatz dazu zeigten HEK Zellen mit 
reduziertem LAP2α Proteinniveau keinen Wachstumseffekt. Da HEK Zellen kein korrekt 
prozessiertes Lamin A exprimieren ist dies ein weiterer Hinweis auf die Zellzyklus 
regulierende Funktion dieser Bindungspartner. Im Rahmen von Co-Lokalisationsstudien 
mittels Immunfluoreszenzen wurde gezeigt, daß ein geringes Proteinniveau von LAP2α, 
keinen Einfluß auf dessen eigene, noch auf die zelluläre Lokalisation von Lamin A, oder die 
von LAP2β hat. Des weiteren blieb die Integrität des Zellkerns trotz LAP2α RNAi erhalten. 
Zusammenfassend konnten wir eine zellzyklusregulierende Funktion von LAP2α durch 
dessen RNAi vermittelte Reduktion zeigen. 
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2. INTRODUCTION 
 
2.1. New RNAi vector application 
2.1.1. RNA Interference (RNAi) 
RNAi is a conserved biological response of animal cells to double-stranded RNA (dsRNA), 
also known as post-transcriptional gene silencing (PTGS) in plants and “quelling” in fungi 
(reviewed in Hannon, 2002; Mittal, 2004; Hannon and Rossi, 2004; Meister and Tuschl, 
2004; Matzke and Birchler, 2005). Depending on the RNA precursor and the organism, RNAi 
mediates a wide range of effects, such as mRNA degradation, translational repression, and 
epigenetic modifications to the genome. 
Nowadays RNAi is used as a modern technique to knock-down target gene expression in a 
highly specific manner at the posttranscriptional level. RNAi became an effective method for 
analysis of gene function in vivo and holds the possibility of therapeutic gene silencing. 
 
2.1.2. History of RNAi 
PTGS was first discovered in plants by experiments on petunia pigmentation (Napoli et al., 
1990; van der Krol et al., 1990). Years later, the phenomenon, that sense or antisense RNA 
molecules equally suppressed gene expression was discovered in the nematode worm 
Caenorhabitis elegans (Guo and Kemphues, 1995). RNAi itself was first described in C. 
elegans as a response to dsRNA which resulted in sequence specific gene silencing (Fire et 
al., 1998). Furthermore dsRNA has been found at least tenfold more effective in targeting 
gene silencing, than sense, or antisense RNA alone. Interestingly, systemic silencing (see 
2.1.3.) in C. elegans could easily be reached by simply feeding dsRNA to the worms 
(Timmons and Fire, 1998). Subsequent studies identified short RNAs of 21-23 nucleotides as 
functional mediators of RNAi (Hamilton and Baulcombe, 1999; Grishok et al., 2000). The 
processing of long dsRNA (>50 nucleotides) to short interfering RNAs (siRNAs) has been 
shown in Drosophila (Zamore et al., 2000). RNAi, mediated by long dsRNA, was quickly 
adapted as tool for reverse genetics in several model organisms. However, in almost all 
somatic cells of higher eukaryotes (mammals), dsRNAs longer than 30 nucleotides induces a 
sequence independent interferon response, resulting in general inhibition of protein synthesis 
(Stark et al., 1998; Gil and Esteban, 2000). This problem could be circumvented 
experimentically by the direct use of siRNAs to target mammalian genes by RNAi (Elbashir 
et al., 2001; Caplen et al., 2001). 
2.1.3. Mechanisms of RNAi 
The short interfering RNA (siRNA) pathway: 
Long, double stranded RNA (dsRNA) is cleaved preferentially by the RNase III family 
member Dicer, into siRNAs in an ATP - dependent manner in the cytoplasm (Figure 2-1b; 
Zamore et al., 2000; Bernstein et al., 2001; Ketting et al., 2001; Billy et al., 2001; Shinagawa 
et al., 2003). These are 21-23 nucleotide long RNA duplexes with symmetric two nucleotide, 
3’ hydroxylated, overhangs and are phosphorylated at their 5’ ends (Figure 2-1a; Elbashir et 
al., 2001). The siRNAs are part of siRNA-duplex-containing ribonucleoprotein particles 
(siRNP), that become incorporated into the multicomponent RNA-induced silencing complex 
(RISC; Hammond et al., 2000) in an ATP dependent manner (Figure 2-1b; Nykänen et al., 
2001; Pham et al., 2004). Most likely this energy is used to unwind the RNA duplex, leaving 
the single antisense strand to guide RISC to its homologous target messenger RNA (mRNA) 
for endonucleolytic cleavage. Each RISC contains a member of the Argonaute (Ago) family, 
which probably binds directly to the siRNA and to Dicer (Hammond et al., 2001; Tahbaz et 
al., 2004). Furthermore, crystal structure of an archaebacterial Ago protein revealed structural 
homology with the RNaseH family (Song et al., 2004), whose members cleave RNA strands 
in RNA / DNA duplexes. So Ago proteins could also be directly involved in target messenger 
RNA degradation. 
 
The micro RNA (miRNA) pathway: 
Endogenous hairpin RNAs or short hairpin RNAs (shRNA) transcribed from exogenous DNA 
are processed to micro RNA (miRNA) precursors by Drosha in the nucleus (Lee et al., 2002; 
Lee et al., 2003). Subsequently the miRNA precursors are exported to the cytoplasm (Yi et 
al., 2003;Bohnsack et al., 2004; Lund et al., 2004), where they are further processed by Dicer 
to miRNAs (Figure 2-1c). In contrast to siRNAs, miRNAs encode at least one mismatch. 
Dicer can also cleave ~70 nucleotide long imperfectly paired hairpin RNAs, leading to double 
stranded, ~21 nucleotides long miRNAs. These miRNAs become also incorporated into a 
RISC-like complex called miRNP (miRNA-duplex-containing ribonucleoprotein particles; 
McManus et al., 2002; Zamore, 2002; Denli et al., 2003) and can base pair with the target 
mRNA and roadblock translation mostly in UTR regions by blocking elongation (Olsen et al., 
1999; Pasquinelli et al., 2002). Alternatively, miRNAs can act similar to siRNAs and guide 
mRNA degradation (Llave et al., 2002; Kasschau et al., 2003; Boutet et al., 2003). The 
decision between these two possibilities seems to depend on the degree of homology between 
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 the miRNA and the mRNA (Carrington et al., 2003). Most endogenous animal miRNAs base 
pair imperfectly and therefore trigger translational repression. 
 
 
Figure 2-1: The RNA interference pathways. (a) Short interfering RNAs (siRNAs) are duplexes of 21 
nucleotides length, with symmetric 2 nucleotide 3’ hydroxylated overhangs and 5’ phosphates. They are 
characteristic products of Dicer (RNase III) cleavage. (b) The siRNA pathway: Long double stranded RNA 
becomes cleaved by Dicer to form siRNA duplexes, which subsequently become separated and incorporated into 
the RNA-induced silencing complex (RISC). This multiprotein complex targets degradation of complementary 
mRNA. (c) The miRNA pathway: Hairpin RNAs with imperfect base pairing become first processed to micro 
RNAs (miRNAs) precursors by Drosha in the nucleus (not shown) by Dicer. Subsequently, they are exported to 
the cytoplasm, where they are cleaved to miRNAs by Dicer and incorporated into miRNPs (miRNA-duplex-
containing ribonucleoprotein particles. These protein complexes are than bound to complementary mRNAs, 
where they block translational elongation. Modified from (Dykxhoorn et al., 2003) 
 
RNAi - induced Heterochromatin formation:  
Knockouts of essential RNAi machinery components (Argonaute, Dicer and RdRP) in fission 
yeast showed that RNAi is involved in heterochromatin formation (Volpe et al., 2002). It has 
been proposed, that transcription of centromeric regions leads to the formation of dsRNA, 
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which becomes processed by Dicer and amplified by RNA-directed RNA polymerase (RdRP; 
see 2.1.3. systemic silencing) activity. These small RNAs are thought to target H3K9 
methylation (methylation of histone 3 on lysine 9), a hallmark of heterochromatin formation, 
to the chromosome. HP1 homologues are targeted to sites of H3K9 methylation, which results 
in transcriptional inhibition (Verdel et al., 2004). 
 
RNA directed DNA methylation (RdDM): 
RdDM leads to sequence specific cytosine methylation in plants (Wassenegger et al., 1994). It 
requires dsRNA, which becomes processed to 21-24 nucleotide RNAs (Mette et al., 2000). 
RNA complementary to DNA promoter regions can trigger its methylation and subsequently 
transcriptional gene silencing. Interestingly, two recent studies demonstrated siRNA induced 
promoter methylation in human cells (Kawasaki and Taira, 2004; Morris et al., 2004). 
 
Systemic silencing: 
An astonishing aspect of RNAi is systemic silencing, the ability of gene silencing to spread 
throughout the whole organism. It has been documented in plants (Palauqui et al., 1997; 
Voinnet et al., 1998) and in C. elegans (Timmons et al., 1998) but has not been observed in 
higher eukaryotes. Therefore a silencing signal, most likely siRNA, has to be amplified to 
move from cell to cell (see below) and induce sequence specific silencing at distant sites 
(Mlotshwa et al., 2002). 
Amplification could occur through a phenomenon called ‘transitive RNAi’. The model 
suggests that single stranded siRNA primes the synthesis of dsRNA along their target mRNA 
by RNA-directed RNA polymerase (RdRP) activity (Lipardi et al., 2001). Newly synthesized 
dsRNA will be processed by Dicer, thereby accumulating siRNAs complementary to regions 
upstream of the original targeting sequence (Sijen et al., 2001). A scenario, where these new 
siRNAs also silence other mRNAs can also be envisaged. 
In plants siRNAs will move from cell to cell through plasmodesmata (cytoplasmic bridges 
between cells), but for longer range silencing they must also pass the plants vasculature 
(Voinnent et al., 1998). In C. elegans a transmembrane protein termed SID-1 has been 
identified as essential for systemic RNAi (Winston et al., 2002). It provides a channel system 
for siRNA transport.  
As there are no paralogues of RdRP in Drosophila (Roignant et al., 2003) and vertebrates 
(Stein et al., 2003), they possess no mechanisms to amplify silencing signals and therefore 
systemic silencing has not been observed so far in these organisms. 
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 2.1.4. Biological functions of RNAi 
Most plant viruses have an RNA genome and synthesize dsRNA during their replication 
cycle. PTGS forms the basis for virally induced gene silencing (VIGS) in plants (Ruiz et al., 
1998; Mourrain et al., 2000). Many plant viruses circumvent VIGS by encoding suppressors 
of PTGS, which are essential for pathogenesis (Hamilton et al., 2002; Mallory et al., 2002). 
Also in Drosophila, an antiviral role of RNAi has been suggested (Li et al., 2002). Antiviral 
mechanisms have also been reported in higher eukaryotes. In mammals, except in non-
differentiated embryonic stem cells and erythroblasts, dsRNA longer than 30 base pairs 
induces a sequence independent interferon response, resulting in general inhibition of protein 
synthesis (Stark et al., 1998; Gil and Esteban, 2000). Long dsRNAs activate the enzymes 
RNAseL and RNA-dependent protein kinase (PKR) and subsequently lead to mRNA 
degradation and inhibition of translation. 
The RNAi machinery is also involved in transposon silencing in C. elegans (Tabara et al., 
1999; Ketting et al., 1999), but heterochromatic packaging of transposons has also been 
shown in other organisms (reviewed in Martienssen and Colot, 2001). The question whether 
RNAi regulates transposons through epigenetic chromatin modifications or by targeting 
mRNAs essential for transposition (e.g. mRNA coding for transposase) remains to be solved. 
Mutations in genes coding for the RNAi machinery (e.g. the Argonaute family), as well as 
miRNAs silencing endogenous gene expression by translational inhibition, have been linked 
to developmental control mechanisms in animals and plants (Carrington et al., 2003; Bartel 
et al., 2003; Hunter et al., 2003). Well studied examples are the let-7 and lin-4 genes in C. 
elegans. Originally termed small temporal RNAs (stRNAs) (Pasquinelli et al., 2000), these 
miRNAs repress regulators of developmental transition, thus control developmental timing 
(Banerjee et al., 2002; Carrington et al., 2003). As computational methods predict over 200 
putative miRNA genes in humans (Lim et al., 2003), translational inhibition by RNAi appears 
to be an important regulatory mechanism and are regarded as RNA-based transcription factor 
equivalents. 
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2.1.5. How to use RNAi as a tool 
There are different methods to make use of RNAi in cells or organisms as a modern molecular 
biological tool. The following short overview is intended to be taken as an application guide 
(reviewed in Hannon and Rossi, 2004; Mittal, 2004). 
 
2.1.5.1. Mediators of RNAi 
Long dsRNA, which becomes processed to several different siRNAs by Dicer, has been used 
to study gene function in various organisms lacking antiviral protection mechanisms, 
including some plants, Drosophila, C. elegans, and embryonic stem cells from mammals. 
This approach is limited in mammalian somatic cells, where dsRNA longer than 30 
nucleotides induces a sequence independent interferon response, resulting in general 
inhibition of protein synthesis (Stark et al., 1998; Gil and Esteban, 2000). 
Alternatively synthetic siRNAs can be used to mediate RNAi also in somatic cells of 
mammals, as these are short enough to escape from antiviral defense mechanisms (Elbashir et 
al., 2001). They consist of two paired, 21 nucleotide RNAs (sense and antisense) with 2 
nucleotide 3’ overhangs and a 3’ OH for better stability. Many alternative designs, ranging 
from 19 to 29 nucleotides length have proven functional. Nowadays longer stems of 29 
nucleotides are preferred. 
Another approach to utilize RNAi in mammalian cells is to ectopically express short hairpin 
RNAs (shRNAs) by DNA vector systems. shRNAs consists of one RNA strand of base 
paired sense and antisense sequence, connected via a small loop structure. Alternatively, 
shRNAs can also be synthesized and transient transfected, as siRNAs 
 
2.1.5.2. Delivery of RNAi mediators into mammalian cells 
Basically RNAi can be applied transiently or permanently to cells. Transient RNAi can be 
mediated by synthetic and vector based systems, stable RNAi requires vector mediated 
systems in mammalian cells. 
siRNAs and shRNAs can be chemically synthesized or in vitro transcribed. Transfection of 
mammalian cells with synthetic siRNAs / shRNAs can be performed by electroporation or 
lipophilic reagents. The efficiency of transient silencing depends on the transfection rate, on 
the potential of the chosen siRNA / shRNA to silence target gene expression and on the 
amount of siRNA / shRNA inside each transfected cell. Drawback of this system is its 
transient character, as mammals lack amplifying mechanisms for the silencing signal. 
vector-based RNAi: 
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 Vector systems can either be used to transcribe sense and antisense strand of siRNAs from 
two separate promoters (Miyagishi et al., 2002; Lee et al., 2002), or to express shRNAs 
(Paddison et al., 2002; Brummelkamp et al., 2002; Sui et al., 2002). Advantages of vector 
based systems compared to synthetic siRNA / shRNA transfection: 
• shRNAs trigger RNAi more effective than siRNAs (Siolas et al, 2005). 
• Transfection efficiency can be controlled by co-expressed markers as GFP. 
• Co-expressed resistance genes can be used to select for transfected cells to improve 
RNAi efficiency read out. 
• Cell lines stably expressing shRNAs can be created for long term gene silencing 
studies. This is especially useful to analyze functions of proteins with long half-lives. 
• Transfection efficiency can be improved by viral vector systems, which also propose 
transfection of non-dividing cell types. 
• Lower expenses 
Several RNA polymerase III promoters (pol III)have been used, as they have a defined start 
site and are active in all cell types (e.g. mouse and human U6 promoter, H1 promoter). In 
addition RNA polymerase III recognizes a cluster of four or more T residues as a termination 
signal for defined transcription. 
RNA polymerase II promoters have only found limited use to express shRNA in 
mammalian cells (Xia et al., 2002) because transcription start and stop sites are not well 
defined. Several groups used this promoter to express long hairpins in lower eukaryotes as C. 
elegans (Tavernarakis et al., 2000) and Drosophila (Kennerdell and Carthew, 2000). 
Alternatively to expression plasmids, viral vectors systems can be used to express shRNAs, 
especially in cells that are difficult to transfect, such as primary cells, neural cells, or stem 
cells: 
Adenoviral systems offer improved transmission rates and do not integrate into the host 
genome (Xia et al., 2002; Shen et al., 2003; Arts et al., 2003). 
Lentiviral vectors are retroviral systems that integrate into the genome of non-proliferating 
cells (e.g. terminally differentiated cells) (Naldini et al., 1996; Rubinson et al., 2003; Stewart 
et al., 2003; Qin et al., 2003). 
 
2.1.5.3. Applications of RNAi 
Several inducible RNAi-vectors have been developed suitable for studies of genes essential 
for cell survival, cell cycle regulation and development (reviewed in Mittal, 2004). 
Commonly tetracycline- or doxycycline - regulated RNA pol III promoters are used for 
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inducible systems, as most regions in type III promoters are exchangeable (Czauderna et al., 
2003; van de Wetering et al., 2003;Wiznerowicz and Trono, 2003; Matsukura et al., 2003; 
Chen et al., 2003). The major drawback of these systems is the relatively high background 
expression in an uninduced state. Recently a tightly regulated ecdysone - inducible system has 
been developed (Gupta et al., 2004). 
 
First double knock down experiments were performed by simply co-transfecting two RNAi 
expression vectors (Yu et al., 2003), or by sequential transduction of cells with two retroviral 
vectors (Schuck et al., 2004). This latter system proposed high transduction rates and fast 
selection by two co-expressed resistance genes, one by each vector. The latest reports describe 
a more sophisticated system that proposes stable knockdowns of multiple genes by one 
expression vector (Jazag et al., 2005). They combine RNAi-cassettes, each encoding a human 
U6 promoter and a region encoding an shRNA, by a classical cloning approach and propose a 
hypothetical limit of >30 RNA-cassettes dependent on the saturation level of the RNAi 
machinery. Furthermore, the vector encodes a selection marker to create stable RNAi knock 
downs. 
 
Another effort to identify gene functions are large scale RNAi screens (reviewed in Mittal, 
2004; Hannon and Rossi, 2004). The availability of genome sequences allows the 
construction of either chemically synthesized siRNA- or vector-based shRNA-libraries which 
are used in cell based RNAi screens. This powerful tool comprises remarkable drawbacks (see 
discussion chapter 4.1). 
 
2.1.6. Aim of this project 
In the first part of the thesis, a new vector-based RNAi application will be presented. As many 
proteins are redundant in their function we wanted to establish an RNAi technique targeting 
several genes simultaneously. To create a cheap and versatile tool, we combined vector 
mediated shRNA expression with the MultiSite-GatewayTM system of Invitrogen. 
This technique offers single vectors for transient RNAi and the ability to use a recombination 
based system for generation of Triple-RNAi-vectors. The single shRNAs can be exchaned 
easily and fast to target different combinations of genes, or to enhance the ability to silence 
one gene with three different shRNAs targeting different regions in this gene. 
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 2.2. Functional LAP2α analysis 
2.2.1. The eukaryotic nucleus 
In contrast to prokaryotes, eukaryotic cells enclose nearly their entire DNA in an internal 
compartment, the nucleus. The nucleus allows spatial and temporal separation of essential 
functions, such as DNA replication, transcription, RNA processing and ribosome assembly, 
from cytoplasmic protein synthesis. 
Inside this largest eukaryotic organelle, a special set of structural proteins builds up a 
proposed nucleoskeleton, also termed nuclear matrix. This framework might be responsible 
for the highly organized structure of chromatin within the nucleus and for regulation of 
nuclear functions (reviewed in Lamond and Earnshaw 1998; Vlcek et al., 2001; Shumaker et 
al., 2003). 
The nucleus is highly organized and includes numerous function-based foci. The most 
prominent of these sub-compartments is the nucleolus, where ribosomal DNA becomes 
transcribed and ribosomes get processed and assembled (reviewed in Taddei et al., 2004). 
 
2.2.2. The nuclear envelope 
The eukaryotic nucleus is enclosed by the nuclear envelope (NE), which is not only essential 
for nuclear structure but also for regulation of nuclear function (reviewed in Shumaker et al., 
2003; Vlcek et al., 2001; Burke and Ellenberg 2002). The NE is formed by two concentric 
lipid bilayer membranes, the inner- and outer nuclear membranes (INM, ONM), and the 
nuclear lamina (see Figure 2-2). The ONM is continuous with the rough endoplasmatic 
reticulum (ER) and therefore often coated with ribosomes. The two nuclear membranes are 
separated by the perinuclear space (lumen) and join at sites where the nuclear pore complexes 
(NPC) are embedded. These numerous NPCs are large multiprotein channels, which mediate 
bidirectional transport of macromolecules between the cytoplasm and the nuclear interior and 
allow free, aqueous diffusion of ions and small molecules below a postulated size limit of 
40kDa. A meshwork of proteins, termed the nuclear lamina, resides beneath the INM. The 
INM with its unique set of proteins is associated with the nuclear lamina via several 
transmembrane proteins, including the lamin B receptor (LBR) and proteins belonging to the 
lamina-associated-polypeptide-1 (LAP-1) and LAP-2 families. 
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Figure 2-2: Schematic picture of a part of the nuclear envelope. The nuclear envelope is composed of the nuclear 
membranes, nuclear pore complexes and the nuclear lamina. The outer nuclear membrane is continuous with the 
rough endoplasmatic reticulum and has ribosomes on its outer surface. The inner nuclear membrane is associated 
with the nuclear lamina on its nuclear surface. The nuclear pore complexes allow transport of macromolecules 
and free, aqueous diffusion of small ions and molecules between the cytoplasm and the nucleoplasm. Modified 
from (Evans et al., 2004) 
 
 
2.2.3. Nuclear Lamins 
The nuclear lamina is a filamentous scaffold structure, positioned underneath the INM 
(reviewed in Gruenbaum et al., 2003; Shumaker et al., 2003). It is composed of a meshwork 
of type V intermediate filament proteins (IFs), the lamins, and lamina-associated proteins. 
The nucleus-specific lamins classify as one out of six different types of vertebrate IFs, itself 
categorized on the basis of sequence homologies (reviewed in Foisner 2001, Hermann and 
Foisner 2003). All IF family members share a central α-helical rod domain, flanked by N- and 
C-terminal globular domains. Lamins differ from cytoplasmic IFs by several features (see 
Figure 2-3): 
• short N-terminal head domains 
• additional 42 amino acid residues in the central rod domain 
• nuclear localization sequence in the C-terminal tail domain 
• C-terminal CaaX motif (except for lamin C) 
The C-terminal CaaX motif (C represents cystein, a means an amino acid with an aliphatic 
side chain, X is any residue) is a target site for post-translational modification, specifically 
farnesylation and subsequent carboxymethylation, which is important, but not sufficient, for 
targeting and anchoring lamins to the INM (Moir et al., 1995; Hofemeister et al., 2000). 
Lamins in vitro exhibit a head-to-tail association of dimeric subunits to form polar head-to-tail 
polymers, which can further assemble laterally (reviewed in Stuurman et al., 1998) to form a 
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 meshwork of 10nm filaments, which has so far only been visualized in Xenopus laevis 
oocytes (Aebi et al., 1986). Lamins become phosphorylated at the onset of mitosis, leading to 
disassembly of the filaments, whereas dephosphorylation initiates re-assembly of the lamin 
meshwork after completion of mitosis. (Collas et al., 1990). 
 
 
 
Figure 2-3: Generalized structure of cytoplasmic intermediate-filament proteins compared to lamins. 
Intermediate-filament proteins have a conserved domain structure consisting of a variable globular head domain, 
a central α-helical coiled-coil dimerization domain (rod domain) and a variable globular tail domain. The major 
differences between lamins and vertebrate cytoplasmic intermediate filaments are: first, the head domains are 
very short (about 33 amino acids); second, a six-heptad extension in the central rod domain (blue), and third, the 
globular tail domain is usually characterized by the presence of a nuclear localization signal (NLS) sequence and 
a site for farnesylation, carboxymethylation and proteolytic cleavage (CaaX). Modified from (Huthison and 
Worman 2004) 
 
Lamins are grouped into two classes (A- and B-type) based on their biochemical and 
structural properties. In mammals, three genes (LMNA, LMNB1 and LMNB2) give rise to 
seven different proteins and splice variants (Cohen et al., 2001). The LMNA-encoded proteins 
lamin A and the smaller splice variant lamin C are expressed in most terminally differentiated 
somatic cells but are not essential for embryonic development. Lamins B1 and B2, encoded 
by LMNB1 and LMNB2, respectively, are constitutively expressed throughout development 
and cell differentiation. All somatic cells express at least one B-type lamin. 
In contrast to B-type lamins, immature pre-lamin A loses its post-translational modification at 
its C-terminal CaaX motif due to proteolytic cleavage, leading to mature lamin A (Lutz et al., 
1992). These differences in post-translational modifications of A- and B-type lamins are the 
reason for their different behaviour throughout the cell cycle (see 2.2.7.). In addition to their 
presence at the nuclear periphery, A-type lamins are also found inside the cell nucleus of 
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interphase cells. These structures appear as discrete foci and filamentous structures (Goldman 
et al. 1992, Bridger et al. 1993, Jagatheesan et al. 1999). A-type lamins become soluble and 
dispersed throughout the cytoplasm during mitosis, whereas B-type lamins preferentially 
remain associated with membrane vesicles (reviewed in Sturman et al., 1998). 
 
2.2.4. Integral Nuclear Membrane Proteins 
Most integral proteins of the inner nuclear membrane interact either directly or indirectly with 
lamins and are considered to be part of the nuclear lamina (reviewed in Ye et al. 1998; 
Gotzmann and Foisner 1999; Holmer and Worman 2001; Gruenbaum et al. 2003). Therefore, 
they can serve as adaptor proteins that link the INM to the lamina filaments and/or chromatin, 
as many lamin-binding proteins were also shown to interact with DNA or chromosomal 
proteins. Binding to the nuclear lamina provides a mechanism for the appropriate localization 
of these integral membrane proteins on the basis of selective retention within the nucleus 
(reviewed in Burke and Ellenberg 2002). According to this model, all proteins that are mobile 
within the ER can access the INM, but only those proteins that specifically interact with 
lamins or chromatin are retained and concentrated in the INM. Therefore, the INM can be 
seen as a specialized domain of the ER with a distinct composition of integral and peripheral 
proteins. 
The first INM proteins were identified by their ability to bind to lamins, like lamin B receptor, 
lamina-associated polypeptide-1, or lamina-associated polypeptide-2 (LAP2). Since then, 
several additional proteins have been identified, including MAN-1, emerin, otefin, nurim, 
ringfinger binding protein (RFBP), nesprin and several others (see Figure 2-4; Mattout-
Drubezki and Gruenbaum, 2003; Gruenbaum, 2005). Recently, a lot of new INM proteins 
have been classified (Schirmer et al., 2005), but so far not verified or characterized. 
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Figure 2-4: Schematic view of the nuclear envelope, including selected interactions between the lamina and 
chromatin. The inner and outer nuclear membranes join at the nuclear pore complexes (NPC) and are separated 
by the nuclear lumen (blue). Lamins (both A- and B-types) are shown as thicker filaments at the nuclear 
periphery and as thinner filaments in the nucleoplasm (red). Also shown are selected proteins of the inner 
nuclear membrane and proteins that interact with lamins in the nuclear interior (green). The green dots represent 
interactions with lamins. Especially indicated are the LEM domain and the LEM-like domain (see 2.2.4.). 
Chromatin at the nuclear periphery is structurally condensed, since it is mostly transcriptionally silent. Modified 
from (Mattout-Drubezki and Gruenbaum, 2003) 
 
2.2.5. The LAP2 family 
The lamina-associated polypeptide 2 (LAP2) family consists of six alternatively spliced 
isoforms (LAP2α, β, γ, δ, ε and ζ) in mammalian cells (see figure 2-5) (Foisner and Gerace 
1993; Furukawa et al., 1995; reviewed in Dechat et al., 2000). They share a common N-
terminal domain (aa1-187), including a LEM-like and a LEM domain (Cai et al., 2001). The 
~40 amino acids long LEM domain was first identified as a common structural motif in 
lamina associated polypeptide2, emerin and MAN1 (Lin et al., 2000). It mediates chromatin 
interaction via the small DNA bridging molecule barrier-to-autointegration-factor (BAF) 
(Furukawa 1999, Shumaker et al., 2001), dimers of which link double-stranded DNA in a 
sequence-independent manner. Additionally, the very N-terminal LEM-like motif may also 
permit direct binding to DNA (Cai et al., 2001). 
LAP2β is the largest isoform integrated into the membrane. Beside its N-terminal 
nucleoplasmic domain it consists of a single transmembrane region and a short C-terminus, 
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located in the lumen. The three smaller spliced isoforms LAP2γ, δ and ε differ only little from 
LAP2β. Compared to LAP2β they lack regions of 40, 72 and 109 amino acids respectively, in 
their nucleoplasmic N-termini (see figure 2-5). These four LAP2 isoforms are type II integral 
membrane proteins of the inner nuclear membrane. LAP2ζ corresponds to the first 219 N-
terminal residues of LAP2β, has five additional C-terminal amino acids and lacks a 
transmembrane domain. LAP2α only shares the N-terminal common domain (first 187aa) 
with the other LAP2 isoforms and its 506 amino acid C-terminus is unique. 
 
 
Figure 2-5: LAP2 isoforms and related LEM protein family. The six alternatively spliced isoforms of the LAP2 
family share the common LEM protein motif (hatched box) with the LEM family, named after lamina associated 
polypeptide 2, emerin and MAN1. The LEM domain mediates binding to BAF, a DNA-bridging protein. The 
LAP2 family shares the N-terminal common domain (yellow) encoding the LEM and a DNA binding LEM-like 
domain (at the very N-terminus). Most of the isoforms are C-terminally membrane bound and structurally 
related. They differ only by small insertions in the nucleoplasmic domain (differently shaded green boxes). In 
contrast LAP2α has a unique C-terminus (blue) without a putative transmembrane region. 
 
LAP2β is restricted to the nuclear envelope, where it interacts with B-type lamins (Foisner 
and Gerace, 1993), chromatin (Dechat et al., 2000) and germ-cell-less (gcl) (Nili et al., 2001). 
Both, LAP2β and gcl are able to repress E2F-dependent gene transcription. However, full 
repression requires both proteins, suggesting that these repressors act cooperatively. Together 
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 with HA95, LAP2β is involved in regulation of DNA replication (Martins et al., 2003). 
Disruption of this association does not interfere with elongation, but stops initialization of 
DNA replication. 
 
2.2.5.1. Lamina-associated-Polypeptide 2 alpha (LAP2α) 
In contrast to LAP2β, γ, δ, ε (see 2.2.5.), LAP2α  has no putative transmembrane region and 
is therefore distributed throughout the nucleus except for nucleoli. The N-terminal LAP2 
common domain encodes the DNA binding LEM-like domain and the LEM domain, which 
interacts with chromatin via BAF (see Figure 2-6). The LAP2α-specific C-terminus contains 
a stretch of basic residues forming a putative nuclear localization signal. Furthermore, the 
unique C-terminus mediates chromosome association and binds to lamin A/C and to tumor 
suppressor retinoblastoma protein (pRb) (Dechat et al., 1998; Vlcek et al., 1999; Dechat et al., 
2000; Markiewicz et al., 2002). 
 
 
 
Figure 2-6: Schematic representation of LAP2α protein regions, found to contain specific interaction sites. The 
LAP2α constant N-terminus (yellow) contains the LEM domain binding to BAF (red) and the LEM-like domain 
binding to DNA (green). The unique C-terminus (blue) has a nuclear localization signal (light blue box), a 
chromosome binding domain (grey) and is capable of interacting with lamin A/C (black) and Rb. 
 
Considering their intranuclear localization, it is likely that LAP2α and A-type lamins help to 
organize chromatin structure all over the nuclear interior. Interactions of LAP2α with 
chromatin and DNA via the LEM motif and the LEM-like motif, respectively, support this 
idea. During mitosis LAP2a becomes cytoplasmic in a phosphorylation dependant manner 
(Gajewski et al., 2004) and relocates to the Chromosomes during late anaphase in a 
characteristic way (see 2.2.6.). Moreover it has been shown that LAP2α is essential for 
nuclear reassembly after mitosis (Vlcek et al., 2002). Additionally, LAP2α and A-type lamins 
were found to exist in a complex with hypophosphorylated pRb implicating a role in cell 
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cycle regulation (see 2.2.7.). Recent data implicated a very C-terminal mutation in LAP2α 
ocess, as nuclear disassembly 
osphatase Cdk1 (Laronne et al., 2003). 
D (Ellenberg et al., 1997; Yang et al., 1997). According to this 
cle populations containing specific protein markers, different 
ummond et al., 1999). 
d spatially 
ual nucleoskeletal proteins to the chromosomal surface 
(4) Transport of lamins into the nucleus 
with Dilated Cardiomyopathy (Taylor et al., 2005). 
 
2.2.6. The nuclear envelope during mitosis 
In vertebrates the NE completely disassembles during mitosis (reviewed in Burke and 
Ellenberg 2002; Foisner 2003; Margalit et al., 2005). This nuclear envelope breakdown 
(NEBD) defines the transition between prophase and prometaphase stages of mitosis. The 
models suggest that NEBD is initiated by phosphorylation of nucleoporins, lamins and lamin 
associated proteins (Heald and Mckeon, 1990; Foisner and Gerace, 1993 Stuurman et al., 
1998). The resulting disassembly weakens nuclear structure and enables chromatin 
condensation. Further on, the disassembling NE is torn apart by microtubule guided motor 
proteins (Beaudouin et al., 2002; Salina et al., 2002). However, this microtubule-dependent 
rupture seems to facilitate NEBD, but is not essential for this pr
can also occur in the absence of microtubule induced mechanical stress (Georgatos et al., 
1997) but not without ph
Two exclusive theories try to describe the fate of nuclear membranes and their integral 
proteins during mitosis: 
The first model suggests that nuclear membranes become fused to the endoplasmatic 
reticulum (ER) after NEB
model, integral membrane proteins of the INM are re-distributed to the endoplasmatic 
reticulum of mitotic cells. 
The second hypothesis predicts domain specific vascularization of the nuclear membrane into 
different populations of vesicles containing different sets of integral membrane proteins. In 
support of this model, two vesi
from the endoplasmatic reticulum, have been found in Xenopus oocytes (Vigers and Lohka, 
1992; Dr
Non-membrane bound proteins like lamin A or LAP2α become dispersed in the cytoplasm by 
NEBD. 
During anaphase and telophase NE reassembly takes place in a temporally an
highly regulated manner. 
(1) Targeting of individ
(2) Membrane recruitment and fusion 
(3) Assembly of NPCs 
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(5) Formation of the nuclear lamina 
The exact chronological order of reassembly of lamina associated proteins and INM proteins 
has not been determined so far. Lamin B receptor (LBR) was detectable associated with 
anaphase chromatin slightly before LAP2α, followed by LAP2β (see figure 2-7) (Dechat et 
al., 2004). However, both LAP2β and LBR first localize to more peripheral sites of the 
chromatin bulk, whereas LAP2α first accumulates on telomeric regions of lagging 
chromosomes, followed by concentration into two ‘core’ structures adjacent to the mid-
spindle and spindle pole area, respectively. These data indicate different chromosome binding 
properties of LAP2 isoforms during nuclear reassembly (Vlcek et al., 2002). In this context, it 
has been shown that the initial association of LAP2α with chromatin required its unique C-
terminal chromosome binding region, while the N-terminal LEM and LEM-like domains were 
ispensable at these stages. 
 
d
 
Figure 2-7: Model depicting the observed chronological order (numbers) of lamina protein relocation to the 
chromatin during nuclear reassembly. Colors distinguish the two pools of proteins which either initially associate 
with telomeres and core regions (red), or with more peripheral regions of the chromatin (green). Modified from 
echat et al., 2004) 
reassembly (Dechat et al., 2004; Shimi et al., 2004). The LAP2α/BAF complex is suggested 
(D
 
Interestingly, a large fraction of BAF colocalized with LAP2α at telomeres and core 
structures (Haragutchi et al., 2001), to form a stable complex at early stages of nuclear 
to trigger changes in chromatin structure, to provide binding sites for other NE proteins, such 
as proteins of the LEM-domain family. 
Like lamina binding proteins differently localizing at the chromosomes, A- and B-type lamins 
also seem to assemble by different pathways. During chromosome separation B-type lamins 
are associated with disassembled “nuclear” membrane structures. B-type lamins could target 
membrane structures to the peripheral chromosome regions by interaction with LBR and 
LAP2β. In contrast, A-type lamins are evenly distributed in the cytoplasm and only a small 
subfraction of lamin C colocalized with LAP2α core structures but the majority of lamin C 
was translocated to the nuclear interior at later stages (Dechat et al., 2004). 
After these crucial events in nuclear reassembly, membranes accumulate and fuse. The main 
fraction of lamins is imported through newly formed NPC and polymerizes to a filament 
network. Further nuclear proteins are imported and the nucleus grows in size. 
 
2.2.7. Functional implication of the nuclear lamina 
The nuclear lamina with its diverse composition of lamins and lamina associated proteins 
fulfills a wide range of functions. Similar to cytoplasmic IF networks, the nuclear lamina 
seems to serve as structural backbone for the nucleus defining its shape (reviewed in Wilson 
2000; Hutchison et al., 2001; Wilson et al., 2001). Lamins are also thought to play an 
important role in higher order chromatin organization and regulation of gene expression via 
several binding partners (reviewed in Mattout-Drubezki and Gruenbaum 2003). In general, 
heterochromatin, including centromeres, telomeres and repetitive DNA, is preferentially 
positioned near the nuclear envelope. It was also shown that human gene-rich and 
transcriptionally highly active chromosomes are often found more centrally in the nucleus, 
whereas gene-poor chromosomes are localized at the periphery (Boyle et al., 2001). 
Moreover, it has been shown that the nuclear lamina affects transcription not only by 
interaction with chromatin, but also with the RNA polymerase II based transcription 
machinery and more specifically with individual transcription factors (reviewed in Mattout-
Drubezki and Gruenbaum 2003). Lamins might also be involved in DNA replication 
(reviewed in Goldman et al., 2002; Gruenbaum et al., 2003) and proper execution of apoptosis 
(Rao et al., 1996; Ruchaud et al., 2002). 
Finally, lamin A/C binds to pocket C of hypophosphorylated pRb (Ozaki et al., 1994; Mancini 
et al., 1994) and both are tightly bound by LAP2α, as shown by blot overlay and 
coimmunoprecipitations assays (Markiewicz et al., 2002). Expression of a dominant negative 
lamin A/C mutant resulted in mislocalization of lamin A/C, LAP2α and partly pRb, 
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 suggesting that hypophosphorylated pRb is anchored in the nucleus by this trimeric complex. 
Furthermore, hypophosphorylated Rb is not anchored in the nucleus in the absence of LAP2α, 
when cells reenter G1 phase from a quiescent state, induced by serum starvation (Markiewicz 
et al., 2002). According to these findings, pRb is mislocalized in Lmna -/- cells and in cells 
with reduced lamin A/C expression (Johnson et al., 2004). In addition, proteasomal 
degradation of pRb was increased in these two cell systems. Both phenotypes, Rb localization 
and proteasomal degradation, could be rescued by reintroduction of GFP-lamin A into Lmna -
/- cells. 
These findings propose a complex of lamin A/C, LAP2α and hypophosphorylated pRb. pRb 
is known to regulate cell cycle progression via binding to members of the E2F transcription 
factor family in a phosphorylation dependent manner and by recruiting histone deacetylase 
complexes (Kaelin, 1999). Conclusively, the nuclear lamina might actively participate in the 
regulatory circuits of cell cycle control. 
 
2.2.8. Laminopathies 
Laminopathies are a group of diverse inherited diseases that were found to arise from 
mutations in genes that code for A-type lamins and lamina-associated proteins (reviewed in 
Gotzmann and Foisner, 2005). Laminopathies affect different tissues, giving rise to muscular 
dystrophy, cardiomyopathy, lipodystrophy, neuropathies, dermopathies and premature aging 
syndromes. Most of these diseases arise from single point mutations in LMNA, despite this 
relation, the symptoms vary over a wide range. For example, two mutations in the C-terminus, 
causing Hutchinson Gilford Progeria (De Sandre-Giovannoli et al., 2003; Erikson et al., 2003) 
and restrictive dermopathy (Navarro et al., 2004), respectively, lead to accumulation of a 
shortened form of pre-lamin A, which misses the C-terminal proteolytic cleaving site and 
therefore remains farnesylated. 
So far, five different not exclusive models have been postulated to explain the phenotypes 
which arise from mutations in LMNA: 
1) The structural model: It predicts nuclear fragility or problems during nuclear assembly 
and / or during nuclear growth due to lamina instability. Preferentially muscle tissues 
are affected due to mechanical stress. 
2) The ER-retention model: Mutations in lamin A cause misslocalization of emerin to the 
ER (Di Blasi et al., 2000). This correlates with the nuclear retention model (see 2.2.3.). 
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3) The gene expression model: Lamin A has been linked to chromatin organization, 
mutations could change gene expression by altering binding properties of lamin A to 
transcription factors, such as pRb, germ-cell-less (gcl), or SREBP-1. 
4) The cell cycle model: Mutations in lamin A could influence cell cycle control by 
deregulating pRb function, as lamin A is essential for pRb localization and stability. 
5) The regeneration model: This very recent hypothesis supposes that lamin A mutations 
affect plasticity or self-renewal potential of mesenchymal stem cells. This would 
explain the late onset of nearly all laminopatic phenotypes during childhood or 
puberty. 
Most likely the different laminopatic diseases are based on different combinations of these 
five hypotheses. 
 
2.2.9. Aim of this project 
In this project we wanted to further characterize LAP2α’s in vivo function by RNAi. 
Therefore, we designed sh-oligonucleotides targeting LAP2α, LAP2 isoforms and other NE 
proteins. First we transiently tested the functionality of the RNAi constructs, than we selected 
stable cell lines and single cell clones. These were used to analyze the proposed role of 
LAP2α in cell cycle regulation, as it has previously been shown to anchor 
hypophosphorylated pRb to the nucleus together with lamin A/C. Additionally, we were 
especially interested in potential changes in the localization of LAP2α binding partners upon 
LAP2α downregulation. 
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3. RESULTS 
 
3.1. Results Triple RNAi 
3.1.1. The Triple-RNAi-Vector strategy 
The goal was to establish an RNAi vector, which allows to simultaneously knock down up to 
three target mRNAs. Cloning and flexibility of the system was facilitated using the MultiSite 
GatewayTM technology (see appendix B). 
First we designed three pairs of primers with appropriate attB overhangs for recombination 
into donor vectors (according to Invitrogen’s manual) and amplified three individual RNAi-
cassettes by PCR using pSHAG as a template (see 5.4.3.; pSHAG provided by Greg Hannon, 
Cold Spring Harbor Laboratories). Each RNAi-cassette is flanked by GatewayTM 
recombination sites, and composed of a human U6 promoter, followed by BseRI and BamHI 
restriction sites for insertion of sh-oligonucleotides. The three PCR-products contained 
suitable recombination sites for three separate BP recombination reactions (see 5.4.5.2.) into 
the respective Donor vectors (see Appendix A). The resulting Entry vectors pMU6-A, pMU6-
B and pMU6-C were sequenced with M13 forward and M13 reverse primers by VBC-
Genomics (Vienna, Austria), to confirm the integrity of the recombination sites and the 
RNAi-cassettes. 
Entry vectors could then be shuttled into a single Destination vector by Invitrogen’s MultiSite 
GatewayTM Technology to form a Triple-RNAi-Vector. The MultiSite GatewayTM LR 
reaction (see 5.4.5.3.) was tested to construct control vector pJG100, encoding three empty 
RNAi-cassettes, each lacking sh-oligonucleotides. 
 
3.1.2. Single RNAi targeting exogenous reporters 
Single RNAi-Entry vectors were now tested for functionality in transient RNAi-assays (see 
5.2.4.). sh-oligonucleotides (see 5.4.1.), designed to target exogenous reporter mRNAs for 
Firefly Luciferase, Renilla Luciferase and ß-Galactosidase, were ligated (see 5.3.12.) each 
into the three different pMU6 Entry vectors (see Table 3-1). 
The resulting vectors were tested by co-transfection of shRNA and reportergene-expressing 
vectors. Substrate-dependent interference was ruled out by testing different combinations of 
reporter constructs and measuring respective enzyme activities in the absence/presence of the 
others (Figure 3-1). 
 
RNAi Entry vector sh-oligo / RNAi target Empty Entry vector / pMU6-X 
pJG177a+b Firefly Luciferase pMU6-A 
pJG178 Renilla Luciferase pMU6-B 
pJG179 ß-Galactosidase 1 pMU6-C 
pCM4 ß-Galactosidase 2 pMU6-C 
pCM5 ß-Galactosidase 3 pMU6-C 
pCM6 ß-Galactosidase 3 pMU6-A 
pCM7 ß-Galactosidase 2 pMU6-B 
pJG173 SUN1 pMU6-A 
Table 3-1: Overview of the used Entry vectors listed with their corresponding sh-oligonucleotides. 
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Figure 3-1: There is no substrate-dependent interference between the respective reporter enzymes. Single 
reporter activity was measured ((A) Firefly Luciferase (FF-Luci), (B) Renilla Luciferase (Ren-Luci), (C) ß-
Galactosidase (ß-Gal) in several single, double and triple reporter plasmid transfections of HEK 293 cells. X-axis 
indicate the reporter enzymes expressed by the cells, Y-axis indicate the measured enzyme activity. The amount 
of each plasmid used for transfection depended on the number of plasmids per transfection, therefore the 
measured enzyme activities vary a lot. 
 
Single RNAi Entry vectors were transfected into HEK 293 cells together with two reporter 
plasmids. The pMU6 vector pJG173 containing an RNAi construct targeting SUN1, a nuclear 
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 envelope protein, served as control. Two days after transfection, we measured the reporter 
enzyme activities. The RNAi efficiency was calculated by normalizing for transfection 
efficiencies with a second reporter enzyme. Each result was determined by at least two 
independent transfection experiments. The RNAi constructs reaching the highest efficiencies 
are shown in Figure 3-2. 
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Figure 3-2: Efficiencies of RNAi mediated reduction of target gene protein levels were determined by 
quantitative enzyme activity assays. HEK 293 cells were transfected with two reporter plasmids (out of pGL3, 
phRL and pSVß-Gal) and one RNAi vector (out of pJG177b (A), pJG178 (B) or pCM4 (C)). Co-transfections 
with pJG173 in all assays served as a control. One reporter was used for normalization of different transfections, 
the other was targeted by RNAi. Efficiencies of RNAi constructs are given as percent enzyme activity relative to 
the level of control transfections. Standard deviations were determined between results of independent 
transfection experiments. 
 
Firefly Luciferase activity could be reduced by 67 ± 12% using pJG177b. pJG178 was even 
more effective reducing Renilla Luciferase reporter activity by 88 ± 12%. For ß-Galactosidase 
we achieved a maximal reduction of 46 ± 7% using pCM4. The other ß-Gal constructs (see 
Table 3-1) were rather ineffective. Since all single RNAi vectors worked in our assay, we 
started creating a Triple-RNAi-Vector targeting all three exogenous reporters. 
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3.1.3. Triple-RNAi-Vector 
MultiSite GatewayTM LR reactions were performed to obtain pCM3 and pCM8 (see 5.4.5.3.). 
Both plasmids encode three independent human U6 promoters, driving transcription of 
shRNA targeting Firefly Luciferase, Renilla Luciferase and ß-Galactosidase (Figure 3-3), 
respectively. The two Triple-RNAi-Vectors are different only in the target sequences for ß-
Galactosidase (see Table 3-1 and Table 5-5). The functionality of the system was tested using 
a co-transfection setup, as follows: We transfected HEK 293 cells with four reporter plasmids 
(pGL3, phRL, pSV-ßGal and pCAT3) and one Triple-RNAi-Vector. Setups containing 
varying amounts of plasmids were used to find the conditions optimized for RNAi-efficiency. 
Plasmids were finally used in rates: 50% RNAi vector; 4x12.5% different reporter plasmids, 
to obtain highest RNAi efficiencies. The cells were lysed 48 hours after transfection and 
enzyme activities were measured. 
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Figure 3-3: RNAi mediated reduction of enzyme activity levels of Firefly Luciferase, Renilla Luciferase and ß-
Galactosidase by the Triple-RNAi-Vectors pCM8 and pCM3, respectively. HEK 293 cells were transfected with 
the reporter plasmids pGL3, phRL, pSV-ßgal, with pCAT3 for normalization) and with a triple RNAi vector 
(pCM3, or pCM8). The control vector (pJG100; see 3.1.1.) served as RNAi-control. 
 
The measured enzyme activities of all lysates of different transfections were normalized by 
their chloramphenicol acetyltransferase activities and compared with the ones of the control 
transfection (pJG100 was used as triple RNAi vector in control transfections.). The results of 
the two Triple-RNAi-Vectors (Figure 3-3) and the ones of the single RNAi tests (Figure 3-2) 
are summarised in Table 3-2. 
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  pCM3 pCM8 single RNAi tests 
Firefly Luciferase -77% -46% -67 ±12% 
Renilla Luciferase -80% -60% -88 ±12% 
ß-Galactosidase -38% -41% -46 ±7% 
Table 3-2: RNAi results of Triple-RNAi-Vectors compared to single RNAi tests. The reduction in reporter 
enzyme activity compared to control is indicated. 
 
Both Triple-RNAi-Vectors resulted in a significant reduction of all three enzyme activities. In 
two cases pCM3 was even more effective than the same RNAi constructs in single RNAi 
tests, but all results of pCM3 were within the range of standard deviation. Luciferase activity 
results using pCM8 showed higher variation compared to the other construct. There are 
several possible explanations for this result.  
To summarize, both Triple-RNAi-Vectors showed clear knockdowns of all three targets. 
Thus, the system works efficiently on three ectopically expressed targets. Two questions 
remain to be answered:  
1. Is the RNAi effect additive in a setup, where one gene is targeted by three different 
shRNAs. 
2. Does the system work also on endogenous genes? 
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3.2. RESULTS LAP2α RNAi 
Lamina-associated polypeptide (LAP) 2α belongs to the LEM-domain protein family. It has 
been described as a multifunctional, intranuclear protein, binding to BAF (Cai et al., 2001), 
lamins A/C, Rb (Markiewicz et al., 2002) and chromosomes (Vlcek et al., 1999). During 
mitosis, LAP2α was shown to associate with telomeres and to form core structures adjacent to 
the spindle in telophase (Dechat et al., 2004). These data suggest, that LAP2α is involved in 
chromatin reorganization during early stages of nuclear reassembly. Additionally, over 
expression studies (Andreas Gajewski, unpublished data) revealed that LAP2α delays cell 
cycle progression. 
To get a deeper insight to nuclear reassembly after mitosis and to confirm a proposed cell 
cycle regulatory role of LAP2α, we decided to reduce LAP2α expression levels by RNAi. 
 
3.2.1. Transient approach to test the functionality of RNAi constructs 
First, we designed RNAi short hairpin oligonucleotides (sh-oligonucleotides) targeting human 
LAP2α, LAP2β, all LAP2 isoforms, Lamin A, emerin, BAF and Lco1 using a software 
applicable for the BseR1/BamH1 strategy (see 5.4.1.). The RNAi targets and the 
corresponding plasmids are listed in Table 3-3, the targeting regions on LAP2 isoforms are 
shown in Figure 3-4. 
 
RNAi target pSHAG (transient RNAi) pTRACER (trans.+stable RNAi) 
all LAP2 isoforms pJG101a pJG111a 
LAP2β, γ, δ pJG102a pJG112a 
Emerin pJG103a pJG113a 
all LAP2 isoforms pJG104a pJG114a 
BAF pJG105a+b pJG115a+b 
LAP2α pJG106a pJG116a 
Lco1 pJG107a+b+c PJG117a+b+c 
LAP2α pJG108a+b pJG118a+b 
LAP2α pJG109a+b pJG119a+b 
Lamin A pJG120a+b pJG120a+b 
Firefly Luciferase (control) pSHAG-FF pJG121 
Table 3-3: RNAi targets listed with their corresponding plasmids. a and b are indicating different bacterial 
clones. For sh-oligonucleotide sequences and more detailed information see 5.4.1.. 
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Figure 3-4: Molecular target-sequence localization of siRNAs on LAP2 isoforms, here represented by LAP2α 
and LAP2ß. Two constructs were used to knock-down all LAP isoforms, three siRNAs were LAP2α – specific, 
whereas one plasmid should interfere with the expression ofLAP2 isoforms β, γ and δ. The RNAi constructs are 
indicated by the number of the respective pSHAG -based pJGx- plasmids (see Table 3-3). 
 
The sh-oligonucleotides were annealed (see 5.4.2.) and ligated (see 5.3.12.) into a 
BseR1/BamH1 digested pSHAG vector, which contains a human U6 promoter driving 
transcription of a hairpin RNA and can be used to analyze RNAi-efficiencies in a transient 
manner. The RNAi cassette is enclosed by GatewayTM (Invitrogen) recombination sites to 
easily shuttle the RNAi-cassette between different GatewayTM-compatible vectors (see 
appendix B). First, we tested the efficiency of the new LAP2α-targeting RNAi hairpin 
constructs by western blot analysis of HeLa cell lysates, processed 48 hours after transfection 
(Figure 3-5). 
The target protein levels were compared to the ones of control transfections (pSHAG-FF and 
pTRACER) and of untransfected HeLa cells. Out of three constructs targeting different 
regions within the LAP2α specific domain (see Figure 3-4) only vectors pJG108a and b 
prooved functional in reducing LAP2α protein levels significantly. A potential down 
regulation of LAP2 protein levels using vector pJG101a was also indicatedin the blot. 
Similarly, Western blots were performed with cells following treatment with the RNAi 
constructs targeting lamin A and emerin (see Table 3-3) but in both cases there was no 
significant reduction in protein levels. 
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Figure 3-5: Western blot analysis of HeLa cells, transiently transfected with RNAi mediating pSHAG vectors 
(pJG101a, pJG102a, pJG104a, pJG106a, pJG108a+b, pJG109a+b). As control we used a pSHAG vector with a 
hairpin construct against Firefly Luciferase (pSHAG-FF), a pTracer vector and untransfected cells. 48h after 
transfection the cells were lysed and equal amounts of protein were probed for LAP2 isoforms using mAb12. 
 
 
3.2.2. Conditions for stable transfection with RNAi constructs 
We next shuttled the RNAi-cassettes into a GatewayTM-compatible pTracer plasmid (see 
appendix B). The pTracer vector is suitable for transient and stable transfection in eukaryotic 
cells (see 5.1.2., 5.1.3.), as it enables selection on Blasticidin by a co-expressed (CMV – 
driven) GFP-Blasticidin resistance fusion protein. We made use of the GFP-based 
fluorescence not only to determine transfection efficiencies but also to clearly distinguish 
transfected from non-transfected cells. Later the blasticidin resistance was exploited to select 
for cells stably expressing a functional RNAi-cassette (see 3.2.3.). 
To test the vector system in transient assays, HEK 293 cells were grown on polylysine coated 
coverslips and transfected with the plasmids pJG111a, pJG112a, pJG114a, pJG116a, 
pJG118a+b, pJG119a+b and pJG120a+b. 48 hours after transfection the cells were processed 
for immunofluorescence (see figure 3-6). 
Two independent transfections with pJG111a targeting all LAP2 isoforms (upper and lower 
panels) are shown. We compared LAP2 protein levels of transfected and untransfected HEK 
cells, which were distinguished by co-expressed GFP (left panels). Monoclonal ab12 was 
used to stain all LAP2 isoforms. This antibody preferentially decorates the NE, where all 
LAP2 isoforms except LAP2α and -ε are located. Therefore, untransfected cells show a clear 
rim-staining, whereas transfected cells show only weak and diffuse background staining. 
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 These results show a clear down regulation of LAP2 by pJG111a, which was also 
demonstrated using pJG118a+b (data not shown and see 3.2.3). 
 
  
Figure 3-6: Confocal immunofluorescence images of HEK 293 cells, transiently transfected with pJG111a, 
expressing a shRNA targeting all LAP2 isoforms. GFP indicates the transfected cells (green), ab12 and Texas 
Red conjugated secondary antibody was used to stain all LAP2 isoforms (red). Bars, 10µm. 
 
Thus, the system and some of the RNAi constructs worked efficiently. We next wanted to 
confirm these data by Western blot analysis of cell lines stabley expressing these RNAi-
cassettes. 
To create stable cell lines, we first determined the blasticidin concentration necessary for 
selection on transfected cells. Therefore we studied its dose dependency on the viability of 
HEK 293 and HeLa cells (Figure 3-7). 
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Figure 3-7: Influence of different Blasticidin concentrations on the viability of HeLa and HEK 293 cells, 
respectively. Cells of cultures with 80% confluency were exposed to culture medium substituted with different 
concentrations of blasticidin [0, 2.5, 5, 10µg/ml]. The amount of viable cells on the culture dish was estimated 
by visual screening of cultures under the light microscope. 
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The cells were grown to a confluence of about 80% before they were exposed to culture 
medium supplemented with blasticidin concentrations ranging from 0 to 10µg/ml. Every other 
day the medium was exchanged for two reasons: 
a) to remove dead cells and cellular degradation products 
b) to ensure an effective blasticidin concentration 
This experiment showed strong variation of blasticidin resistance between these two cell lines. 
HeLa cells reacted more sensitively and started to die after 24 hours, when exposed to 
blasticidin concentrations >2.5µg/ml. After five days of treatment no viable HeLa cells were 
detectable. On the other hand, HEK 293 cells sustained Blasticidin concentration of 2.5µg/ml 
and proliferated like untreated cells. Nonetheless, HEK cells proofed sensitive to higher 
concentrations (>2.5µg/ml) of blasticidin and efficiently died within 4-5 days. 
As HEK 293 cells were able to grow at low blasticidin concentration, we first started selection 
for stable transfected cell lines at 15 µg/ml blasticidin in culture medium. In later experiments 
we raised the concentration up to 25µg/ml which turned out to be adequate to achieve fast and 
highly efficient selection. 
 
3.2.3 Stable RNAi 
With this basic knowledge, we started to select for pools of cells stably expressing either 
pJG111a, pJG112a, pJG113a, pJG114a, pJG116a, pJG118a+b, pJG119a+b, pJG120a+b or 
pJG121 (Table 3-3) in HEK 293 cells. These pools were examined for the expression levels of 
targeted proteins, by Western blot analyzis of cell lysates. As controls, we used pools of HEK 
293 cells, stably transfected with pJG121, targeting Firefly Luciferase (HEK 121). RNAi 
constructs encoded by plasmids pJG118a+b showed very high efficiency in knocking down 
LAP2α, which was also successfully targeted by pJG116a and pJG111a. As the knock-down 
effect varied significantly within these pools we decided to select for single HEK cell clones 
expressing plasmids pJG111a, pJG116a and pJG118a. We also generated stable transfected 
cell pools and single cell clones of HeLa cells expressing pJG118a, pJG113a and pJG121 
(HeLa 121) for control purpose. The selected single cell clones were again tested by Western 
blot analyzis of total cell lysates (Figure 3-8). 
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Figure 3-8: Stable RNAi single cell clones tested by Western blot. To obtain single cell clones, we first selected 
on transfected cells with Blasticidin to generate stable cell pools. Afterwards, we either picked single clones 
(HeLa), or achieved them by limited dilution (HEK). Protein levels of whole cell lysates of the single cell clones 
were compared with stable cell pools transfected with pJG121. Aliquots of cells marked with # were stored in 
liquid nitrogen. (a) HEK cells transfected with pJG111a targeting LAP2 common domain. Either LAP2α and 
LAP2ß were stained with ab12 (left panels), or LAP2α was stained with ab15/2, LAP2ß with ab16 and actin as 
loading control (right panels). (b) HEK cells transfected with pJG116a targeting LAP2α, which was stained with 
ab12, which also stained LAP2ß, shown as loading control. (c) Single cell clones of HEK 293 and HeLa cells 
transfected with pJG118a, targeting LAP2α, which was stained with ab 15/2. LAP2ß was used as loading control 
and was stained with ab 16. 
Clones indicated with an asterisk were used for further investigations. 
 
Several single cell clones expressing plasmid pJG111a were tested for LAP2α protein levels 
(Figure 3-8 (a), left panels). All clones showed reduced LAP2α levels compared to the control 
(HEK 121), whereas the amount of LAP2β remained constant. As pJG111a targets the LAP2 
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common domain we made further immunoblots of clones 1, 5 and 11 with specific antibodies 
to LAP2α, LAP2ß and actin as loading control (Figure 3-8 (a) right panels). All three single 
cell clones displayed reduced LAP2α protein levels. Considering the different amounts of 
loaded protein (compare actin lanes, right lower panel), LAP2ß was moderately affected by 
RNAi. 
Only some of the single cell clones expressing pJG116a functionally reduced LAP2α protein 
level (Figure 3-8 (b). 
The most efficient RNAi effect was achieved by expressing pJG118a (Figure 3-8 (c)). In 
several single cell clones LAP2α protein levels were hardly detectable. 
For further experiments, we chose single cell clones of plasmid pJG118a, notably clone 5 in 
HeLa cells (HeLa 118a/5) and clone 8 in HEK 293 cells (HEK 118a/8). HEK 293 and HeLa 
cell pools stably transfected with pJG121 (HEK 121 and HeLa 121),respectively, served as 
controls. First, the strong RNAi effect on LAP2α, shown by Western blot analyzes (Figure 3-
8 (c)), was confirmed by immunofluorescence (Figure 3-9). 
Four cell lines were separately plated on coverslips and processed for immunofluorescence. 
Confocal images showed a strong decrease in LAP2α fluorescence intensity in LAP2α RNAi 
clones versus control cells (Figure 3-9 (a)). For better demonstration of the silencing effect, 
we also co-cultivated HeLa 118a/5 with HeLa 121 control cells (Figure 3-9 (b)). A clear 
difference in the amount of LAP2α (left panel) became obvious between the LAP2α-RNAi 
cells (right side) and the control cells (left side). To test whether the residual LAP2α is 
distributed normally, we analyzed the same cells at higher detector sensitivity levels to make 
little protein levels detectable (right panel). Neither the shape of the nucleus nor the 
localization of remnant LAP2α seemed to be altered. 
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Figure 3-9: Confocal immunofluorescence images of LAP2α RNAi single cell clones stained for LAP2α 
compared to control cell lines. The cells were grown on polylysine coated coverslips and processed for 
immunofluorescence microscopy. LAP2α was stained with ab 245-2, DNA by Hoechst dye. (a) Single cell 
clones HEK 118a/8 and HeLa 118a/5 compared to HEK 121 and HeLa 121 control cell lines (b) LAP2α RNAi 
single cell clone HeLa 118a/5 co-cultivated with control cell line HeLa 121. The LAP2α image was made twice 
with altered detector sensitivity. Bars, 10µm. 
 
 
As we were able to generate single cell clones with strong downregulation of LAP2α, we 
were interested to determine the cellular phenotype. We analyzed nuclear integrity, cell cycle 
behaviour and the localization of LAP2α’s intranuclear binding partner lamin A/C in LAP2α 
deficient cells. 
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3.2.4. Reduced levels of LAP2α have no influence on nuclear integrity 
LAP2α has been described as a multifunctional protein, binding to BAF, DNA (Cai, M. et al., 
2001), lamins A/C, Rb (Markiewicz et al., 2002) and chromosomes (Vlcek et al., 1999). We 
wanted to see, if low levels of LAP2α might influence nuclear shape. 
We co-cultivated single cell clone HEK 118a/8 with mock transfected HEK 293 cells and 
performed immunofluorescence co-stainings for LAP2α, and an unaffected protein, the 
nuclear pore protein 62 (NUPp62), scaffold attachment factor SAF-A and LAP2β (Figure 3-
10). 
 
 
Figure 3-10: The nuclear integrity is not affected by LAP2α RNAi. HEK 118a/8 and mock transfected HEK 
cells were co-cultivated for two days and processed for immunofluorescence with ab 245-2 to stain LAP2α, ab 
NUP p62 for nuclearpore protein 62 (NUP p62), ab 16 for LAP2ß and ab K371 to stain scaffold attachment 
factor A (SAF-A). Confocal images are shown. Bars, 10µm. 
 
To distinguish HEK 118a/8 from mock transfected cells, we made use of GFP, which was 
only expressed by HEK 118a/8 (not shown). For better illustration, stainings were 
pseudocoloured. The three mock transfected cells (a) in the upper panel show normal LAP2α 
expression. In contrast, LAP2α was nearly absent in HEK 118a/8 cells (all the other cells). 
Nevertheless, localization and distribution of nuclear pore complexes remained unaffected, as 
can be seen by the rim staining of nuclear pore protein p62. Also LAP2β and SAF-A were 
unafacted. Similar stainings were performed for lamin A and emerin all revealing no 
irregularities of interphase nuclei with respect to shape and size. Moreover, the localization of 
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all tested proteins remained normal. Thus, the nuclear integrity seems unaffected by loss of 
LAP2α. 
 
3.2.5. Proliferation rate is increased by reduction of LAP2α levels 
Preliminary data indicated an involvement of LAP2α in cell cycle regulation: It has 
previously been shown that LAP2α−lamin A/C form a complex with the retinoblastoma 
protein (Rb) (Markiewicz et al., 2002), which regulates cell cycle progression in G1 phase. 
HeLa cells over-expressing LAP2α showed reduced cell proliferation compared to control 
cells (Dorner et al., 2006). To verify these data, we performed comparable growth rate 
experiments with the LAP2α RNAi single cell clones HeLa 118a/5 and HEK 118a/8 in 
comparison to the control cell lines HeLa 121 and HEK 121 (Figure 3-11). 
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Figure 3-11: Cumulative cell number of LAP2α RNAi cells compared to control cells. Identical numbers of cells 
of each type were seeded into 14 individual dishes and were grown in semi-conditioned medium for up to 7 
days. Each day the cells of two dishes were counted to determine cell numbers. [(a) 5x104 HeLa 118a/5 and 
HeLa 121 cells were grown in complete medium (10% FCS). (b) HeLa 118a/5 and HeLa 121 cells were stepwise 
adapted to low serum (0,5% FCS) conditions. Then an experiment as shown in (a) was started with 5x105 cells 
per plate. (c) Growth curves of HEK 118a/8 and HEK 121 in complete medium (10% FCS) were done. One 
experiment was started with 5x104 cells per plate (left panel), the other started with 2x105 cells per plate (right 
panel).] 
 
In brief, we plated identical numbers of cells on 14 dishes per cell type and grew them in 
semi-conditioned medium. Each day the cells of two plates were counted to obtain 
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proliferation kinetics over a period of seven days. HeLa cells with reduced LAP2α expression 
were growing faster than the control cells at normal serum conditions (Figure 3-11 (a)). The 
effect was even more pronounced under serum starvation (Figure 3-11 (b)). Interestingly, 
there was no proliferation effect in HEK cells cultivated in full serum (Figure 3-11 (c)). The 
reason for the absence of a proliferation effect could be the lack of mature lamin A/C in HEK 
cells (Figure 3-12). 
 
  
Figure 3-12: HEK 293 cells lack mature lamins A/C expression. Ponceau stain after PAGE and Western blot of 
HEK 121 control cell line and HeLa cells stable transfected with pJG120a. Lamin A/C was stained with McKeon 
l lysates of HEK 121 and HeLa cells stably transfected with pJG120a were used for 
munoblotting. The Ponceau stain of the blot membrane indicated that similar protein 
lear 
d the influence of reduced LAP2α protein 
antibody. 
 
Total cel
im
amounts were loaded, but Western blot showed strong lamin A/C bands only in HeLa cell 
lysates, while no lamin A and hardly any lamin C were detected in HEK 121 cell lysates. 
To analyze the cell cycle phenotype in more detail, we performed DNA FACS analysis of the 
four cell lines (Figure 3-13). Reduced levels of LAP2α however, did not result in c
changes in the number of G1 and S-phase cells. 
To sum up, these experiments confirmed the involvement of LAP2α - lamin A/C complexes 
in cell cycle regulation. Finally, we investigate
levels on lamin A/C localization during the cell cycle or on nuclear envelope reassembly. 
 
  
Figure 3-13: FACS analysis of HeLa 118a/5, HeLa 121, HEK 118a/8 and HEK 121. 
 
 
3.2.6. LAP2α and lamin A/C localization during cell cycle 
LAP2α was shown to dissociate from chromatin during NEBD and to relocalize to 
chromosomes during early stages of nuclear reassembly in late anaphase, before other nuclear 
envelope proteins like LAP2β, emerin or lamins accumulate around decondensing chromatin 
(Dechat et al., 2004). Therefore, LAP2α seems to be one of the first nucleoskeletal proteins, 
which associates with chromosomes during nuclear envelope reassembly. These findings 
suggest a pivotal role of LAP2α during very early stages of post-mitotic nuclear envelope 
reassembly. Furthermore, LAP2α is part of a complex with lamin A/C and Rb (Markiewicz et 
al., 2002). We wanted to see if markedly reduced amounts of LAP2α due to RNAi exert an 
influence on nuclear envelope reformation, or cellular distribution of lamin A/C. 
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3.2.6.1. wt-localization of LAP2α and lamin A/C during cell cycle 
The wt-situation was illustrated by analyzing HeLa 121 control cells at differnet cell cycle 
stages in confocal immunofluorescence microscopy. We could confirm the typical LAP2α 
localization in this cell line throughout the whole cell cycle (Figure 3-14 (a-e)). 
 
HeLa 121; antibody McKeon to lamin A/C 
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HeLa 121; antibody 2H10 to lamin A/C 
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HeLa 121; antibody 133A2 to lamin A 
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HeLa 121; antibody C-20 to pre-lamin A 
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HeLa 121; antibody 16 to LAP2β 
Figure 3-14: LAP2α, lamin A/C and LAP2ß localization throughout cell cycle in HeLa 121 control cells. The 
cells expressing shRNA targeting Firefly Luciferase, were processed for immunofluorescence microscopy using 
antibody 245-2 to LAP2 and Hoechst dye to stain DNA. The co-stainings were done with: (a) McKeon antibody 
to lamin A/C, (b) lamin A/C antibody 2H10, (c) lamin A antibody 133A2 (d) pre-lamin A antibody C20 (e) 
Antibody 16 to stain LAP2ß. Confocal images are shown. Bars, 10µm. 
 
During interphase LAP2α is nucleoplasmic excluding the nucleoli. In metaphase most of it 
becomes cytoplasmic, excluding condensing chromosomes (Dechat et al., 2004). Interestingly 
LAP2α starts to associate with telomeres in anaphase, followed by its accumulation in two 
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 ‘core’ structures on chromatin adjacent to the spindle in telophase. During cytokinesis, 
LAP2α started to accumulate in the nucleoplasm, where it remained throughout interphase. 
As lamins A/C are binding partners of LAP2α (Dechat et al., 2000), we analyzed there 
localization during mitosis and post-mitotic nuclear reassembly by immunofluorescence 
microscopy. Different mitotic stages were identified by LAP2α localization, which was 
identical in HeLa 121 and wt cells. Thus, we compared immunofluorescence images using 
different antibodies to decorate either lamin A/C (McKeon, 2H10), exclusively lamin A 
(133A2), or pre-lamin A. LAP2β was used as a control to stain the NE (Figure 3-14). Since 
the antibodies to lamins A/C stained differently, a reference picture for the respective 
antibodies was generated in HeLa 121 control cells: 
• McKeon antibody stains nucleoplasmic lamins A/C in interphase in proliferating cells 
(Figure 3-14 (a)). Similar to LAP2α the nucleoli were excluded, but in the merged 
image of LAP2α and lamin A/C, a narrow rim staining became visible, suggesting that 
this antibody also decorates lamin A/C underneath the inner nuclear membrane. In 
meta- and anaphase lamin A/C was cytoplasmic, excluding the condensed 
chromosomes and only partial spatial overlap with core structures was detected. At the 
end of telophase or during cytokinesis, lamin A/C was translocated to the nuclear 
interior. 
• Antibody 2H10 to lamin A/C labelled large intranuclear speckles or foci in interphase 
cells (Figure 3-14 (b)). These speckles have been shown to colocalize with RNA 
splicing factors (Jagatheesan et al., 1999). During meta- and anaphase ab 2H10 also 
showed a cytoplasmic localization of lamins A/C excluding the condensed 
chromosomes. Surprisingly this ab showed only weak nucleoplasmic staining of 
lamins A/C at the end of cytokinesis and still strong cytoplasmic localization. 
Drawback of ab 2H10 is that it is not exclusively decorating lamins A/C but also other 
nuclear proteins that have not been identified yet (Vecerova et al., 2004). 
• Antibody 133A2 stained a rim at the nuclear periphery in interphase cells (Figure 3-14 
(c)). As suspected this antibody recognized lamin A in the cytoplasm during anaphase, 
excluding the condensed chromosomes. Lamin A stained by 133A2 started to 
concentrate on the chromosomes during early telophase. 
• The last lamin antibody we tested was C20, labeling pre-lamin A (Figure 3-14 (d)). 
We observed two different stainings in interphase cells: An exclusively diffuse 
cytoplasmic staining was detectable as well as cells which displayed a significant 
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• Finally, we performed co-stainings of LAP2α and LAP2β (Figure 3-14 (e)). As 
LAP2β is anchored within the inner nuclear membrane, we observed a pronounced 
rim pattern in interphase cells, together with a weak intranuclear staining. In 
metaphase, LAP2β was cytoplasmic, excluding the condensing chromosomes. During 
late anaphase, LAP2α first locates to the telomeres, before it forms core structures, 
whereas LAP2β lines up at the periphery and the outer core region of the chromatin 
(Dechat et al., 2004). At this stage labelling of the two proteins showed a partial 
overlap at the outer core region and the periphery. In late telophase and during 
cytokinesis, both isoforms LAP2α and LAP2β enclosed decondensing chromatin. 
To summarize, we tested three lamin A antibodies in immunofluorescence and observed three 
different inner nuclear stainings in interphase cells. An even nucleoplasmic distribution of 
lamin A/C detected with McKeon antibody, a characteristic speckled pattern of lamin A/C by 
antibody 2H10, or a rim staining of the nuclear lamina underlying the inner nuclear membrane 
by lamin A antibody 133A2. During meta- and anaphase they all showed cytoplasmic 
localization of lamin A, excluding the condensed chromosomes, but they stained different 
structures of lamin A in reassembling nuclei. 
These extensive localization studies in HeLa 121 control cells confirmed former results of 
LAP2α, lamin A/C and LAP2β and interesting antibody-specific differences became evident. 
 
3.2.6.2. Reduced levels of LAP2α does not alter its cellular localization 
We next investigated the distribution of remnant LAP2α in HeLa 118a/5 cells during the cell 
cycle (Figure 3-15). For better visualisation of low levels of LAP2α, laser excitation energy 
and detector sensitivity were increased. Thus, we got strong cytoplasmic background during 
nuclear reassembly, which was not seen under normal conditions. 
There was no obvious difference to LAP2α stainings in control cells. The protein was 
cytcoplasmic until anaphase, when it started to translocate to the tips of chromosome ends and 
the inner core region, directly followed by additional localization to the outer core structure. 
While wt-HeLa interphase cells showed uniform diffuse distribution of LAP2α throughout 
the nucleoplasm, in HeLa 118a/5 LAP2α appeared in a grainy, spotted staining pattern. 
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Figure 3-15: LAP2α distribution during cell cycle in HeLa 118a/5 LAP2α RNAi cells. Cells were processed for 
immunofluorescence with ab 245-2 to LAP2α and Hoechst dye to stain DNA. Confocal images are shown. Bar, 
10µm. Note that LAP2α RNAi immunofluorescence images were overexposed to detect the fluorescence signal. 
 
 
3.2.6.3. LAP2α RNAi does not affect lamin A/C localization 
LAP2α is thought to cooperate with lamin A/C in anchoring Rb within the nucleus 
(Markiewicz et al., 2002). We analyzed possible implications of LAP2α RNAi on lamin A/C 
localization. We compared LAP2α / lamin A/C confocal immunofluorescence co-stainings in 
HeLa 121 and HeLa 118a/5 cells (Figure 3-16). 
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Antibodies McKeon to lamin A/C (red) and 245-2 to LAP2α (green) 
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Antibodies C-20 to pre-lamin A (red) and 245-2 to LAP2α (green) 
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Antibodies 2H10 to lamin A/C (red) and 245-2 to LAP2α (green) 
Figure 3-16: Comparison of LAP2α (green) and lamin A (red) localization of HeLa 118a/5 and HeLa 121 cells 
during cell cycle. Cells were processed for immunofluorescence with ab 245-2 to LAP2α, McKeon ab to lamins 
A/C (a), pre-lamin A ab C20 (b), lamins A/C ab 2H10 (c) and Hoechst dye to stain DNA. Confocal images are 
shown with two detector sensitivities for LAP2α RNAi cells. Bars, 10µm. 
 
As shown before, HeLa 121 and HeLa 118a/5 cells showed normal LAP2α stainings, which 
we used for the identification of the different cell cycle stages. 
• McKeon antibody yielded a uniform intranuclear lamin A/C pattern in HeLa 118a/5 
interphase cells, as well as a lamin A/C redistribution during cell division 
indistinguishable of control cells (Figure 3-16 (a)). 
• Pre-lamin A was cytoplasmic from metaphase to cytokinesis and partially 
nucleoplasmic in interphase cells, like in the control (Figure 3-16 (b)). 
• Similarly, lamin A/C antibody 2H10 labeled large intranuclear speckles in interphase 
cells and the typical mitotic staining pattern seen in control (Figure3-16 (c)). 
Thus, neither in interphase, nor in mitotic stages, we were able to detect any difference of 
lamin A localization between HeLa 118a/5 and HeLa 121 cell lines. Therefore, we focused on 
a short time period after M-phase, to determine whether reduced levels of LAP2α influence 
lamin A/C relocation to the nucleus. Three different lamin A/C antibodies (stainings a, b, c) 
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 were used to co-stain lamin A/C and LAP2α at three time points with defined 
LAP2α distribution in HeLa 121 control cells (Figure 3-17). 
• The first time point (Figure 3-17 left panel column) shows a strong rim staining of 
LAP2α, during early redistribution to the nuclear interior. 
• The second time point (Figure 3-17 middle panel column) depicts LAP2α nearly 
completely translocated to the nucleoplasm, with only a weak rim staining remaining 
at the reassembling nuclear envelope. 
• The third time point (Figure 3-17 right panel column) indicates even distribution of 
LAP2α in the nucleoplasm during interphase. 
Lamin A staining of these cells with the three different antibodies revealed the following. 
a) Antibody 2H10 (Figure 3-17 (a)), showed lamin A/C relocation to the nucleus after 
cytokinesis, shortly after LAP2α started to dissociate from the rim to the nuclear interior. As 
soon as subfractions of lamin A/C were detectable in the nucleoplasm, they concentrated to 
speckles, characteristic for this antibody in interphase. 
b) In the case of McKeon antibody (Figure 3-17 (b)), we were not able to detect initial stages 
of lamin A/C relocation. Most lamin A/C was already redistributed to the nuclear interior, 
when LAP2α was only partially translocated from the rim into the nucleus. 
c) Antibody 133A2 (Figure 3-17 (c)), revealed lamin A evenly distributed throughout the cell, 
when LAP2α started to relocate from the rim to the nucleus. We observed a dispersed nuclear 
staining of lamin A, when LAP2α was nearly completely translocated to the nuclear interior, 
but the rim staining, typical for lamin A antibody 133A2 in interphase cells, had not formed 
yet. 
Thus the three antibodies (2H10, McKeon, 133A2) detect differnt lamin A pools, which 
varied not only in their localization during interphase but showed also different redistribution 
kinetics to the nuclear interior during cytokinesis. 
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Figure 3-17: Lamin A during the formation of the nuclear envelope in HeLa 121 control cells. Cells were 
processed for immunofluorescence with ab 245-2 to LAP2α, lamin A ab 2H10 (a), McKeon ab to lamin A (b) 
and lamin A antibody 133A2 (c). Confocal images are shown. Bar, 10µm. 
 
 
We next took a closer look at LAP2α / lamin A/C redistribution from telophase to interphase 
in LAP2α-deficient HeLa 118a/5 cells (labeled with McKeon antibody to lamin A/C) (Figure 
3-18). 
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 While LAP2α localized to chromosome tips and core structures during telophase, lamin A/C 
was still evenly distributed in the cytoplasm (upper panels). When cytokinesis had already 
started (second row of panels), lamin A/C was still exclusively cytoplasmic. However, at the 
end of cytokinesis, most of lamin A/C was concentrated inside the reassembling nucleus 
(panels of row 3 and 4). The lowest panels show lamin A/C completely inside the nucleus, 
even before LAP2α was totally translocated to the nucleoplasm. 
 
 
Figure 3-18: LAP2α and lamin A during formation of the nuclear envelope in HeLa 118a/5 RNAi cells. LAP2α 
RNAi cells were processed for immunofluorescence with ab 245-2 to LAP2α, McKeon ab to lamin A and 
Hoechst dye to stain DNA. Confocal images are shown. Bar, 10µm. Note that LAP2α RNAi 
immunofluorescence images were overexposed to detect fluorescence signals. 
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Since the kinetics of lamin A redistribution during mitosis did not significantly change upon 
LAP2α downregulation, we have to conclude that LAP2α is not required for lamin A 
localization (as suggested previously) or that the remaining LAP2α in LAP2α-downregulated 
cells is sufficient to regulate lamin A kinetics. 
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4. DISCUSSION 
 
4.1. Discussion of the Triple-RNAi-Vector system 
RNAi based gene silencing has revolutionized biological research as it is an efficient tool for 
functional protein analysis. The advantages of RNAi are that it is a fast, cheap and also 
versatile technique, as it can be used in several cell types as well as in vivo. Therefore RNAi 
can be a competing alternative to transgenic or knock out mice. One problem of functional 
protein studies in general is the functional redundancy of different groups of proteins, or the 
existence of alternative pathways transducing the same extracellular signal. As a result, 
revealing the function of a protein may require inhibition of several proteins activities. 
Therefore, an important potential application for RNAi is the simultaneous inhibition of 
multiple genes. In this study we established a vector based RNAi system, which allows to 
simultaneously knock down up to three target mRNAs to meet this challenge. So far the 
system proved highly efficient on three ectopically expressed reporters in HEK 293 cells. 
The latest effort to knock down multiple genes at once is based on combining RNAi-cassettes, 
each consisting of a human U6 promoter and encoding an shRNA, by classical cloning. (Jazag 
et al., 2005). This system proposed a hypothetical limit of >30 RNA-cassettes dependent on 
the saturation level of the RNAi machinery and stable transfection via a co-expressed 
selection marker. Compared to the presented Triple-RNAi-Vector, this system proposes an 
optional number of RNAi constructs within one vector combined with higher labour efforts 
and less variability in expression vector properties. 
Genome-wide loss-of-function analysis (reviewed in Mittal, 2004; Hannon and Rossi, 2004) 
by RNAi libraries are a powerful technology especially for easily detectable phenotypes, such 
as apoptosis. Nonetheless this technique bears several limitations: First, insufficient silencing 
creates false negative results of for example 10-30% in C. elegans (Simmer et al., 2003). 
Second, experimental variability in the efficiency of RNAi makes detailed functionally 
analysis difficult. We realised these differences for example between pCM3 and pCM8. Both 
encode the same RNAi constructs against Firefly and Renilla Luciferases, but the efficiency 
of silencing varied noticeably. Third, unspecific side effects due to high siRNA 
concentrations could cause false phenotypes. 
The Triple-RNAi-Vector system is based on human U6 promoter driven shRNA expression in 
mammalian cells. It makes use of the MultiSite GatewayTM technology which allows fast 
shuttling of three RNAi-cassettes from respective Entry vectors into one Destination vector. 
This feature makes the Triple-RNAi-Vector highly flexible in combining two or three 
arbitrary RNAi-cassettes within one plasmid. Furthermore, the properties of the expression 
vector are variable by making the plasmid of choice as a MultiSite GatewayTM Destination 
vector. To summarise, the Triple-RNAi-Vector system provides highly flexible, fast and 
cheap knockdown of up to three genes in mammalian cells and is therefore an ideal tool for 
detailed functional analysis of proteins and protein complexes. 
 
Future prospects 
Which type of endogenous proteins are potential targets? 
General considerations on attributes of potential target proteins lead to the conclusion that 
their half-lives should not be too long. This is because our vector mediates transient gene 
silencing, which is most pronounced from second to fourth day post transfection. A long half-
live of target proteins would weaken the observed silencing effect, because already existing 
proteins are not affected by RNAi. Furthermore, the lifespan of the two, or three targeted 
proteins should be about the same length, to obtain the silencing effect at the same time. 
Proteins with longer half-lives can be silenced by stable transfection, therefore another 
MultiSite GatewayTM compatible Destination vector encoding a selection marker has to be 
chosen. 
 
What will happen, if one targets three RNAi constructs at one gene? 
This interesting question remains to be answered. Several possibilities are supposable: First, 
the RNAi induced silencing effect could be additive and thereby especially effective. Second, 
the RISC complexes could sterically inhibit each other if the target sequences were chosen to 
near to each other, so that no increased silencing will be observed compared to only one 
RNAi construct targeting the same gene. Third, the capacity of the RNAi machinery could be 
saturated and for this reason lose efficiency. Contrary evidence for this hypothesis comes 
from our preliminary data, that the efficiency of the Triple-RNAi-Vector pCM3 was not 
affected. Other studies using multiple knockdowns also did not reach the limits of the cellular 
RNAi machinery (Yu et al., 2003; Jazag et al., 2005). Furthermore, overloading the RNAi 
machinery may compromise the regulatory function of cellular miRNAs, leading to unspecific 
side effects. Finally, working at high enzyme (RISC) to substrate (mRNA) ratios is likely to 
affect the enzyme’s specificity and could not only increase silencing of the targeted gene but 
also result in unspecific silencing (Bridge et al., 2003; Hannon and Rossi, 2004). Rescue 
experiments can be used to ensure the specificity of an observed effect. 
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 4.2. Discussion of functional LAP2α analysis 
In this study we wanted to reveal a functional implication of LAP2α on cell cycle control and 
post-mitotic nuclear reassembly. Therefore, we transiently and stably knocked down LAP2α 
by RNAi. Reduced levels of LAP2α increased cell proliferation in HeLa cells especially 
under serum starvation conditions, an effect we could not observe in HEK cells. Furthermore, 
we could not make out an effect of decreased LAP2α levels on nuclear reassembly. 
 
What are the advantages of stable versus transient RNAi? 
To determine whether our RNAi constructs were functional or not we tested several 
constructs by transient transfection of mammalian cells. 48h after transfection we performed 
immunoblots of total cell lysates and monitored differences in target protein level. In most 
cases we were not able to realise a clear decrease in protein quantity. In cell lysates of stably 
transfected cells the knockdown effect of RNAi was obviously more pronounced. There are 
three reasons for this effect: 
• transfection efficiency 
• RNAi efficiency 
• protein stability 
For example, a transfection efficiency of 40% paired with 50% of RNAi efficiency ended up 
in a reduction of only 20% of target protein level in total cell lysates of transient transfections. 
Proteins with long half lives are even less affected. In stably transfected cells, the effect of 
transfection efficiency is excluded and the variability of RNAi efficiency can be eliminated by 
single cell cloning. Consequently, RNAi efficiency depends on protein stability, if only 
threshold levels of target protein remain due to single cell cloning. 
 
How does LAP2α influence cell cycle control? 
It has been shown that LAP2α together with lamin A/C plays an important role in nuclear 
anchorage of hypophosphorylated retinoblastoma protein (pRb) (Markiewicz et al., 2002). 
One function of pRb is to control cell cycle progression in G1-S phase transition by 
negatively regulating the transcription factor E2F in a phosphorylation dependent manner 
(Chellappan et al., 1991, Classon and Harlow, 2002). Our data of increased cell proliferation 
due to decreased LAP2α levels fit to the hypothesis that LAP2α influences cell cycle control 
via E2F activity in an Rb mediated manner. Furthermore, over-expression studies of LAP2α 
caused a reduction of cell proliferation in HeLa cells (unpublished data, Andreas Gajewski).  
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An explanation for the even more increased cell proliferation rate under serum starvation 
conditions in HeLa cells is that LAP2α is downregulated when nutrients become scarce in 
HeLa cells (unpublished data, Nana Naetar). These observations suggest that LAP2α protein 
levels in LAP2α RNAi single cell clones could be further reduced upon serum starvation and 
thereby pronounce the effect of increased proliferation rates. In line with this suggestion, it 
has been shown that hypophosphorylated Rb is not anchored in the nucleus in primary skin 
fibroblasts due to reduced levels of LAP2α under shortage of nutrients (Markiewicz et al., 
2002) 
LAP2α RNAi did not cause a cell cycle effect in HEK cells. We propose that a complex of 
LAP2α, lamin A/C and Rb is required for inhibiting E2F activity. Lamins A/C are expressed 
in a differentiation dependent manner. We found that both are expressed at the mRNA level in 
HEK cells, but only lamin C seems to get correctly processed to mature proteins. This implies 
that the proposed hetero-trimeric complex is not functional in HEK cells. Supporting this idea, 
co-expression of lamin A and LAP2α in HEK cells reduced endogenous E2F activity by 20-
30% (unpublished data, Daniela Dorner). 
Furthermore it has been shown that lamins A/C are essential for proper pRb localization 
(Marciewicz et al., 2002; Johnson et al., 2004) and proteasomal degradation of pRb was found 
increased in Lmna -/- cells (Johnson et al., 2004). 
Based on the data known so far, we suggest that nucleoplasmic complexes of LAP2α and 
lamins A/C anchor hypophosphorylated pRb to the nucleus in a phosphorylation dependent 
manner, where it represses E2F activity. 
 
What is the role of LAP2α in post-mitotic nuclear reassembly? 
Previous results indicated that LAP2α is among the first lamina proteins in post-mitotic 
nuclear reassembly (Dechat et al., 2004). The unique C-terminus is essential and sufficient for 
early association of LAP2α on telomeres of lagging chromosomes during anaphase, followed 
by further concentration to core structures adjacent to the midspindle and spindle poles (Vlcek 
et al., 1999; Dechat et al., 2004). Interestingly, BAF, which localizes to the entire chromatin 
and to the cytoplasm in metaphase, also localizes to telomeric structures before it accumulates 
at core structures together with LAP2α. Slightly afterwards a small subfraction of lamin C, 
emerin and a small amount of LAP2β relocalize to the core region (Dechat et al., 2004). In 
vitro nuclear assembly studies have previously shown that C-terminal LAP2α fragments bind 
to chromatin, but not to BAF, and inhibit chromatin decondensation as well as assembly of 
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 nuclear membranes and lamin A/C around chromatin (Vlcek et al., 2002). These data indicate 
an important role of LAP2α in post-mitotic nuclear reassembly. On the one hand LAP2α 
together with BAF may be involved in chromatin organization during decondensation. On the 
other hand LAP2α could target other lamina proteins to the chromatin, or directly interact 
with DNA via its LEM-like domain. As lamins A/C are important nuclear binding partners of 
LAP2α, we wanted to determine a potential role of LAP2α in targeting lamins A/C to the 
nucleus during early stages of nuclear reassembly. Therefore, we performed co-localization 
studies of these two proteins in LAP2α RNAi cells. Our data show that reduced levels of 
LAP2α were sufficient for proper post-mitotic nuclear reassembly and had no obvious effect 
on nuclear shape or lamin A/C localization. According to these results overexpression of the 
clinical relevant mutated LAP2α, which showed less binding affinity to lamins A/C in vitro 
(Tayler et al., 2005), did not alter lamin A/C localization. Either low levels of LAP2α are 
sufficient to target lamin A/C to the post-mitotic nucleus, or this is the function of another 
binding partner of lamin A/C. 
Conclusively, very small amounts of LAP2α are essential and sufficient for its role in nuclear 
reassembly. Perhaps LAP2α together with an N-terminal binding partner, evidence for this 
comes from ectopic expression of LAP2α fragments (Vlcek et al., 2002), fulfills the function, 
which still has to be determined, during nuclear reassembly. 
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5. MATERIALS AND METHODS 
 
5.1. Cell biology 
5.1.1. Cell Culture 
In the present study the human epithelial cervix carcinoma cell line HeLa, the human 
embryonic kidney cell line HEK 293 and the mouse fibroblast cell line 3T3 F442A were used. 
Cells were routinely maintained in DMEM (Dulbecco’s modified Eagle’s Medium) 
supplemented with 10% fetal calf serum (FCS), 2mM glutamine, 50U/ml penicillin and 
50μg/ml streptomycin (all from Gibco-Invitrogen, Carlsbad, CA, USA) at 37°C in a 
humidified atmosphere containing 8.5% CO2. Confluent cells were split according to the 
following protocol: Cells were washed once with PBS, pH 7.4, (Gibco-Invitrogen, Carlsbad, 
CA, USA) and incubated with 0.5ml trypsin-EDTA / 10cm dish (Nunc, Roskilde, Denmark) 
(0.25% trypsin + 0.5M EDTA in PBS) for 1-5 minutes at 37°C to detach cells from the plastic 
surfaces. The cell suspension was resuspended in 4.5ml of culture medium and the respective 
volume of cell suspension (split ratio 1:3 - 1: 20) was seeded into new cell culture dishes 
containing culture medium (e.g. 10ml for 10cm dishes). 
For freezing, the trypsinized cells were supplemented with 9.5ml culture medium and 
centrifuged for 3 minutes at 110g (800rpm) in a Heraeus centrifuge (Megafuge 1.0). The cell 
pellet was resuspended in FCS containing 10% dimethylsulfoxide (DMSO; Fluka, Buchs, 
Switzerland). Cells were transferred to a cryo tube (Nunc, Roskilde, Denmark) and were 
slowly cooled down to -80°C in a polystyrene box. For long-term storage cells were 
transferred to liquid nitrogen containers. 
For thawing, frozen cells were incubated at 37°C in a water bath. Thawed cells were 
transferred to a Falcon tube containing 10ml of culture medium and centrifuged for 3 minutes 
at 110g (800rpm) to remove residual DMSO followed by resuspension in 5-10ml of fresh 
culture medium to remove residual DMSO. The cell suspension was transferred to a new 6cm 
or 10cm cell culture dish and incubated at 37°C. 
 
5.1.2. Transfection of HeLa and HEK 293 cells with lipofectamine 2000 
For transfection, HeLa cells or HEK 293 cells were seeded in culture medium without 
antibiotics and grown to a confluency of 90-95%. In the case of 6-well plates, in total 4μg of 
plasmid DNA were diluted in 250μl of Opti-MEM medium (Gibco-Invitrogen, Carlsbad, CA, 
USA). If the cells were transfected with more than one plasmid, the amount of DNA was 
 distributed asymmetrically (e.g. 2µg RNAi vector; 4x0.5µg different reporter plasmids). In 
addition, 10μl of lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) were diluted in 250μl 
of Opti-MEM medium and incubated for 5 minutes at room temperature. The two dilutions 
were combined, mixed gently and incubated for 20 minutes at room temperature. Cells were 
washed once with PBS and covered with 2ml of antibiotic-free culture medium, containing 
2% FCS. The lipofectamine-DNA mix was added to the cells while rocking them gently back 
and forth for mixing. After 3-5h incubation at 37°C, transfection medium was replaced by 
fresh antibiotic-free culture medium containing 10% FCS. After incubating the cells for 15-
24h at 37°C they reached confluency and were replated into larger culture dishes. For 
immunofluorescence microscopy (see 5.2.3.) the cells were initially seeded on poly-L-lysine 
(Sigma-Aldrich, St. Louis, Mo, USA) coated glass coverslips (Christine Gröpl, Tulln, 
Austria) prior transfection. 48h after transfection, the samples were either processed for 
biochemical protein analyses (Western blot (see 5.2.2.), reporter assays (see 5.2.4.)) or 
immunofluorescence microscopy (see 5.2.3.). 
 
5.1.3. Cell lines stably expressing shRNA constructs 
The plasmids pJG111, pJG112, pJG113, pJG114, pJG116, pJG118, pJG119, pJG120 and 
pJG121 (see Table 5-5 for sh-oligonucleotides or 5.4.6. for cloning strategy) were chosen for 
stable expression of shRNA constructs in HEK 293 and HeLa cells. As control we used the 
pRi 6-1 plasmid, a pTracer with a human U6 promoter, but without an RNAi construct. These 
vectors express a GFP-Blasticidin resistance chimera gene for selection purpose. 
One day after transfection (see 5.1.2.), the cells were split and seeded at about 10% 
confluency in DMEM selection medium (+ 10% FCS, + 25µg/ml Blasticidin; Invitrogen, 
Carlsbad, CA, USA). At least half of the medium was exchanged every second day during 
selection. To passage the stably transfected cells, a Blasticidin concentration of 10µg/ml has 
proven to be sufficient. 
 
5.1.4. Single cell clones 
Stably transfected cell pools (see 5.1.3) were tested by Western Blot (see 5.2.2). Single cell 
clones were generated out of those cell pools (see below), which showed a strong RNAi 
effect. The single cell clones were named by the cell type, the number of the plasmid with 
which the cells were transfected and the number of the obtained clone (e.g. HeLa 118/5). 
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5.1.4.1. Limited dilution 
HEK 293 cells of stable transfected cell pools (see 5.1.2.), expressing one of the following 
plasmids - pJG111, pJG116, pJG118 - were chosen to obtain single cell clones by limited 
dilution. 
The cells were trypsinized (see 5.1.1.) and two aliquots per plate were counted three times 
each with a Coulter Counter Z2. In several steps we diluted the cell suspension to two 
different concentrations of 1 cell/ml and 2.5 cells/ml DMEM supplemented with 10µg/ml 
Blasticidin (Invitrogen, Carlsbad, CA, USA) and 10% FCS. These suspensions were 
transferred to 96-well plates, 200µl per well, by the means of a multichannel pipette 
(Eppendorf Research pro). After 7 – 10 days the single cell clones were transferred to larger 
dishes and tested by Western blot (see 5.2.2.). 
 
5.1.4.2. Isolating individual cell colonies 
Single cell clones can also be obtained by isolating individual cell colonies. This technique 
was performed with HeLa cells, expressing either pJG113 or pJG118. 
During the selection period for stable transfected cells (see 5.1.3.), resistant cells grew in 
small colonies, could be isolated with the help of cloning cylinders. First we selected colonies 
under the microscope and marked their positions on the culture dish. The cloning cylinders 
were placed on the nearly dry culture dish, surrounding the marked cells colonies. These were 
detached with 10µl of trypsin-EDTA inside the cylinders and resuspended in additional 30µl 
of culture medium, supplemented with 10µg/ml Blasticidin (Invitrogen, Carlsbad, CA, USA). 
5µl of these cell suspensions were diluted into 100µl of medium per 96-well. After several 
days the cell clones were transferred to larger dishes and tested by Western blot (see 5.2.2.). 
 
5.1.5. Growth rate experiments 
LAP2α overexpression experiments showed an inhibitory influence of LAP2α on cell cycle. 
To affirm these results, we performed growth rate experiments with LAP2α RNAi single cell 
clones (HeLa 118/5 and HEK 118/8; see 5.1.4). As control, we used cell pools of the same 
cell type, stably transfected with pJG121 (see 5.1.3). 
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 5.1.5.1. Growth rate at full serum 
On day zero 5x104 HEK 293 or HeLa cells were seeded on each of the fourteen 10cm culture 
dishes per experiment. Every 24h the cells of two dishes were trypsinized (see 5.1.1.) and the 
cell number was determined by counting two aliquots per plate, three times each, with a 
Coulter Z2. Throughout the experiment cells were grown in semi-conditioned medium, which 
was adjusted every day. 
 
5.1.5.2. Growth rate of serum starved cells 
Using a step by step procedure HeLa cells were adapted to low serum growth conditions by 
reducing FCS down to 2% over a period of two days, followed by reduction to 0.5% FCS for 
another 20h. 5x105 of these cells were seeded on each of the fourteen 10cm dishes. The 
following seven days cells were counted and culture medium supplemented with 0.5% FCS 
was adjusted as described above (see 5.1.5.1). 
 
 
 
5.2. Biochemistry and Immunology 
 
5.2.1. Preparation of total cell lysates for Western blot analyses 
To prepare total cell lysates, proliferating cells were trypsinized (see 5.1.1.) and supplemented 
with culture medium, followed by 3 minutes of centrifugation at 110g (800rpm) in a Heraeus 
centrifuge (Megafuge 1.0). The pellet was washed twice in PBS with additional 0.5mM 
MgCl2 and 0.1mM CaCl2. The pellet was resuspended in a small volume of ice-cold 
hypotonic buffer (10µl / 105 cells) and incubated for 10 minutes on ice. Subsequently the 
same volume of 3x SDS PAGE sample buffer was added and the lysate was heated for 5 
minutes at 95°C. The samples were frozen in liquid nitrogen and stored at -20°C. 
 
Solutions: Hypotonic buffer  10mM HEPES pH 7.4 
      10mM NaCl 
      5mM MgCl2 
      1x Complete EDTA-free protease inhibitor 
cocktail (added freshly; Roche, Basel, 
Switzerland) 
 
3x SDS PAGE sample 186mM Tris-HCl pH 6.8 
  buffer    30% Glycerol 
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      6% SDS 
      300mM DTT 
      0.1% Bromphenol blue 
 
5.2.2. SDS PAGE and Western blot analyses 
For electrophoretic separation of proteins on SDS polyacrylamide gels, the discontinuous 
buffer system (Laemmli 1970) was used. According to the size of the proteins, resolving gels 
with different concentrations of acrylamide/bisacrylamide were prepared and overlaid with 
4% stacking gels (see Table 5-1). 
 
 Resolving gel 
(4 gels) 
Stacking gel 
(4 gels) 
Concentration of monomer 6.25% 7.5% 10% 12.5% 15% 4% 
acrylamide/bisacrylamide 3.75ml 4.5ml 6ml 7.5ml 9ml 1ml 
dH2O 9.75ml 9ml 7.5ml 6ml 4.5ml 4ml 
Resolving gel buffer 4.5ml 4.5ml 4.5ml 4.5ml 4.5ml -- 
Stacking gel buffer -- -- -- -- -- 1.67ml 
10% Ammonium persulfate 120μl 120μl 120μl 120μl 120μl 47μl 
TEMED 12μl 12μl 12μl 12μl 12μl 8μl 
Table 5-1: Composition of resolving and stacking gels for SDS PAGE 
 
 
Solutions: Acrylamide/   Acrylamide M-Bis 
  Bisacrylamide   30% Stock solution 
      for 3% crosslinked acrylamide gels 
 
Resolving gel   1.5M Tris-HCl pH 8.8 
  buffer    0.4% SDS 
 
Stacking gel   0.5M Tris-HCl pH 6.8 
  buffer    0.4% SDS 
 
 
Protein samples in 1x SDS PAGE sample buffer were incubated at 95°C for 5 minutes and 5-
15μl were loaded on the gels. For exact size calculation 3-10μl of precision plus protein 
standard (all blue or unstained; Bio-Rad, Hercules, CA, USA) were loaded in a separate lane. 
Electrophoretic separation of proteins was performed at 12-30mA per gel in 1xSDS PAGE 
buffer using the Mini Protean III gel electrophoresis system (Bio-Rad, Hercules, CA, USA). 
After separation of proteins, gels were either directly stained in Coomassie solution for 1h, 
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 washed with dH2O, destained in 10% acetic acid over night and again washed with dH2O or 
were used for immunoblot analysis. 
For immunoblot analysis, proteins were blotted at 400mA for 1h onto a nitrocellulose 
membrane (pore size 0.2μm; Schleicher&Schuell, Dassel, Germany) in 1x blot buffer using 
the Mini Trans-blot electrophoretic transfer system from Bio-Rad (Hercules, CA, USA). A 
positive replica for better evaluation was prepared according to Gotzmann and Gerner, 2000. 
Membranes were shortly incubated in ponceau solution to stain the protein bands. The 
background was cleared by washing in dH2O. A positive replica of the Ponceau stained 
nitrocellulose was created by simply placing it protein-side up on a sheet of already fixed and 
developed photo paper. Subsequently the membrane was destained in dH2O with some drops 
of NaOH. To prevent unspecific binding of antibodies, membranes were blocked in 5% 
gelatine in TBS (at least 10ml per blot) for 1h at room temperature or over night at 4°C. After 
washing twice with TBS, membranes were incubated for one hour at room temperature or 
over night at 4°C with primary antibodies or antisera diluted in PBST (for dilutions see Table 
5-2). Membranes were washed with TBS, TBS high salt and TBS, followed by incubation for 
one hour at room temperature with either alkaline phosphatase (AP)- or horseradish 
peroxidase (HRP)-coupled secondary antibodies (for dilution see Table 5-3). After washing 3 
times with TBS or TBS high salt, membranes were incubated in AP staining solution until 
appearance of bands or in case of HRP-coupled secondary antibodies in lumino 
enhancer/peroxidase solution (1:1) using the SuperSignal ECL detection system (Pierce, 
Rockford, IL, USA). The membranes were exposed to X-ray films (Kodak X-omat LS or 
BioMax MR / Light; Kodak, Rochester, NY, USA) for suitable times until the detection of 
bands. 
 
Solutions: 3x SDS PAGE sample 186mM Tris-HCl pH 6.8 
  buffer    30% Glycerol 
      6% SDS 
      300mM DTT 
      0.1% Bromphenol blue 
 
1x SDS PAGE buffer  25mM Tris-HCl pH 8.3 
      192mM Glycin 
      0.1% SDS 
 
Coomassie solution  45% Methanol 
      10% Acetic acid 
      0.4% Coomassie B-brilliant blue R250 
 
1x Blot buffer   48mM Tris-HCl pH 9.1 
      40mM Glycin 
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Ponceau solution  0.2% Ponceau-S 
      3% Trichloroacetic acid 
 
TBS    20mM Tris 
    150mM NaCl 
 
TBS high salt   20mM Tris 
    500mM NaCl 
 
PBST    0.05% Tween in PBS 
 
AP staining solution  100mM Tris-HCl pH 9.5 
      100mM NaCl 
      50mM MgCl2 
      0.033% Nitroblue tetrazolium (66μl of 50mg/ml  
NBT in 70% dimethylformamide per 10ml  
solution) 
      0.0165% Bromo-chloro-indolylphosphate (33μl  
of 50mg/ml BCIP in 70% dimethylformamide per  
10ml solution) 
 
Antibody WB dilution IF dilution characterization 
11/2 --- undiluted monoclonal mouse antibody to LAP2α, 
hybridoma supernatant (Dechat et al., 1998) 
12 1:1-1:10 in 
PBST 
undiluted monoclonal mouse antibody to LAP2, 
hybridoma supernatant (Dechat et al., 1998) 
15-2 1:2 in PBST undiluted monoclonal mouse antibody to LAP2α, 
hybridoma supernatant (Dechat et al., 1998) 
245-2 --- 1:500 in 
PBS 
polyclonal rabbit antiserum to LAP2α 
(Vlcek et al., 2002) 
16 undiluted undiluted monoclonal mouse antibody to LAP2ß, 
hybridoma supernatant (Dechat et al., 1998) 
17 --- undiluted monoclonal mouse antibody to LAP2ß, 
hybridoma supernatant (Dechat et al., 1998) 
133A2 1:5000 in 
PBST 
1:100 in 
PBS 
monoclonal mouse antibody to lamin A 
(Hozak et al., 1995) 
McKeon 1:1000 in 
PBST 
1:100 in 
PBS 
monoclonal mouse antibody to lamin A/C, 
(Loewinger and McKeon 1988) 
LA-2H10 --- 1:10 in 
PBS 
monoclonal mouse ab to lamin A/C, 
hybridoma supernatant 
(Jagatheesan et al. 1999) 
C-20 --- 1:10 in 
PBS 
polyclonal goat antibody to pre-lamin A 
(Santa Cruz, Santa Cruz, CA, USA) 
MANEM5 1:100 in 
PBST 
1:30 in 
PBS 
monoclonal mouse antibody to emerin 
(Glenn Morris; North East Wales Institute 
of Higher Education) 
MANEM15 1:50 in 
PBST 
--- monoclonal mouse antibody to emerin 
(Glenn Morris; North East Wales Institute 
of Higher Education) 
MAN1 1:250 in --- polyclonal goat antibody to MAN-1 
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 PBST (Santa Cruz, Santa Cruz, CA, USA) 
Nucleoporin 62 --- 1:150 in 
PBS 
monoclonal mouse antibody to 
Nuclear Pore Complex protein p62 
(BD Pharmingen, San Jose, CA, USA) 
K371 --- 1:100 in 
PBS 
polyclonal rabbit antiserum to SAF-A/B 
(Romig et al., 1992) 
Anti-Luciferase 
pAb 
1:1000 in 
PBST 
1:100 in 
PBS 
polyclonal goat antibody to Firefly 
Luciferase (Promega, Madison, WI, USA) 
Firefly 
Luciferase 
1:1000 in 
PBST 
--- polyclonal rabbit antibody to Firefly 
Luciferase (Sigma, St. Louis, MO, USA) 
Renilla 
Luciferase 
1:1000 in 
PBST 
1:200 in 
PBS 
monoclonal mouse antibody to Renilla 
Luciferase (Chemicon, Temecula, CA, 
USA) 
ß-Galactosidase 1:1000 in 
PBST 
1:1000 in 
PBS 
monoclonal mouse antibody to 
ß-Galactosidase (Promega, Madison, WI, 
USA) 
ß-Galactosidase 1:1000 in 
PBST 
--- polyclonal rabbit antibody to 
ß-Galactosidase (Molecular Probes-
Invitrogen, Carlsbad, CA, USA) 
Anti-GFP 1:2000 in 
PBST 
--- monoclonal mouse antibody to GFP 
(Roche, Basel, Switzerland) 
Anti-Actin 1:200 PBST --- polyclonal rabbit antibody to actin 
(Sigma, St. Louis, MO, USA) 
Table 5-2: Primary antibodies used for Western blotting and immunofluorescence microscopy 
 
 
Antibody 
 
Dilution Characterization 
AP anti-rabbit 1:10.000 in PBST AffiniPure goat anti-rabbit IgG (H+L)  
AP conjugate (Jackson IR Laboratories, 
West Grove, PA, USA) 
AP anti-mouse 1:5000 in PBST AffiniPure goat anti-mouse IgG (H+L) 
AP conjugate (Jackson IR Laboratories, 
West Grove, PA, USA) 
HRP anti-rabbit 1:40.000 in PBST AffiniPure goat anti-rabbit IgG (H+L) 
HRP conjugate (Jackson IR Laboratories, 
West Grove, PA, USA) 
HRP anti-mouse 1:10.000 in PBST AffiniPure goat anti-mouse IgG (H+L) 
HRP conjugate (Jackson IR Laboratories, 
West Grove, PA, USA) 
HRP anti-goat 1:10.000 in PBST AffiniPure donkey anti-goat IgG (H+L) 
HRP conjugate (Jackson IR Laboratories, 
West Grove, PA, USA) 
Table 5-3: Secondary antibodies used for Western blotting 
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5.2.3. Immunofluorescence microscopy studies 
HeLa or HEK 293 cells grown on poly-L-lysine coated glass coverslips (see 5.1.2.) to 70% 
confluency were washed once with PBS and fixed with 3.7% formaldehyde or 2% p-
formaldehyde in PBS for 20 minutes at room temperature. Cells were washed twice with PBS, 
and incubated in 50mM NH4Cl in PBS for 5 minutes at room temperature. After two washes 
with PBS, cells were permeabilized in 0.1% Triton X-100 in PBS for 5 minutes at room 
temperature. The coverslips were washed twice with PBS and blocked with 0.2% gelatine in 
PBS for 30-60 minutes at room temperature, followed by incubation with primary antibodies 
(see Table 5-2) in a humidified chamber for 60 minutes at room temperature. After three 
washing steps in PBS, the coverslips were incubated with secondary antibodies in PBS (see 
Table 5-4) likewise. Coverslips were again washed 3 times in PBS and incubated in Hoechst 
solution (1μg/ml in PBS) for 10 minutes at room temperature to counterstain for DNA. After 
washing twice with dH2O and air-drying, coverslips were mounted on microscope slides 
(Menzel Gläser, Braunschweig, Germany) in Mowiol, dried over night and stored at 4°C in 
the dark. Confocal images of stained cells were obtained using a ZEISS Axiovert 200M 
microscope equipped with a ZEISS LSM 510 confocal laser scanning unit. 
 
Solutions: Mowiol   2.4g Mowiol 4-88 (Hoechst, Frankfurt, Germany) 
      6g Glycerol 
      6ml dH2O 
      Incubation for 2h at room temperature 
      Addition of 12ml 0.2M Tris-HCl pH 8.5 
      Stirring for 10 minutes 
      Heating to 50°C for 10 minutes 
      Centrifugation at 5000xg for 15 minutes 
      Aliquoting of supernatant and storage at -20°C 
 
 
Phosphate buffered saline 137mM NaCl 
  (PBS)    2.6mM KCl 
      8mM Na2HPO4 
      1.5mM KH2PO4 
      pH 7.4 
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 Antibody 
 
Dilution Characterization 
Texas Red  
anti-mouse 
1:200 in PBS AffiniPure goat anti-mouse IgG (H+L) 
TexasRed dye conjugate (Jackson IR 
Laboratories, West Grove, PA, USA) 
Texas Red  
anti-rabbit 
1:200 in PBS AffiniPure goat anti-rabbit IgG (H+L) 
TexasRed dye conjugate (Jackson IR 
Laboratories, West Grove, PA, USA) 
Texas Red  
anti-goat 
1:200 in PBS AffiniPure donkey anti-goat IgG (H+L) 
TexasRed dye conjugate (Jackson IR 
Laboratories, West Grove, PA, USA) 
Alexa 488  
anti-mouse 
1:1000 in PBS goat anti-mouse IgG (H+L) 
Alexa fluor 488 conjugate (Molecular Probes, 
Invitrogen, Carlsbad, CA, USA) 
Alexa 488  
anti-rabbit 
1:1000 in PBS donkey anti-rabbit IgG (H+L) 
Alexa fluor 488 conjugate (Molecular Probes, 
Invitrogen, Carlsbad, CA, USA) 
Cy3 anti-mouse 1:150 in PBS donkey anti-mouse Cy3 conjugate 
Cy3 anti-goat 1:200 in PBS donkey anti-goat Cy3 conjugate 
Cy5 anti-mouse 1:150 in PBS donkey anti-mouse Cy5 conjugate 
Cy5 anti-rabbit 1:150 in PBS donkey anti-rabbit Cy5 conjugate 
Table 5-4: Secondary antibodies used for immunofluorescence microscopy 
 
5.2.4. Reporter assays 
HEK 293 cells were transfected (see 5.1.2.) with a combination of reporter plasmids and 
corresponding RNAi vectors, to first test the RNAi constructs and then establish the Triple-
RNAi-Vector. The following reporter plasmids (Promega, Madison, WI, USA) were used 
(vector maps see appendix A): 
pGL3 for SV40 promoter driven Firefly Luciferase expression 
phRL for Thymidine kinase promoter driven Renilla Luciferase expression 
pSVß-Gal for SV40 promoter driven ß-galactosidase expression 
pCAT3 for SV40 promoter driven chloramphenicol acetyltransferase expression 
 
The corresponding single RNAi vectors (MuliSite GatewayTM Entry vectors (Invitrogen’s 
Gateway technology see appendix B)) all contained an RNAi cassette, consisting of a human 
U6 promoter driving transcription of an shRNA construct (sh-oligonucleotides see 5.4.1.): 
pJG177 RNAi target Firefly Luciferase 
pJG178 RNAi target Renilla Luciferase 
pJG179, pCM4 to pCM7 RNAi target ß-galactosidase 
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Triple-RNAi-vectors cloned out of the single RNAi vectors (see 5.4.7., appendix A): 
• pCM3, pCM8 RNAi targeting Firefly Luciferase, Renilla Luciferase and ß-
galactosidase 
• pJG100 control plasmid, identical to pCM3 and pCM8, but without RNAi constructs 
 
5.2.4.1. Preparation of cells for reporter assays 
48h after transfection (see 5.1.2.) the cells were collected by centrifugation for 3 minutes at 
110g (800rpm) in a Heraeus Megafuge 1.0, washed three times in PBS, and were either 
aliquoted and/or cell pellets were processed accordingly for the different reporter assays. 
 
5.2.4.2. Luciferase reporter assay 
To simultaneously test two independent luciferase enzymatic activities within one sample we 
chose the Dual-Luciferase Reporter Assay System of Promega (Madison, WI, USA). The cell 
pellet was lysed for 15 minutes at room temperature in 1xPLB (Passive Lysis Buffer), 
immediately followed by measurement on a luminometer (Anthos Lucy 3). 
Two 20µl aliquots of each sample were pipetted into a 96-well plate suitable for luminometric 
measurement. The luminometer was programmed to first add 100µl LAR II to the lysates and 
shake the reaction mixture for two seconds, before Firefly Luciferase activity was measured 
for 10 seconds. Addition of 100µl Stop&Glow was again followed by two seconds mixing 
and 10 seconds measurement of Renilla Luciferase activity. 
 
7.2.4.3. ß-Galactosidase reporter assay 
In a third reporter assay, activities of β-galactosidase were measured spectrophotometrically. 
The cells were resuspended in 4°C cold lysis buffer and centrifuged for 10 minutes at 16100g 
(13.200rpm) at 4°C (Eppendorf Centrifuge 5415D). 45µl of the supernatant were mixed with 
268µl 0.1M sodium phosphate solution, 4µl 100x Mg solution and 88µl ONPG (o-nitrophenyl 
ß-D-galactopyranoside; Sigma-Aldrich, St. Louis, MO, USA). After 30 minutes of incubation 
at 37°C, the optical density was measured at 420nm with a Hitachi U-2000 
spectrophotometer. 
 
Solutions: lysis buffer   0.25M Tris/HCl pH 7.5 
      0.5% Triton X-100 
 
  0.1M sodium phosphate 16.4ml 0.5M Na2HPO4 
  solution   9ml 0.2M NaH2PO4 
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       74.6ml H2O 
 
  100x Mg solution  0.1M MgCl2 
      4.5M ß-Mercaptoethanol 
 
1x ONPG 4mg/ml ONPG (Sigma-Aldrich, St.Louis, MO, 
USA) in 0.1M sodium phosphate solution  
(pH 7.5) 
 
 
5.2.4.4. CAT enzyme assay 
As an independent reporter system for normalization of transfections in a triple RNAi 
experiment we used the CAT (Chloramphenicol Acetyltransferase) Enzyme Assay System of 
Promega (Madison, WI, USA). After 15 minutes of incubation in 1x Reporter Lysis Buffer at 
room temperature, the samples were placed on ice and vortexed for 10-15 seconds. The 
lysates were heated to 60°C (Eppendorf Thermomixer compact) for 10 minutes and 
centrifuged (Eppendorf Centrifuge 5415C) for 2 minutes. Each supernatant was used for two 
independent reaction mixtures, each containing: 
90µl cell extract 
1.5µl [14C] Chloramphenicol (0.1mCi/ml) (Moravek Biochemicals, Brea, CA, USA) 
5µl n-Butyryl CoA 
28.5µl dH2O 
The reaction mixture was incubated for 75 minutes at 37°C, briefly spinned and mixed with 
300µl of mixed Xylenes (Aldrich). After 30 seconds of vortexing, the phases were separated 
by three minutes of centrifugation at 16000g. The upper, organic, phase was mixed with 
100µl of 0.25M Tris/HCl (pH 8.0) by vortexing and again separated by centrifugation. 200µl 
of the xylene phase were mixed with scintillation fluid (Ready Safe; Beckman Coulter, 
Fullerton, CA, USA) and radioactivity was measured with a liquid scintillation analyzer 
(Packard 2000CA). 
 
5.2.4.5. Normalization, Interpretation 
Two aliquots of each sample were measured to calculate an average value. To determine the 
efficiency of RNAi constructs, we correlated reporter enzyme activities of co-transfections of 
reporter plasmids with either RNAi vectors or control vectors (identical RNAi vectors without 
an inserted sh-oligonucleotide). The reporter activity of control transfection was set to 100%. 
Different transfections were normalized by the use of an independent reporter assay (e.g. CAT 
enzyme assay) and standard deviations were calculated from the differences in RNAi 
efficiency of repeated transfections. 
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5.2.5. FACS (Fluorescence-activated cell sorter) 
FACS analysis was performed to determine the cell cycle stage distribution. The cell lines 
HEK 118/8, HeLa 118/5 and the stable cell pools HEK 121 and HeLa 121, respectively, (also 
used for growth rate experiments (see 5.1.5.)) were grown on 6cm dishes until the cells 
reached a density of 70-80%. The cells were trypsinized and centrifuged at 110g (800rpm) for 
3 minutes in a Heraeus Megafuge 1.0. The cell pellets were resuspended in 0.5ml of ice cold 
PBS and pipetted drop by drop into 4ml of –20°C cold 85% ethanol, which was moderately 
vortexed. The cell suspensions were stored at -20°C until FACS was performed with a Becton 
Dickinson LSR flow cytometer (thanks to Thomas Sauer). 
 
 
5.3. Molecular Biology 
 
5.3.1. CaCl2 competent E.Coli 
One liter of LB medium was inoculated with 50ml of over-night culture of E. coli and shaken 
(180rpm) at 37°C until reaching an optical density (600nm) of 0.5 - 0.6. From now on, all 
working steps were performed at 4°C, using sterile and pre-cooled material. The bacteria were 
centrifuged for five minutes at 2700g (4000rpm, Sorvall RC5C) and the pellet was carefully 
resuspended in 500ml of 100mM CaCl2. 45 minutes of incubation were followed by a second 
identical centrifugation. This time the pellet was gently resuspended in 10ml of 100mM CaCl2 
and supplemented with glycerol to a final concentration of 10%. The competent E.Coli were 
aliquoted, frozen in liquid nitrogen and stored at –80°C. 
 
Solutions: LB medium   1% Bacto tryptone 
      0.5% Yeast extract 
      0.5% NaCl 
      pH 7 and autoclaving 
 
5.3.2. Transforming E.Coli 
10-100ng of plasmid DNA were added to 100µl of competent bacteria and incubated on ice 
for 30 minutes. After 30 seconds at 42°C, the bacteria were cooled on ice for 3 minutes. 200µl 
LB medium were added and the bacteria were incubated at 37°C for 30-60 minutes, followed 
by plating on prewarmed LB-agar dishes. To select transformed E.Coli, antibiotics were used 
at the following concentrations: 
ampicillin [100µg/ml], kanamycin [40µg/ml], chloramphenicol [50µg/ml] 
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 Solutions: LB-agar    1% Bacto tryptone 
      0.5% Yeast extract 
      0.5% NaCl 
      1.5% agar 
      pH 7 and autoclaving 
 
5.3.3. Glycerolstocks 
The bacteria were grown at 37°C in fresh LB medium supplemented with a suitable antibiotic. 
After 1-3h 800µl of bacterial solution were mixed with 200µl of glycerol and stored at –80°C. 
 
5.3.4. Expression and analysis of recombinant proteins 
100ml LB medium supplemented with antibiotics were inoculated with 5ml of over-night 
culture of E. coli BL21 (DE3), transformed with an expression vector (pSV65, or pSV92 or 
pSV105 designed by Sylvia Vlcek). The cultures were incubated at 37°C until an OD600 of 0.4 
– 0.6 was reached. 200μl aliquots of the cell suspensions were taken as uninduced controls for 
SDS PAGE analysis (see 5.2.2.). The remaining culture was used to induce recombinant 
protein expression by addition of 0.5mM IPTG (isopropyl-β-D-thiogalactopyranosid; Sigma-
Aldrich, St. Louis, MO, USA), followed by incubation at 30°C for 3 - 4h. The uninduced 
controls and 200μl aliquots of IPTG-induced bacteria were removed and pelletized by 
centrifugation at 1500g (4000rpm) for 10 minutes in an Eppendorf Centrifuge 5415D. 
Bacterial pellets were resuspended in 20μl of dH2O and lysed by addition of 20μl of 3x SDS 
PAGE sample buffer. The samples were heated to 95°C for 5 minutes and stored at -20°C 
until testing on Western Blots (see 5.2.2.). The remaining induced bacteria were centrifuged at 
3000g (4000rpm) for 10 minutes in a Heraeus Megafuge 1.0R and pellets were frozen at -
20°C, ready for purification of recombinant protein: 
Bacterial cell pellets were thawed on ice, resuspended in 5ml of lysis buffer and sonicated 
(5x20 seconds, intensity 80%, cycle 50). 10µg/ml of DNAseI and of lysozyme (Sigma-
Aldrich, St. Louis, MO, USA) were added, followed by incubation on ice for 30 minutes. A 
20µl aliquot of the whole lysate was mixed with 10µl of 3x SDS PAGE sample buffer, 
incubated at 95°C for 5 minutes and stored at -20°C. The remaining sample was centrifuged at 
23400g (14000rpm) for 10 minutes (4°C) using SS-34 centrifugation tubes and a pre-cooled 
SS-34 rotor in a Sorvall centrifuge RC5C. The supernatants were mixed with 3x SDS PAGE 
sample buffer and tested by SDS PAGE (see 5.2.2.), whereas the pellets were resuspended in 
5ml of lysis buffer and stored at 4°C. 
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Solutions: Lysis buffer   1/5 Phosphate buffer 
      100mM NaCl 
      1mM Dithiothreitol (DTT) 
      1/50 50x Protease inhibitor mix 
 
  Phosphate buffer  0.5M NaH2PO4 (pH 7) 
 
5.3.5. Miniprep DNA purification 
We purified plasmid DNA from bacterial cultures with the Wizard Plus Miniprep DNA 
Purification System of Promega (Madison, WI, USA) according to manufacturer’s instruction. 
In brief, 1.5ml of an over night culture were centrifuged 3 minutes at 2300g (5000rpm, 
Eppendorf Centrifuge 5415D). The pellet was resuspended in 250µl of resuspension solution. 
The addition of 250µl of cell lysis solution was followed by inverting the tube four times. 
After addition of 250µl of neutralization solution the lysate was again mixed by inverting the 
tube. During centrifugation at 15700g (13000rpm), the Minicolumn/syringe barrel assembly 
was fixed on a vacuum manifold and filled with 1ml of resuspended resin. The supernatant of 
the lysate was transferred to the column and vacuum was applied until the liquid was sucked 
out of the column. 2ml of wash solution (95% ethanol) were added and the column was dried 
by applying vacuum. The Minicolumn was transferred to a microtube and centrifuged for two 
minutes at full speed (15700g / 13000rpm), to remove residual wash solution. Afterwards the 
Minicolumn was transferred to a new collection tube, 50µl of ddH2O were added and after 
one minute of incubation, the dissolved plasmid DNA was eluted by 20 seconds of 
centrifugation. 
 
5.3.6. Midiprep DNA purification 
To purify bigger amounts of plasmid DNA of bacterial cultures, we used the JETstar Plasmid 
Midi Kit (Genomed, Löhne, Germany). Therefore, we equilibrated the purification column 
with 10ml of solution E4 and centrifuged 100ml of over night culture for 3 minutes at 3000g 
(4000rpm) in a Heraeus Megafuge 1.0R. The bacterial pellet (which can alternatively be 
stored at –20°C without loss in efficiency) was resuspended in 4ml of RNase containing 
solution E1. After addition of 4ml of solution E2, the tube was inverted 10 times and 
incubated for 5 minutes at room temperature. To stop cell lysis, 4ml of neutralizing solution 
E3 were added and the tube was again inverted 10 times. The lysate was centrifuged for 15 
minutes at 3000g (4000rpm) and the supernatant was transferred to the equilibrated column, 
which flows by gravity. The dry column was washed with 20ml of solution E5, followed by 
elution of the DNA with 5ml of solution E6. 3.5ml of isopropanol were mixed to the DNA 
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 containing solution, which was centrifuged for 30 minutes at 13400g (9000rpm) and 4°C (pre-
cooled HB-4 rotor, Sorvall centrifuge RC5C). The pellet was washed with 5ml of 70% 
ethanol and centrifuged again, this time for 5 minutes. The opaque DNA pellet was air dried 
and was resolved in up to 100µl of ddH2O. The DNA concentration of an 1:100 aqueous 
dilution was measured spectrophotometrically at 260nm. 
 
5.3.7. DNA restriction digest 
reaction mixture: 2µl of recommended 10x reaction buffer 
   0.5-1µg DNA (e.g. 5µl miniprep) 
   0.3µl of each restriction enzyme 
   ddH2O to a final volume of 20µl 
First 10x reaction buffer was diluted in ddH2O, than the DNA sample was mixed to the 
solution. Finally the reaction was started by the addition of restriction enzyme, followed by  
1-3h of incubation at 37°C. 
For preparative digestion of DNA (up to 10µg) it is useful to choose a bigger overall volume 
(up to 100µl), to incubate for a longer time (e.g. over night) and to use more restriction 
enzyme (the amount of glycerol should not exceed 10%). Digested DNA was stored at 4°C, 
for long term storage it was kept on –20°C. 
 
5.3.8. DNA agarose gel electrophoresis 
Agarose (0.8% to 2%; Sigma, St. Louis, MO, USA) was suspended in 1x TAE buffer and 
dissolved by boiling in the microwave. The solution was cooled down to about 60°C and 
ethidiumbromide (0.01 mg/ml) was added prior to pouring the gel. The gel was overlaid with 
1x TAE and the samples were mixed with 1/10 volume of 10x DNA loading buffer, before 
loaded on the gel together with 1μg of a DNA marker (1Kb Plus, Invitrogen). Gels were run 
for 1-2h at 70-110V in 1x TAE buffer and DNA bands were detected by UV light (UV 
Transilluminator, UVP). 
 
Solutions: 1x TAE buffer  40mM Tris acetate pH 8 
      1mM EDTA pH 8 
  
  10x DNA loading buffer 10mM Na3PO4 pH 6.7 
      50% Glycerol 
      0.1% Bromphenol blue 
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5.3.9. Elution of DNA fragments from agarose gel 
To elute DNA from agarose gels, we used the QIAquick Gel Extraction Kit (Qiagen, Hilden, 
Germany). After electrophoresis, the desired band was cut out of the gel and weighed. The gel 
was dissolved in a threefold of buffer QG (100mg gel = 300µl buffer) by incubation for 10 
minutes at 50°C (Eppendorf Thermomixer compact). The sample was applied to a spin 
column, which was placed in a microtube. The columns were centrifuged at 15700g 
(14.000rpm) for one minute (Eppendorf Centrifuge 5415D) and the flow-through was 
discarded. 750µl of buffer PE were added to the column and 2-5 minutes of incubation were 
followed by a second centrifugation step. Again the flow-through was discarded and the 
column was centrifuged again to remove residual ethanol from buffer PE. The column was 
placed into a new tube and incubated for one minute with 30µl of ddH2O. Afterwards the 
dissolved DNA was eluted by centrifugation at top speed. The dissolved DNA fragment was 
stored at -20°C, or for short term storage at 4°C. 
 
5.3.10. Dephosphorylation of DNA fragments 
To prevent religation of a once digested vector backbone during ligation with an insert, we 
performed dephosphorylation of the linearized plasmid. 
An aqueous solution of a DNA fragment, not exceeding 5µg of DNA, was mixed with 10µl of 
CIP buffer (Roche, Basel, Switzerland) and diluted with ddH2O to 97.5 µl. 2.5 µl of CIP (calf 
intestinal phosphatase; Roche, Basel, Switzerland) were added, the mixture was vortexed and 
spinned down (Eppendorf Centrifuge 5415D), followed by incubation for 30 minutes at 37°C 
(Eppendorf Thermomixer compact). Further 2.5µl of CIP were added and the solution was 
incubated for 45 minutes at 55°C. Afterwards 2.5µl of 20% SDS, 1µl of 0.5M EDTA (pH 8.0) 
and 0.5µl of proteinase K [20mg/ml] (Invitrogen, Carlsbad, CA, USA) were added and the 
mixture was again vortexed, spinned down and incubated for 30 minutes at 37°C. The 
solution was diluted with 100µl of ddH2O and extracted with 200µl of PCI (25x phenol, 24x 
chloroform, 1x isoamyl alcohol). The aqueous phase was collected and the organic phase was 
re-extracted with 200µl of ddH2O. The DNA collected in the aqueous phases was precipitated 
with ethanol to achieve a higher DNA concentration. 
 
5.3.11. Ethanol precipitation of DNA 
To concentrate DNA samples or to clean it from bacterial remnants, we precipitated DNA 
with ethanol. Therefore, we mixed an aqueous solution of DNA with half the volume of 7.5M 
ammonium acetate or 1/10 volume of 2.5M sodium acetate. 2.5 volumes of ethanol were 
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 added and the mixture was vortexed vigorously. 15 minutes to 1h of incubation at -20°C were 
followed by centrifugation at 15700g (13.000rpm) for 10 – 20 minutes (Eppendorf Centrifuge 
5415D). The pellet was washed with 70% ethanol, centrifuged for another 10 minutes and 
dried at room temperature. Finally the DNA was resolved in a small volume of ddH2O. 
 
5.3.12. DNA ligation  
To ligate DNA, we mixed the aqueous solutions of a digested vector-backbone from gel-
elution with 2µl of 10x ligase buffer (Roche, Basel, Switzerland). In most cases, a surplus of 
smaller DNA fragments as annealed oligonucleotides (see 5.4.2), or a gel eluted insert (see 
5.3.9) after restriction digest (see 5.3.7), or PCR (see 5.4.4) was added and the volume was 
adjusted to 19µl with ddH2O. Finally 1µl of T4 DNA Ligase (Roche, Basel, Switzerland) was 
added to start the ligation. The reaction was either incubated at room temperature for three 
hours, at 16°C over night, or at 4°C over the weekend. 
 
5.3.13. Zero Blunt TOPO PCR cloning 
As normal ligation did not work on a blunt-end PCR product (see 5.4.4.), we decided to try 
the Zero Blunt TOPO PCR cloning of Invitrogen (Carlsbad, CA, USA). The reaction mixture 
consisted of: 4.5µl of PCR product eluted from agarose gel (see 5.3.9.), 1µl of salt solution 
and 0.5µl of linearized pCR-Blunt II-TOPO vector (with covalently bound and activated 
topoisomerase I). The reaction was incubated at room temperature for 15 minutes and cooled 
on ice. Half of the reaction mixture was transformed (see 5.3.2.) into E.Coli DB 3.1, the other 
3µl to E.Coli TOP 10F’. 
 
5.3.14. Poly(A+) mRNA isolation 
We made use of the mRNA isolation kit from Roche (Basel, Switzerland) to prepare mRNAs 
from HeLa, HEK 293 and 3T3 F442A cells. The cells were trypsinized, centrifuged and the 
cell pellet was washed two times in ice cold PBS. 1.5ml of lysis buffer were added to about 
107 cells, which were sheared mechanically by passing through a 21 gauge needle (Braun, 
Melsungen, Germany). Streptavidin magnetic particles were resuspended and 150µl were 
transferred to a new tube. They were magnetically separated from the storage buffer and 
washed once in 250µl of lysis buffer, which was entirely removed afterwards. 1.5µl of biotin-
labelled oligo (dT)20 probe were pipetted to the lysate and the magnetic particles were 
resuspended in the mixture. The sample was incubated for 5 minutes at 37°C to immobilize 
the mRNA via its hybridised biotin-labelled oligonucleotides onto the magnetic particles. 
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These were magnetically separated and washed three times each with 250µl of washing 
buffer. After the washing buffer was removed quantitatively, the particles were resuspended 
in 25µl of RNase-free water. To elute the mRNA from the particles, the sample was incubated 
for 2 minutes at 65°C, the particles were separated and the supernatant was transferred to a 
new tube. The mRNA sample was stored on –20°C, for longterm storage on –80°C. 
 
5.3.15. cDNA synthesis 
cDNA synthesis was performed with the SuperScriptTM III First-Strand Synthesis System for 
RT-PCR from Invitrogen (Carlsbad, CA, USA). 12µl of poly(A+) mRNA (see 5.3.14.) were 
mixed with 1.5µl of 50µM oligo (dT)20 primer and 1.5µl of 10mM dNTP mix. The sample 
was incubated at 65°C for five minutes, followed by incubation on ice for at least one minute. 
In the meantime, a cDNA synthesis mix consisting of 3µl of 10xRT buffer, 6µl of 25mM 
MgCl2, 3µl of 0.1M DTT, 1.5µl of RNaseOUT (40 U/µl) and 1.5µl of SuperScriptTM III 
reverse transcriptase (200 U/µl) per sample was prepared. 15µl of cDNA synthesis mix were 
added to each RNA/primer mixture. The tube was gently mixed and shortly spinned. The 
reaction was incubated at 50°C for 50 minutes and terminated at 85°C for five minutes. The 
mixture was cooled on ice and spinned down, followed by addition of 1.5µl of RNaseH and 
incubation at 37°C for 20 minutes. The cDNA samples were directly used for RT-PCR (see 
5.3.16.), the remaining samples were stored at –20°C. 
 
5.3.16. RT-PCR 
For expression analyses of LAP2 isoforms in different human and murine tissues, as well as 
during differentiation of murine embryonic stem cells to cardiomyocytes (cDNAs generated 
by Martina Stary), cDNAs (see 5.3.15.) generated from poly(A)+ mRNAs (see 5.3.14.) were 
normalized based on GAPDH (human and mouse) and RhoA (mouse) expression levels. 10μl 
of normalized cDNAs were supplemented with 30pmol of forward and reverse primers 
specific for LAP2β or GAPDH, or RhoA and ddH2O to a final volume of 25µl. The sample 
was heated to 95°C for five minutes, cooled on ice and spinned in an Eppendorf Centrifuge 
5415D. Finally puReTaq ready-to-go PCR beads (Amersham Biosciences, Little Calfont, 
Buckinghamshire, UK) were added and PCR was performed using a Biometra T3 
thermocycler system. 
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 The following primers and PCR parameters were used: 
Primers: 
LAP2β: 
Forward primer: 
LAP2com_hm1 5’ – GTG GGA ACA ACC AGG AAG CTA TAT GA – 3’ 
Reverse primer: 
LAP br_hm1  5’ – CTC CCA CTT CAG CTC TTG TCA ATG – 3’ 
 
GAPDH: 
Forward primer: 
GAPmh1:  5’ – CATCACCATCTTCCAGGAGCGA – 3’ 
Reverse primer: 
GAPmh2:  5’ – CCTGCTTCACCACCTTCTTGAT – 3’ 
 
RhoA: 
Forward primer: 
Rho1:   5’ – GTGGAATTC-GCCTTGCATCTGAGAAGT – 3’ 
Reverse primer: 
Rho2:   5’ – CACGAATTC-AATTAACCGCATGAGGCT – 3’ 
 
PCR parameters:  2 cycles 95°C 5min 
      64°C 1min 10sec 
      72°C 4min 
    2 cycles 95°C 50sec 
      62°C 1min 
      72°C 3min 
32 cycles 95°C 45sec 
      60°C 55sec 
      72°C 2min 10sec 
    once  72°C 10min 
    hold  4°C 
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5.4. RNAi cloning strategy 
5.4.1. short hairpin oligonucleotides – RNAi constructs 
The short hairpin oligonucleotides (sh-oligonucleotides) were designed to form shRNAs after 
transcription, which are further processed to functional siRNAs by the cell-intrinsic RNAi-
machinery. Candidate oligonucleotides for respective target mRNAs were calculated using a 
software available at ‘www.cshl.edu/public/SCIENCE/hannon.html’. By the use of the 
BLAST database we excluded sequence homology of our oligonucleotides with others than 
the target genes. Features of the sh-oligonucleotides: 
• Oligonucleotides A encode an antisense, a loop and a sense strand. 
• Termination of transcription was mediated by a run of Ts at the end of oligonucleotide 
A. 
• The eight nucleotide loop-structure of the hairpin oligonucleotides (oligonucleotide A: 
GAAGCTTG) includes a HindIII restriction site. 
• Oligonucleotides B were designed complementary to oligonucleotides A with 
additional asymmetric overhangs (5’ GATC…..CG 3’) to enable unidirectional 
ligation (see 7.3.12) of the annealed oligonucleotides (see 5.4.2) into a BseRI/BamHI 
digested vector. 
• Some G-U pairings in the RNA hairpin stem were included to stabilize hairpins during 
propagation in bacteria. 
Short hairpin oligonucleotides A and B used in our studies are listed in Table 5-5. 
 
Plasmid 
name 
target 
(organism) 
oligo 
A/B 
sequence (5’-3’) cDNA 
coding nt-
region 
pJG101 
pJG111 
LAP2 general 
(h, m) 
A TGAGGTGCTGCAGGTAGAGCTGGAAGCTTGCAGCTCTACC
TGCAGCACCTCACTTTTTT 
115-137 
  B GATCAAAAAAGTGAGGTGCTGCAGGTAGAGCTGCAAGCTT
CCAGCTCTACCTGCAGCACCTCACG 
 
pJG102 
pJG112 
LAP2ß,γ,ε 
(h, m, r) 
A TCTGAGAATTCAGTGATTGGCAGAATAGGAAGCTTGCTATT
CTGCCGATTACTGAGTTCTCGGACATTTTTTT 
919-946 
  B GATCAAAAAAATGTCCGAGAACTCAGTAATCGGCAGAATA
GCAAGCTTCCTATTCTGCCAATCACTGAATTCTCAGACG 
 
pJG103 
pJG113 
emerin (h) A CAGCAAGGTGGTCAGCTCGGTATCCGAAGAAGCTTGTTCG
GATGCCGAGTTGACCGCCTTGTTGCGCTTTTTT 
20-49 
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   B GATCAAAAAAGCGCAACAAGGCGGTCAACTCGGCATCCGA
ACAAGCTTCTTCGGATACCGAGCTGACCACCTTGCTGCG 
 
pJG104 
pJG114 
LAP2 general 
(h) 
A GTTGCGAGCCGTGAGGTGCTGCAGGTAGGAAGCTTGCTAC
TTGTAGCACTTCACGGCTCGCGACCGGTTTTT 
120-147 
  B GATCAAAAACCGGTCGCGAGCCGTGAAGTGCTACAAGTAG
CAAGCTTCCTACCTGCAGCACCTCACGGCTCGCAACCG 
 
pJG105 BAF (h, m, r) A GCTCTGCCACGAAGTCTCGGTGCGAAGCTTGGCACCGAGA
CTTCGTGGCAGAGCTTTTT 
18-40 
  B GATCAAAAAGCTCTGCCACGAAGTCTCGGTGCCAAGCTTC
GCACCGAGACTTCGTGGCAGAGCCG 
 
pJG106 
pJG116 
LAP2α (h, m) A GAGGACGGGTGGAGATTTCAGGGAAGCTTGCCTGAAATCT
CCACCCGTCCTCTTTTT 
663-698 
  B GATCAAAAAGAGGACGGGTGGAGATTTCAGGCAAGCTTCC
CTGAAATCTCCACCCGTCCTCCG 
 
pJG107 Lco1 (h) A ATTGTCTTGCCCAATCAAGTAACACTTGGAAGCTTGCGAGT
GTTACTTGGTTGGGTAAGACGATCATTTTTTT 
260-287 
  B GATCAAAAAAATGATCGTCTTACCCAACCAAGTAACACTC
GCAAGCTTCCAAGTGTTACTTGATTGGGCAAGACAATCG 
 
pJG108 
pJG118 
LAP2α (h) A ACTGATCAATTCTCTTCTGGAAGCTTGCAGAAGAGAATTGA
TCAGTCTTTTTT 
1225-1245
  B GATCAAAAAAGACTGATCAATTCTCTTCTGCAAGCTTCCAG
AAGAGAATTGATCAGTCG 
 
pJG109 
pJG119 
LAP2α (h) A GCACTGTGTTCAGGCTGAGAAGATGACGGAAGCTTGCGTC
GTCTTCTCAGCCTGAGCATAGTGCTATTTTTTT 
878-908 
  B GATCAAAAAAATAGCACTATGCTCAGGCTGAGAAGACGAC
GCAAGCTTCCGTCATCTTCTCAGCCTGAACACAGTGCCG 
 
pJG110 
pJG120 
laminA (h, m) A AGTTGCCCAGGAGGTAGGAGCGGGTGACGAAGCTTGGTCA
TCCGCTTCTGCCTCCTGGGCAGCTCCATTTTTT 
1925-1953
  B GATCAAAAAATGGAGCTGCCCAGGAGGCAGAAGCGGATG
ACCAAGCTTCGTCACCCGCTCCTACCTCCTGGGCAACTCG 
 
pJG177 
pCM3 
Firefly 
Luciferase 
A GATTCCAATTCAGCGGGAGCCACCTGATGAAGCTTGATCA
GGTGGCTCCTGCTGAGTTGGAGTCTATTTTTTT 
 
pCM8  B GATCAAAAAAATAGACTCCAACTCAGCAGGAGCCACCTGA
TCAAGCTTCATCAGGTGGCTCCCGCTGAATTGGAATCCG 
 
pJG178 
pCM3 
Renilla 
Luciferase 
A ACGTACTTGTAGTGATCCAGGAGGCGATGAAGCTTGATCG
TCTTCTGGATCACTATAAGTATCTCACTTTTTT 
 
pCM8  B GATCAAAAAAGTGAGATACTTATAGTGATCCAGAAGACGA
TCAAGCTTCATCGCCTCCTGGATCACTACAAGTACCTCG 
 
pJG179 
pCM3 
ß-
galactosidase1 
A CGTTCGACCCAGGCGTTAGGGTCAATGCGAAGCTTGGTATT
GATCCTAATGCCTGGGTCGAGCGCTGTTTTTT 
 
  B GATCAAAAAACAGCGCTCGACCCAGGCATTAGGATCAATA
CCAAGCTTCGCATTGACCCTAACGCCTGGGTCGAACGCG 
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pCM4 
pCM7 
ß-
galactosidase2 
A CCGTAGCGGTCGCACAGCGTGTACCACAGAAGCTTGTGTG
GTATACGCTGTGTGATCGCTATGGCCTTTTTTT 
 
pCM8  B GATCAAAAAAAGGCCATAGCGATCACACAGCGTATACCAC
ACAAGCTTCTGTGGTACACGCTGTGCGACCGCTACGGCG 
 
pCM5 
pCM6 
ß-
galactosidase3 
A CTCATCCGCCACATATCCTGATCTTCCAGAAGCTTGTGGAG
GATTAGGATGTGTGGCGGATGAGTGGTTTTTT 
 
  B GATCAAAAAACCACTCATCCGCCACACATCCTAATCCTCCA
CAAGCTTCTGGAAGATCAGGATATGTGGCGGATGAGCG 
 
Table 5-5: short hairpin oligonucleotides used to clone RNAi plasmids (h, m, r in the target-column indicate the 
organism - human, mouse, rat - the oligonucleotides are specific for)  
 
 
5.4.2. Annealing of oligonucleotides for ligation 
The lyophilized oligonucleotides were dissolved to a final concentration of 100pmol/µl by 
incubation for 30 minutes at 37°C in buffer TE with additional 50mM NaCl. Small aliquots 
were diluted to 10pmol/µl and the corresponding oligonucleotides were mixed, resulting in a 
final concentration of 5pmol/µl of each oligonucleotide. These solutions were heated to 95°C 
for three minutes and slowly cooled down to room temperature simply by turning off the 
Eppendorf Thermomixer compact. The annealed oligonucleotides were used for ligation (see 
5.3.12.) into BseRI / BamHI digested vectors. 
 
Solutions: 1x buffer TE   10mM Tris-HCl (pH 8) 
      1mM EDTA 
 
5.4.3. Generation of RNAi – compatible MultiSite GatewayTM Entry vectors 
Aim of this PCR was to amplify three RNAi-cassettes out of pSHAG (see 5.4.5.; appendix 
A), differing only in their GatewayTM recombination sites, as tools for MultiSite GatewayTM 
cloning (cloning strategy see 5.4.7., Invitrogen’s Gateway technique see appendix B). 
The 25µl reaction mixtures contained 1µg of pSHAG DNA, 2.5µl of 10x Pfu Ultra Reaction 
Buffer (Stratagene, La Jolla, CA, USA), 2.5µl of dNTPs [2.5mM], 30pmol of each primer and 
0.8µl of Pfu Ultra Hot Start [2.5U/µl] (Stratagene, La Jolla, CA, USA). PCR was performed 
using a Biometra T3 thermocycler system. The following primers and PCR parameters were 
used: 
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 Primers: 
Element A:  
Forward primer:  
B4f 5’ – GGGGACAACTTTGTATAGAAAAGTTG-TCACCGAGGGCCTATTTCCCATG - 3’ 
Reverse primer:  
B1r-2 5’ – GGGGACTGCTTTTTTGTACAAACTTG-GGTCGGCGCGCCCACCCTTG – 3’ 
Element B: 
Forward primer:  
B1f 5’ – GGGGACAAGTTTGTACAAAAAAGCAGGCTCC - 3’ 
Reverse primer:  
B2r 5’ – GGGGACCACTTTGTACAAGAAAGCTGGGTCG - 3’ 
Element C: 
Forward primer:  
B2f 5’ – GGGGACAGCTTTCTTGTACAAAGTGG-CCTATTTCCCATGATTCCTTC - 3’ 
Reverse primer:  
B3r 5’ – GGGGACAACTTTGTATAATAAAGTTG-GGTCGGCGCGCCCACCCTTG - 3’ 
PCR parameters:  1 cycle 95°C 5min 
      64°C 1min 
      72°C 3min 
    2 cycles 95°C 1min 
      62°C 1min 
      72°C 3min 
27 cycles 95°C 40sec 
      60°C 45sec 
      72°C 2min 32sec 
    once  72°C 4min 
    hold  4°C 
 
The PCR products were used for BP reaction (see 5.4.5.2.) to give three different MultiSite 
GatewayTM Entry vectors. 
 
5.4.4. PCR to clone a MultiSite GatewayTM destination vector 
Our aim was to amplify the GatewayTM – compatible cassette of Invitrogen’s pDEST R4-R3 
vector (see appendix A) and to ligate it into other plasmids, to obtain different Destination 
vectors. The PCR product includes recombination sites (attR4 and attR3, see appendix B), a 
Chloramphenicol resistance gene and the ccdB gene, which is useful for negative selection 
after recombination. 
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To test the primers, we performed the PCR with puReTaq ready-to-go PCR beads (Amersham 
Biosciences, Little Calfont, Buckinghamshire, UK). Therefore, we mixed 30pmol of each 
primer and 100ng of pDEST R4-R3 with ddH2O to an overall volume of 25µl and added one 
PCR bead. 
The PCR product we used for cloning, was generated by a proof reading DNA polymerase. 
The 25µl reaction mixture included 2.5µl of 10x Pfu Reaction buffer (Stratagene, La Jolla, 
CA, USA), 4µl of dNTPs [2.5mM], 30pmol of each primer, 100ng of pDEST R4-R3 and 1µl 
of Pfu Turbo Hot Start DNA Polymerase (Stratagene, La Jolla, CA, USA). 
PCR was performed using a Biometra T3 thermocycler system. The following primers and 
PCR parameters were used: 
Primers: 
Forward primer:  
RFM1 5’ – GCGATATCTACGCCAAGCTATCAAC – 3’ 
Reverse primer:  
RFM2 5’ – CGGATATCAACGACGGCCAGTGAAT – 3’ 
PCR parameters:  1 cycle  95°C 5min 
      56°C 1min 
      72°C 10min 
    1 cycle  95°C 1min 
      56°C 1min 
      72°C 10min 
28 cycles 95°C 50sec 
      58°C 1min 
      72°C 10min 
    once  72°C 15min 
    hold  4°C 
 
As the primers have non-base-pairing overhangs coding for EcoRV restriction sites, we 
performed the first two PCR cycles with a lower annealing temperature. 
 
5.4.5. GatewayTM recombination reactions (Invitrogen, Carlsbad, CA, USA) 
For information on the GatewayTM system, see appendix B. 
 
5.4.5.1. LR recombination reaction 
We used the LR recombination reaction to shuttle the functional RNAi cassettes from pSHAG 
(pJG101 – pJG110) to GatewayTM compatible pTracer (pJG111 – pJG120) (see 5.4.6.). 
The reaction mixture included 3µl of 5x LR Clonase reaction buffer, 1µl of pSHAG Entry 
clone, 1µl of pTracer Destination vector and buffer TE (pH 8) (see 5.4.2.) to a total volume of 
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 13µl. Finally LR Clonase was thawed on ice for two minutes, vortexed twice and spinned 
briefly. The enzyme was stored at –80°C immediately after 2µl were added to the reaction. 
The reaction was mixed briefly by vortexing two times, followed by short spinning. Then it 
was incubated for 1-3 hours at room temperature. Afterwards 1.5µl of proteinase K [2µg/µl] 
were added and the recombination reaction was terminated at 37°C for 10 minutes. 10µl of 
the solution were transformed into competent E.Coli DH5α (see 5.3.1.). 
 
5.4.5.2. BP recombination reaction 
In our case the BP recombination reaction was used to shuttle PCR products (see 5.4.3.) into 
Donor vectors to clone MultiSite GatewayTM Entry vectors (see 5.4.7.). Element A was 
transferred to pDONR P4-P1R, forming pMU6-A. Element B was recombinated with pDONR 
221, to form pMU6-B and Element C was shuttled into pDONR P2R-P3, to form pMU6-C. 
The reaction mixture included 4µl of buffer TE (pH 8) (see 5.4.2.), 3µl of 5x BP Clonase 
reaction buffer, 5µl of PCR product (Element A, B, or C, see 5.4.3.), 1µl of corresponding 
Donor vector (pDONR P4-P1R, pDONR 221, or pDONR P2R-P3, each [1µg/µl]; vector maps 
see appendix A) and finally 2µl of BP Clonase (procedure see LR Clonase 5.4.5.1.). The 
whole reaction was mixed briefly by vortexing two times, before it was incubated for 2.5 
hours at room temperature. Afterwards 1.5µl of proteinase K [2µg/µl] were added and the 
reaction was incubated at 37°C for 10 minutes. 10µl of the recombination reaction were 
transformed into competent E.Coli DH5α (see 5.3.1.). 
 
5.4.5.3. MultiSite GatewayTM LR reaction 
The MultiSite GatewayTM LR reaction was used to shuttle three RNAi-cassettes from three 
different Entry vectors into one Destination vector (pDEST R4-R3). As Entry vectors we 
used: 
pMU6-A, pMU6-B and pMU6-C to clone pJG100 
pJG177, pJG178 and pJG179 to clone pCM3 
pJG177, pJG178 and pCM4 to clone pCM8 
The reaction mixture contained: about 20-25fmol of each plasmid (60ng pDEST R4-R3, 45ng 
of each Entry vector), 4µl of 5x LR ClonaseTM Plus Reaction Buffer and buffer TE (pH 8) 
(see 5.4.2.) to 16µl. The LR ClonaseTM Plus was thawed on ice for 2 minutes, vortexed twice 
and spinned briefly. The enzyme was stored at –80°C immediately after 4µl were added to the 
reaction. The reaction was mixed briefly by vortexing two times, followed by short spinning. 
Then it was incubated for 16-20 hours at room temperature. Afterwards 2µl of proteinase K 
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[2µg/µl] were added and the recombination reaction was terminated at 37°C for 10 minutes. 
10µl of the solution were transformed into competent E.Coli DH5α (see 5.3.1.). 
 
5.4.6. Cloning strategy for single target RNAi vectors 
The sh-oligonucleotides (see 5.4.1.) were annealed (see 5.4.2.) and ligated (see 5.3.12.) into a 
BseR1/BamH1 digested pSHAG vector (obtained from G. Hannon, CSHL; plasmids pJG101 
to pJG110, see Table 5-5 or appendix A). This vector has a bacterial origin of replication and 
encodes a kanamycin resistance for bacterial amplification and selection. As the cloning site 
for sh-oligonucleotides is located directly behind a human RNA polymerase III U6 promoter, 
the pSHAG vector is also suitable for transient transfection of human cells. 
The human U6 promoter and the restriction sites for BseRI and BamHI are surrounded by 
GatewayTM (Invitrogen) recombination sites (attL sites) to easily shuttle the RNAi-cassette 
between different gateway compatible vectors (see appendix B). The GatewayTM compatible 
pTracer plasmid was selected as destination vector for this transfer (see 5.4.5.1.), leading to 
plasmids pJG111 to pJG121 (see Table 5-5 or appendix A). The pTracer vector is suitable for 
transient and stable transfection in eukaryotic cells (see 5.1.2., 5.1.3.), as it enables double-
selection on a co-expressed CMV driven GFP-Blasticidin chimera. Furthermore the pTracer 
vector encodes a bacterial origin of replication and an ampicillin resistants for bacterial 
amplification and selection. The GFP-Blasticidin chimera can also be used for bacterial 
selection, as it is also EM7 driven. 
 
5.4.7. The Triple-RNAi-Vector approach 
The aim was to design three MultiSite GatewayTM Entry vectors (see appendix B), each 
encoding an RNAi-cassettes (see 5.4.6.), which then could be shuttled into a Destination 
vector, forming a Triple-RNAi-Vector. 
First we designed three pairs of primers according to Invitrogen’s manual, to amplify three 
RNAi-cassettes out of pSHAG with suitable recombination sites for MultiSite GatewayTM 
reactions (see 5.4.3.). The three PCR products were transferred to Donor vectors by separate 
BP recombination reactions (see 5.4.5.2.). The resulting Entry vectors pMU6-A, pMU6-B and 
pMU6-C were sequenced with M13 forward and M13 reverse primers by VBC-Genomics, to 
confirm the integrity of the recombination sites. Afterwards MultiSite GatewayTM LR reaction 
(see 5.4.5.3.) was tested and control vector pJG100 was cloned. RNAi constructs (see 5.4.1.), 
targeting exogenous reporter proteins (Firefly Luciferase, Renilla Luciferase and ß-
galactosidase), were ligated (see 5.3.12.) into the pMU6 plasmids, leading to plasmids 
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 pJG177, pJG178, pJG179, pCM4, pCM5, pCM6 and pCM7. These constructs were tested in 
co-transfection experiments. Finally two more MultiSite GatewayTM LR reactions were 
performed to obtain pCM3 and pCM8 (see 5.4.5.3.) The functionality of the system was 
tested by co-transfection experiments. 
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6. APPENDIX 
 
6.1. Appendix A 
Vector maps of GatewayTM and reporter plasmids 
 
 
p-SHAG-1
2850 bps
SapI
BsaHI
Psp1406I
BbsI
HincII
HpaI
AhdI
AflII
AvaI
ApaI
PspOMI
BtgI
SacII
NotI
Eco52I
BsaAI
NdeI
BseRI
BamHI
StyI
AscI
BssHII
EcoRV
NruI
EcoNI
SspI
SgfI
PvuI
BsmBI
Bpu10I
Van91I
Eco57I
Eco57MI
AlwNI
ApaLI
BsiHKAI
BciVI
BssSI
DrdI
NspI
PciI
attL1
hU6-Promoter
attL2
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 GatewayTM compatible pTracer 
 
 
r-pTRACER-B-RFB-SspI
7704 bps
Acc65I
KpnI
SpeI
EcoRI
EcoRV
NotI
XbaI
PmeI
BclI
SphI
SnaBI
BsmBI
RsrII
MscI
AccIII
BsrGI
Bst1107I
PpuMI
PvuII
BsaBI
Bpu1102I
PsiI
BsmI
SapI
AhdI
FspI
ScaI
AflII
BspMI
FseI
NaeI
NgoMIV
BstAPI
BbvCI
BbeI
KasI
NarI
SfoI
MCS
CMV
EM7
GFP-Bsd
ori
Amp-R
RFB
hEF1-promoter
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Triple-RNAi-Vector control vector (three promoters, but no RNAi constructs) 
pJG-100
3378 bps
BtgI
SacII
NotI
Eco52I
PvuII
BbeI
KasI
NarI
SfoI
BstAPI
AatII
SspIXmnI
ScaI
BpmI
BsaI
AhdI
AlwNI
AflIII
PciI
U6-A
U6-B
U6-C
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 Triple-RNAi-Vector to target Firefly Luciferase, Renilla Luciferase and β-galactosidase 
pCM3
3551 bps
BbeI
KasI
NarI
SfoI
BstAPI
NdeI
PfoI
EcoO109I
AatII
ZraI
BsrBI
XmnI
AseI
AhdI
BseYI
AflIII
PciI
attB4
hU6-RNAi FF
attB1
hU6-RNAi Ren
attB2
hU6-RNAi ßGal
attB3
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Triple-RNAi-Vector to target Firefly Luciferase, Renilla Luciferase and β-galactosidase 
pCM8
3551 bps
BclI
BtgI
SacII
NotI
EagI
BbsI
DraIII
AccI
Bst1107I
PvuII
BbeI
KasI
NarI
SfoI
BstAPI
AatII
ZraI
BsrBI
SspI
XmnI
ScaI
BpmI
Cfr10I
BsaI
AhdI
AlwNI
AflIII
PciI
attB4
hU6-RNAi FF
attB1
hU6-RNAi Ren
attB2
hU6-RNAi ßGal
attB3
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 pGL3 for SV40 driven Firefly Luciferase expression (Promega) 
 
 
 
 
 
 
phRL for Thymidine kinase driven Renilla Luciferase expression (Promega) 
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pSVß-Gal for SV40 driven ß-galactosidase expression (Promega) 
 
 
 
 
 
 
pCAT3 for SV40 driven chloramphenicol acetyltransferase expression (Promega) 
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6.2. Appendix B 
6.2.1. The GatewayTM Technology 
The GatewayTM system is a universal cloning method based on the site-specific integration of 
bacteriophage lambda into the E. coli chromosome (Landy, 1989). The system had been 
adapted to improve cloning specificity and efficiency (Bushman et al., 1985). A Clonase 
enzyme mix mediates the recombination between specific attachment sites (att) of the 
interacting DNA molecules. The recombination is conservative, which means that there is no 
gain or loss of nucleotides. Originally lambda integration occurred between attP sites (lambda 
chromosome) and attB sites (E. coli chromosome) and gave rise to attL and attR sites. 
The proposed cloning strategy starts with the gene of interest in an attB flanked expression 
vector, or by amplifying the gene together with the recombination sites by PCR. The gene of 
interest can than easily be shuttled into a donor vector, resulting in an entry clone by BP 
reaction (see Figure 6-1 (A)). The ccdB gene initially encoded by the donor vector and after 
the BP reaction by the by-product, can be used for negative selection. The ccdB protein 
interferes with E. coli DNA gyrase (Bernard and Couturier, 1992) and thereby inhibits growth 
of most E. coli strains. In succession, the gene of interest can easily be shuttled into a 
destination vector of choice by an LR reaction to give an expression clone (see Figure 6-1 
(B)). In this reaction, the attL and attR sites recombine to attB and attP sites. 
 
(A) 
 
(B) 
 
Figure 6-1: Schematic view of GatewayTM mediated recombination. (A) BP Clonase shuttles a gene of interest, 
flanked by attB sites, which can be amplified by PCR, or encoded by an Expression clone, into a Donor vector 
(attP sites). The BP reaction results in an Entry Clone encoding the gene, flanked by attL sites and a by-product 
(attR sites). (B) LR reaction mediated by LR Clonase between an Entry Clone (attL sites) encoding the gene of 
interest and a Destination vector (attR sites) results in an Expression Clone (attB sites) carrying the gene and a 
by-product (attP sites). Modified from GatewayTM Technology manual (Invitrogen). 
 
6.2.2. The MultiSite GatewayTM Technology 
This system is a further development of the GatewayTM system. It offers rapid and efficient 
construction of an expression clone encoding three fragments of choice (e.g. promoter, gene 
of interest and termination sequence, or in our case three RNAi-cassettes) in a defined order 
and orientation. Therefore the att sites have been further modified to enable simultaneous, 
recombination of three fragments. Instead of two att sites in the standard GatewayTM system, 
the MultiSite GatewayTM Technology uses four different att sites The att sites thereby remain 
highly specific (e.g. attB1 only recombines with attP1, resulting in attL1 and attR1). 
Three steps to create a MultiSite GatewayTM Expression clone: 
1) First, the three genes of interest must be separately amplified by PCR and specific attB 
primers, to obtain three PCR products, flanked by attB4 – 5’ element - attB1, attB1 – 
central element - attB2 and attB2 – 3’ element – attB3. 
2) To create Entry Clones, the PCR products are shuttled into Donor vectors 
(pDONRTMP4-P1R, pDONRTM221, pDONRTMP2R-P3) by three separate BP 
recombination reactions. These are normal BP reactions, like in the standard 
GatewayTM system, except the recombination between attB1 of the 5’ element and 
P1R of pDONRTMP4-P1R, which leads to an attR1 site (similar for the reaction of the 
attB2 site of the 3’ element and the P2R recombination site of pDONRTMP2R-P3). 
The three Entry Clones are schematically shown in the upper part of Fig. B-2. 
3) Finally, a single MultiSite GatewayTM LR recombination reaction between the three 
Entry Clones and one Destination vector has to be performed to obtain an Expression 
Clone encoding all three genes of interest in a defined order and orientation (see 
Figure 6-2). 
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Figure 6-2: Schematic view of a MultiSite GatewayTM LR recombination reaction. Three Entry Clones, each 
encoding a DNA sequence of interest flanked by specific att sites and a Destination vector recombinate to give 
an Expression Clone, encoding the three DNA sequences in a defined order and orientation. Modified from 
MultiSite GatewayTM Technology manual (Invitrogen). 
 
Appendix B  101 
102  References 
7. REFERENCES 
 
Aebi, U., Cohn, J., Buhle, L. and Gerace, L. (1986). The nuclear lamina is a meshwork of 
intermediate-type filaments. Nature 323, 560-4. 
Arts, G. J., Langemeijer, E., Tissingh, R., Ma, L., Pavliska, H., Dokic, K., Dooijes, R., 
Mesic, E., Clasen, R., Michiels, F. et al. (2003). Adenoviral vectors expressing 
siRNAs for discovery and validation of gene function. Genome Res 13, 2325-32. 
Banerjee, D. and Slack, F. (2002). Control of developmental timing by small temporal 
RNAs: a paradigm for RNA-mediated regulation of gene expression. Bioessays 24, 
119-29. 
Bartel, B. and Bartel, D. P. (2003). MicroRNAs: at the root of plant development? Plant 
Physiol 132, 709-17. 
Beaudouin, J., Gerlich, D., Daigle, N., Eils, R. and Ellenberg, J. (2002). Nuclear envelope 
breakdown proceeds by microtubule-induced tearing of the lamina. Cell 108, 83-96. 
Bernard, P., and Couturier, M. (1992). Cell killing by the F plasmid CcdB protein involves 
poisoning of DNA-topoisomerase II complexes. J Mol Biol 226, 735-745. 
Bernstein, E., Caudy, A. A., Hammond, S. M. and Hannon, G. J. (2001). Role for a 
bidentate ribonuclease in the initiation step of RNA interference. Nature 409, 363-6. 
Billy, E., Brondani, V., Zhang, H., Muller, U. and Filipowicz, W. (2001). Specific 
interference with gene expression induced by long, double-stranded RNA in mouse 
embryonal teratocarcinoma cell lines. Proc Natl Acad Sci U S A 98, 14428-33. 
Bohnsack, M. T., Czaplinski, K. and Gorlich, D. (2004). Exportin 5 is a RanGTP-
dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. Rna 
10, 185-91. 
Boutet, S., Vazquez, F., Liu, J., Beclin, C., Fagard, M., Gratias, A., Morel, J. B., Crete, 
P., Chen, X. and Vaucheret, H. (2003). Arabidopsis HEN1: a genetic link between 
endogenous miRNA controlling development and siRNA controlling transgene 
silencing and virus resistance. Curr Biol 13, 843-8. 
Boyle, S., Gilchrist, S., Bridger, J. M., Mahy, N. L., Ellis, J. A. and Bickmore, W. A. 
(2001). The spatial organization of human chromosomes within the nuclei of normal 
and emerin-mutant cells. Hum Mol Genet 10, 211-9. 
Bridger, J. M., Kill, I. R., O'Farrell, M. and Hutchison, C. J. (1993). Internal lamin 
structures within G1 nuclei of human dermal fibroblasts. J Cell Sci 104 ( Pt 2), 297-
306. 
 Brummelkamp, T. R., Bernards, R. and Agami, R. (2002). A system for stable expression 
of short interfering RNAs in mammalian cells. Science 296, 550-3. 
Burke, B. and Ellenberg, J. (2002). Remodelling the walls of the nucleus. Nat Rev Mol Cell 
Biol 3, 487-97. 
Bushman, W., Thompson, J. F., Vargas, L. and Landy, A. (1985). Control of directionality 
in lambda site specific recombination. Science 230, 906-11. 
Cai, M., Huang, Y., Ghirlando, R., Wilson, K. L., Craigie, R. and Clore, G. M. (2001). 
Solution structure of the constant region of nuclear envelope protein LAP2 reveals two 
LEM-domain structures: one binds BAF and the other binds DNA. Embo J 20, 4399-
407. 
Caplen, N. J., Parrish, S., Imani, F., Fire, A. and Morgan, R. A. (2001). Specific 
inhibition of gene expression by small double-stranded RNAs in invertebrate and 
vertebrate systems. Proc Natl Acad Sci U S A 98, 9742-7. 
Carrington, J. C. and Ambros, V. (2003). Role of microRNAs in plant and animal 
development. Science 301, 336-8. 
Chellappan, S. P., Hiebert, S., Mudryj, M., Horowitz, J. M. and Nevins, J. R. (1991). The 
E2F transcription factor is a cellular target for the RB protein. Cell 65, 1053-61. 
Chen, Y., Stamatoyannopoulos, G. and Song, C. Z. (2003). Down-regulation of CXCR4 by 
inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer 
Res 63, 4801-4. 
Classon, M. and Harlow, E. (2002). The retinoblastoma tumour suppressor in development 
and cancer. Nat Rev Cancer 2, 910-7. 
Cohen, M., Lee, K. K., Wilson, K. L. and Gruenbaum, Y. (2001). Transcriptional 
repression, apoptosis, human disease and the functional evolution of the nuclear 
lamina. Trends Biochem Sci 26, 41-7. 
Collas, P. and Robl, J. M. (1990). Factors affecting the efficiency of nuclear transplantation 
in the rabbit embryo. Biol Reprod 43, 877-84. 
Czauderna, F., Santel, A., Hinz, M., Fechtner, M., Durieux, B., Fisch, G., Leenders, F., 
Arnold, W., Giese, K., Klippel, A. et al. (2003). Inducible shRNA expression for 
application in a prostate cancer mouse model. Nucleic Acids Res 31, e127. 
De Sandre-Giovannoli, A., Bernard, R., Cau, P., Navarro, C., Amiel, J., Boccaccio, I., 
Lyonnet, S., Stewart, C. L., Munnich, A., Le Merrer, M. et al. (2003). Lamin a 
truncation in Hutchinson-Gilford progeria. Science 300, 2055. 
References  103 
Dechat, T., Gajewski, A., Korbei, B., Gerlich, D., Daigle, N., Haraguchi, T., Furukawa, 
K., Ellenberg, J. and Foisner, R. (2004). LAP2alpha and BAF transiently localize to 
telomeres and specific regions on chromatin during nuclear assembly. J Cell Sci 117, 
6117-28. 
Dechat, T., Gotzmann, J., Stockinger, A., Harris, C. A., Talle, M. A., Siekierka, J. J. and 
Foisner, R. (1998). Detergent-salt resistance of LAP2alpha in interphase nuclei and 
phosphorylation-dependent association with chromosomes early in nuclear assembly 
implies functions in nuclear structure dynamics. Embo J 17, 4887-902. 
Dechat, T., Korbei, B., Vaughan, O. A., Vlcek, S., Hutchison, C. J. and Foisner, R. 
(2000a). Lamina-associated polypeptide 2alpha binds intranuclear A-type lamins. J 
Cell Sci 113 Pt 19, 3473-84. 
Dechat, T., Vlcek, S. and Foisner, R. (2000b). Review: lamina-associated polypeptide 2 
isoforms and related proteins in cell cycle-dependent nuclear structure dynamics. J 
Struct Biol 129, 335-45. 
Denli, A. M. and Hannon, G. J. (2003). RNAi: an ever-growing puzzle. Trends Biochem Sci 
28, 196-201. 
Dorner D., Vlcek S., Foeger N., Gajewski A., Makolm C., Gotzmann J., Hutchison C.J. 
and Foisner R. (2006). Lamina-associated polypeptide 2 regulates cell cycle 
progression and differentiation via the retinoblastoma-E2F pathway. J Cell Biol., 173, 
83-93. 
Drummond, S., Ferrigno, P., Lyon, C., Murphy, J., Goldberg, M., Allen, T., Smythe, C. 
and Hutchison, C. J. (1999). Temporal differences in the appearance of NEP-B78 
and an LBR-like protein during Xenopus nuclear envelope reassembly reflect the 
ordered recruitment of functionally discrete vesicle types. J Cell Biol 144, 225-40. 
Dykxhoorn, D. M., Novina, C. D. and Sharp, P. A. (2003). Killing the messenger: short 
RNAs that silence gene expression. Nat Rev Mol Cell Biol 4, 457-67. 
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. and Tuschl, T. 
(2001a). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured 
mammalian cells. Nature 411, 494-8. 
Elbashir, S. M., Lendeckel, W. and Tuschl, T. (2001b). RNA interference is mediated by 
21- and 22-nucleotide RNAs. Genes Dev 15, 188-200. 
Elbashir, S. M., Martinez, J., Patkaniowska, A., Lendeckel, W. and Tuschl, T. (2001c). 
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila 
melanogaster embryo lysate. Embo J 20, 6877-88. 
104  References 
 Ellenberg, J., Siggia, E. D., Moreira, J. E., Smith, C. L., Presley, J. F., Worman, H. J. 
and Lippincott-Schwartz, J. (1997). Nuclear membrane dynamics and reassembly in 
living cells: targeting of an inner nuclear membrane protein in interphase and mitosis. 
J Cell Biol 138, 1193-206. 
Eriksson, M., Brown, W. T., Gordon, L. B., Glynn, M. W., Singer, J., Scott, L., Erdos, 
M. R., Robbins, C. M., Moses, T. Y., Berglund, P. et al. (2003). Recurrent de novo 
point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423, 
293-8. 
Evans, D. E., Bryant, J. A. and Hutchison, C. (2004). The nuclear envelope: a comparative 
overview. Symp Soc Exp Biol, 1-8. 
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E. and Mello, C. C. (1998). 
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis 
elegans. Nature 391, 806-11. 
Foisner, R. (2001). Inner nuclear membrane proteins and the nuclear lamina. J Cell Sci 114, 
3791-2. 
Foisner, R. (2003). Cell cycle dynamics of the nuclear envelope. ScientificWorldJournal 3, 1-
20. 
Foisner, R. and Gerace, L. (1993). Integral membrane proteins of the nuclear envelope 
interact with lamins and chromosomes, and binding is modulated by mitotic 
phosphorylation. Cell 73, 1267-79. 
Fukagawa, T., Nogami, M., Yoshikawa, M., Ikeno, M., Okazaki, T., Takami, Y., 
Nakayama, T. and Oshimura, M. (2004). Dicer is essential for formation of the 
heterochromatin structure in vertebrate cells. Nat Cell Biol 6, 784-91. 
Furukawa, K. (1999). LAP2 binding protein 1 (L2BP1/BAF) is a candidate mediator of 
LAP2-chromatin interaction. J Cell Sci 112 ( Pt 15), 2485-92. 
Furukawa, K., Pante, N., Aebi, U. and Gerace, L. (1995). Cloning of a cDNA for lamina-
associated polypeptide 2 (LAP2) and identification of regions that specify targeting to 
the nuclear envelope. Embo J 14, 1626-36. 
Gajewski, A., Csaszar, E., and Foisner, R. (2004). A phosphorylation cluster in the 
chromatin-binding region regulates chromosome association of LAP2alpha. J Biol 
Chem 279, 35813-35821. 
Georgatos, S. D., Pyrpasopoulou, A. and Theodoropoulos, P. A. (1997). Nuclear envelope 
breakdown in mammalian cells involves stepwise lamina disassembly and 
References  105 
microtubule-drive deformation of the nuclear membrane. J Cell Sci 110 ( Pt 17), 
2129-40. 
Gil, J. and Esteban, M. (2000). Induction of apoptosis by the dsRNA-dependent protein 
kinase (PKR): mechanism of action. Apoptosis 5, 107-14. 
Goldman, A. E., Moir, R. D., Montag-Lowy, M., Stewart, M. and Goldman, R. D. (1992). 
Pathway of incorporation of microinjected lamin A into the nuclear envelope. J Cell 
Biol 119, 725-35. 
Goldman, R. D., Gruenbaum, Y., Moir, R. D., Shumaker, D. K. and Spann, T. P. (2002). 
Nuclear lamins: building blocks of nuclear architecture. Genes Dev 16, 533-47. 
Gotzmann, J. and Foisner, R. (1999). Lamins and lamin-binding proteins in functional 
chromatin organization. Crit Rev Eukaryot Gene Expr 9, 257-65. 
Gotzmann, J. and Foisner, R. (2005). A-type lamin complexes and regenerative potential: a 
step towards understanding laminopathic diseases? Histochem Cell Biol, 1-9. 
Gotzmann, J. and Gerner, C. (2000). A method to produce Ponceau replicas from blots: 
application for Western analysis. Electrophoresis 21, 523-5. 
Grishok, A., Tabara, H. and Mello, C. C. (2000). Genetic requirements for inheritance of 
RNAi in C. elegans. Science 287, 2494-7. 
Gruenbaum, Y., Goldman, R. D., Meyuhas, R., Mills, E., Margalit, A., Fridkin, A., 
Dayani, Y., Prokocimer, M. and Enosh, A. (2003). The nuclear lamina and its 
functions in the nucleus. Int Rev Cytol 226, 1-62. 
Gruenbaum, Y., Margalit, A., Goldman, R. D., Shumaker, D. K. and Wilson, K. L. 
(2005). The nuclear lamina comes of age. Nat Rev Mol Cell Biol 6, 21-31. 
Guo, S. and Kemphues, K. J. (1995). par-1, a gene required for establishing polarity in C. 
elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. 
Cell 81, 611-20. 
Gupta, S., Schoer, R. A., Egan, J. E., Hannon, G. J. and Mittal, V. (2004). Inducible, 
reversible, and stable RNA interference in mammalian cells. Proc Natl Acad Sci U S A 
101, 1927-32. 
Hamilton, A., Voinnet, O., Chappell, L. and Baulcombe, D. (2002). Two classes of short 
interfering RNA in RNA silencing. Embo J 21, 4671-9. 
Hamilton, A. J. and Baulcombe, D. C. (1999). A species of small antisense RNA in 
posttranscriptional gene silencing in plants. Science 286, 950-2. 
106  References 
 Hammond, S. M., Bernstein, E., Beach, D. and Hannon, G. J. (2000). An RNA-directed 
nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404, 
293-6. 
Hammond, S. M., Boettcher, S., Caudy, A. A., Kobayashi, R. and Hannon, G. J. (2001). 
Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 293, 
1146-50. 
Hannon, G. J. (2002). RNA interference. Nature 418, 244-51. 
Hannon, G. J. and Rossi, J. J. (2004). Unlocking the potential of the human genome with 
RNA interference. Nature 431, 371-8. 
Haraguchi, T., Koujin, T., Segura-Totten, M., Lee, K. K., Matsuoka, Y., Yoneda, Y., 
Wilson, K. L. and Hiraoka, Y. (2001). BAF is required for emerin assembly into the 
reforming nuclear envelope. J Cell Sci 114, 4575-85. 
Heald, R. and McKeon, F. (1990). Mutations of phosphorylation sites in lamin A that 
prevent nuclear lamina disassembly in mitosis. Cell 61, 579-89. 
Herrmann, H. and Foisner, R. (2003). Intermediate filaments: novel assembly models and 
exciting new functions for nuclear lamins. Cell Mol Life Sci 60, 1607-12. 
Hofemeister, H., Weber, K. and Stick, R. (2000). Association of prenylated proteins with 
the plasma membrane and the inner nuclear membrane is mediated by the same 
membrane-targeting motifs. Mol Biol Cell 11, 3233-46. 
Holmer, L. and Worman, H. J. (2001). Inner nuclear membrane proteins: functions and 
targeting. Cell Mol Life Sci 58, 1741-7. 
Hozak, P., Sasseville, A. M., Raymond, Y. and Cook, P. R. (1995). Lamin proteins form an 
internal nucleoskeleton as well as a peripheral lamina in human cells. J Cell Sci 108 ( 
Pt 2), 635-44. 
Hunter, C. and Poethig, R. S. (2003). miSSING LINKS: miRNAs and plant development. 
Curr Opin Genet Dev 13, 372-8. 
Hutchison, C. J., Alvarez-Reyes, M. and Vaughan, O. A. (2001). Lamins in disease: why 
do ubiquitously expressed nuclear envelope proteins give rise to tissue-specific disease 
phenotypes? J Cell Sci 114, 9-19. 
Hutchison, C. J. and Worman, H. J. (2004). A-type lamins: guardians of the soma? Nat 
Cell Biol 6, 1062-7. 
Jagatheesan, G., Thanumalayan, S., Muralikrishna, B., Rangaraj, N., Karande, A. A. 
and Parnaik, V. K. (1999). Colocalization of intranuclear lamin foci with RNA 
splicing factors. J Cell Sci 112 ( Pt 24), 4651-61. 
References  107 
Jazag, A., Kanai, F., Ijichi, H., Tateishi, K., Ikenoue, T., Tanaka, Y., Ohta, M., 
Imamura, J., Guleng, B., Asaoka, Y. et al. (2005). Single small-interfering RNA 
expression vector for silencing multiple transforming growth factor-beta pathway 
components. Nucleic Acids Res 33, e131. 
Johnson, B. R., Nitta, R. T., Frock, R. L., Mounkes, L., Barbie, D. A., Stewart, C. L., 
Harlow, E. and Kennedy, B. K. (2004). A-type lamins regulate retinoblastoma 
protein function by promoting subnuclear localization and preventing proteasomal 
degradation. Proc Natl Acad Sci U S A 101, 9677-82. 
Kaelin, W. G., Jr. (1999). Functions of the retinoblastoma protein. Bioessays 21, 950-8. 
Kasschau, K. D., Xie, Z., Allen, E., Llave, C., Chapman, E. J., Krizan, K. A. and 
Carrington, J. C. (2003). P1/HC-Pro, a viral suppressor of RNA silencing, interferes 
with Arabidopsis development and miRNA unction. Dev Cell 4, 205-17. 
Kawasaki, H. and Taira, K. (2004). Induction of DNA methylation and gene silencing by 
short interfering RNAs in human cells. Nature 431, 211-7. 
Kennerdell, J. R. and Carthew, R. W. (2000). Heritable gene silencing in Drosophila using 
double-stranded RNA. Nat Biotechnol 18, 896-8. 
Ketting, R. F., Fischer, S. E., Bernstein, E., Sijen, T., Hannon, G. J. and Plasterk, R. H. 
(2001). Dicer functions in RNA interference and in synthesis of small RNA involved 
in developmental timing in C. elegans. Genes Dev 15, 2654-9. 
Ketting, R. F., Haverkamp, T. H., van Luenen, H. G. and Plasterk, R. H. (1999). Mut-7 
of C. elegans, required for transposon silencing and RNA interference, is a homolog of 
Werner syndrome helicase and RNaseD. Cell 99, 133-41. 
Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227, 680-5. 
Lamond, A. I. and Earnshaw, W. C. (1998). Structure and function in the nucleus. Science 
280, 547-53. 
Landy, A. (1989). Dynamic, structural, and regulatory aspects of lambda site-specific 
recombination. Annu Rev Biochem 58, 913-49. 
Laronne, A., Rotkopf, S., Hellman, A., Gruenbaum, Y., Porter, A. C. and Brandeis, M. 
(2003). Synchronization of interphase events depends neither on mitosis nor on cdk1. 
Mol Biol Cell 14, 3730-40. 
Lee, N. S., Dohjima, T., Bauer, G., Li, H., Li, M. J., Ehsani, A., Salvaterra, P. and Rossi, 
J. (2002a). Expression of small interfering RNAs targeted against HIV-1 rev 
transcripts in human cells. Nat Biotechnol 20, 500-5. 
108  References 
 Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., Radmark, O., 
Kim, S. et al. (2003). The nuclear RNase III Drosha initiates microRNA processing. 
Nature 425, 415-9. 
Lee, Y., Jeon, K., Lee, J. T., Kim, S. and Kim, V. N. (2002b). MicroRNA maturation: 
stepwise processing and subcellular localization. Embo J 21, 4663-70. 
Li, H., Li, W. X. and Ding, S. W. (2002). Induction and suppression of RNA silencing by an 
animal virus. Science 296, 1319-21. 
Lim, L. P., Glasner, M. E., Yekta, S., Burge, C. B. and Bartel, D. P. (2003). Vertebrate 
microRNA genes. Science 299, 1540. 
Lin, F., Blake, D. L., Callebaut, I., Skerjanc, I. S., Holmer, L., McBurney, M. W., 
Paulin-Levasseur, M. and Worman, H. J. (2000). MAN1, an inner nuclear 
membrane protein that shares the LEM domain with lamina-associated polypeptide 2 
and emerin. J Biol Chem 275, 4840-7. 
Lipardi, C., Wei, Q. and Paterson, B. M. (2001). RNAi as random degradative PCR: 
siRNA primers convert mRNA into dsRNAs that are degraded to generate new 
siRNAs. Cell 107, 297-307. 
Llave, C., Xie, Z., Kasschau, K. D. and Carrington, J. C. (2002). Cleavage of Scarecrow-
like mRNA targets directed by a class of Arabidopsis miRNA. Science 297, 2053-6. 
Loewinger, L. and McKeon, F. (1988). Mutations in the nuclear lamin proteins resulting in 
their aberrant assembly in the cytoplasm. Embo J 7, 2301-9. 
Lund, E., Guttinger, S., Calado, A., Dahlberg, J. E. and Kutay, U. (2004). Nuclear export 
of microRNA precursors. Science 303, 95-8. 
Lutz, R. J., Trujillo, M. A., Denham, K. S., Wenger, L. and Sinensky, M. (1992). 
Nucleoplasmic localization of prelamin A: implications for prenylation-dependent 
lamin A assembly into the nuclear lamina. Proc Natl Acad Sci U S A 89, 3000-4. 
Mallory, A. C., Reinhart, B. J., Bartel, D., Vance, V. B. and Bowman, L. H. (2002). A 
viral suppressor of RNA silencing differentially regulates the accumulation of short 
interfering RNAs and micro-RNAs in tobacco. Proc Natl Acad Sci U S A 99, 15228-
33. 
Mancini, M. A., Shan, B., Nickerson, J. A., Penman, S. and Lee, W. H. (1994). The 
retinoblastoma gene product is a cell cycle-dependent, nuclear matrix-associated 
protein. Proc Natl Acad Sci U S A 91, 418-22. 
Margalit, A., Vlcek, S., Gruenbaum, Y. and Foisner, R. (2005). Breaking and making of 
the nuclear envelope. J Cell Biochem 95, 454-65. 
References  109 
Markiewicz, E., Dechat, T., Foisner, R., Quinlan, R. A. and Hutchison, C. J. (2002). 
Lamin A/C binding protein LAP2alpha is required for nuclear anchorage of 
retinoblastoma protein. Mol Biol Cell 13, 4401-13. 
Martienssen, R. A. and Colot, V. (2001). DNA methylation and epigenetic inheritance in 
plants and filamentous fungi. Science 293, 1070-4. 
Martins, S., Eikvar, S., Furukawa, K. and Collas, P. (2003). HA95 and LAP2 beta mediate 
a novel chromatin-nuclear envelope interaction implicated in initiation of DNA 
replication. J Cell Biol 160, 177-88. 
Matsukura, S., Jones, P. A. and Takai, D. (2003). Establishment of conditional vectors for 
hairpin siRNA knockdowns. Nucleic Acids Res 31, e77. 
Mattout-Drubezki, A. and Gruenbaum, Y. (2003). Dynamic interactions of nuclear lamina 
proteins with chromatin and transcriptional machinery. Cell Mol Life Sci 60, 2053-63. 
Matzke, M. A. and Birchler, J. A. (2005). RNAi-mediated pathways in the nucleus. Nat Rev 
Genet 6, 24-35. 
McManus, M. T. and Sharp, P. A. (2002). Gene silencing in mammals by small interfering 
RNAs. Nat Rev Genet 3, 737-47. 
Meister, G. and Tuschl, T. (2004). Mechanisms of gene silencing by double-stranded RNA. 
Nature 431, 343-9. 
Mette, M. F., Aufsatz, W., van der Winden, J., Matzke, M. A. and Matzke, A. J. (2000). 
Transcriptional silencing and promoter methylation triggered by double-stranded 
RNA. Embo J 19, 5194-201. 
Mittal, V. (2004). Improving the efficiency of RNA interference in mammals. Nat Rev Genet 
5, 355-65. 
Miyagishi, M. and Taira, K. (2002). U6 promoter-driven siRNAs with four uridine 3' 
overhangs efficiently suppress targeted gene expression in mammalian cells. Nat 
Biotechnol 20, 497-500. 
Mlotshwa, S., Voinnet, O., Mette, M. F., Matzke, M., Vaucheret, H., Ding, S. W., Pruss, 
G. and Vance, V. B. (2002). RNA silencing and the mobile silencing signal. Plant 
Cell 14 Suppl, S289-301. 
Mochizuki, K., Fine, N. A., Fujisawa, T. and Gorovsky, M. A. (2002). Analysis of a piwi-
related gene implicates small RNAs in genome rearrangement in tetrahymena. Cell 
110, 689-99. 
Moir, R. D., Spann, T. P. and Goldman, R. D. (1995). The dynamic properties and possible 
functions of nuclear lamins. Int Rev Cytol 162B, 141-82. 
110  References 
 Morris, K. V., Chan, S. W., Jacobsen, S. E. and Looney, D. J. (2004). Small interfering 
RNA-induced transcriptional gene silencing in human cells. Science 305, 1289-92. 
Mourrain, P., Beclin, C., Elmayan, T., Feuerbach, F., Godon, C., Morel, J. B., Jouette, 
D., Lacombe, A. M., Nikic, S., Picault, N. et al. (2000). Arabidopsis SGS2 and 
SGS3 genes are required for posttranscriptional gene silencing and natural virus 
resistance. Cell 101, 533-42. 
Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M. and 
Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells 
by a lentiviral vector. Science 272, 263-7. 
Napoli, C., Lemieux, C. and Jorgensen, R. (1990). Introduction of a Chimeric Chalcone 
Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous 
Genes in trans. Plant Cell 2, 279-289. 
Navarro, C. L., De Sandre-Giovannoli, A., Bernard, R., Boccaccio, I., Boyer, A., 
Genevieve, D., Hadj-Rabia, S., Gaudy-Marqueste, C., Smitt, H. S., Vabres, P. et 
al. (2004). Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization 
and identify restrictive dermopathy as a lethal neonatal laminopathy. Hum Mol Genet 
13, 2493-503. 
Nili, E., Cojocaru, G. S., Kalma, Y., Ginsberg, D., Copeland, N. G., Gilbert, D. J., 
Jenkins, N. A., Berger, R., Shaklai, S., Amariglio, N. et al. (2001). Nuclear 
membrane protein LAP2beta mediates transcriptional repression alone and together 
with its binding partner GCL (germ-cell-less). J Cell Sci 114, 3297-307. 
Nykanen, A., Haley, B. and Zamore, P. D. (2001). ATP requirements and small interfering 
RNA structure in the RNA interference pathway. Cell 107, 309-21. 
Olsen, P. H. and Ambros, V. (1999). The lin-4 regulatory RNA controls developmental 
timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the 
initiation of translation. Dev Biol 216, 671-80. 
Ozaki, T., Saijo, M., Murakami, K., Enomoto, H., Taya, Y. and Sakiyama, S. (1994). 
Complex formation between lamin A and the retinoblastoma gene product: 
identification of the domain on lamin A required for its interaction. Oncogene 9, 2649-
53. 
Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J. and Conklin, D. S. (2002). 
Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. 
Genes Dev 16, 948-58. 
References  111 
Paddison, P. J. and Hannon, G. J. (2002). RNA interference: the new somatic cell genetics? 
Cancer Cell 2, 17-23. 
Palauqui, J. C., Elmayan, T., Pollien, J. M. and Vaucheret, H. (1997). Systemic acquired 
silencing: transgene-specific post-transcriptional silencing is transmitted by grafting 
from silenced stocks to non-silenced scions. Embo J 16, 4738-45. 
Pasquinelli, A. E., Reinhart, B. J., Slack, F., Martindale, M. Q., Kuroda, M. I., Maller, 
B., Hayward, D. C., Ball, E. E., Degnan, B., Muller, P. et al. (2000). Conservation 
of the sequence and temporal expression of let-7 heterochronic regulatory RNA. 
Nature 408, 86-9. 
Pasquinelli, A. E. and Ruvkun, G. (2002). Control of developmental timing by micrornas 
and their targets. Annu Rev Cell Dev Biol 18, 495-513. 
Pham, J. W., Pellino, J. L., Lee, Y. S., Carthew, R. W. and Sontheimer, E. J. (2004). A 
Dicer-2-dependent 80s complex cleaves targeted mRNAs during RNAi in Drosophila. 
Cell 117, 83-94. 
Qin, X. F., An, D. S., Chen, I. S. and Baltimore, D. (2003). Inhibiting HIV-1 infection in 
human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. 
Proc Natl Acad Sci U S A 100, 183-8. 
Rao, L., Perez, D. and White, E. (1996). Lamin proteolysis facilitates nuclear events during 
apoptosis. J Cell Biol 135, 1441-55. 
Roignant, J. Y., Carre, C., Mugat, B., Szymczak, D., Lepesant, J. A. and Antoniewski, C. 
(2003). Absence of transitive and systemic pathways allows cell-specific and isoform-
specific RNAi in Drosophila. Rna 9, 299-308. 
Romig, H., Fackelmayer, F. O., Renz, A., Ramsperger, U. and Richter, A. (1992). 
Characterization of SAF-A, a novel nuclear DNA binding protein from HeLa cells 
with high affinity for nuclear matrix/scaffold attachment DNA elements. Embo J 11, 
3431-40. 
Rubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., 
Rooney, D. L., Ihrig, M. M., McManus, M. T., Gertler, F. B. et al. (2003). A 
lentivirus-based system to functionally silence genes in primary mammalian cells, 
stem cells and transgenic mice by RNA interference. Nat Genet 33, 401-6. 
Ruchaud, S., Korfali, N., Villa, P., Kottke, T. J., Dingwall, C., Kaufmann, S. H. and 
Earnshaw, W. C. (2002). Caspase-6 gene disruption reveals a requirement for lamin 
A cleavage in apoptotic chromatin condensation. Embo J 21, 1967-77. 
112  References 
 Ruiz, M. T., Voinnet, O. and Baulcombe, D. C. (1998). Initiation and maintenance of virus-
induced gene silencing. Plant Cell 10, 937-46. 
Salina, D., Bodoor, K., Eckley, D. M., Schroer, T. A., Rattner, J. B. and Burke, B. (2002). 
Cytoplasmic dynein as a facilitator of nuclear envelope breakdown. Cell 108, 97-107. 
Schuck, S., Manninen, A., Honsho, M., Fullekrug, J. and Simons, K. (2004). Generation 
of single and double knockdowns in polarized epithelial cells by retrovirus-mediated 
RNA interference. Proc Natl Acad Sci U S A 101, 4912-7. 
Shen, C., Buck, A. K., Liu, X., Winkler, M. and Reske, S. N. (2003). Gene silencing by 
adenovirus-delivered siRNA. FEBS Lett 539, 111-4. 
Shimi, T., Koujin, T., Segura-Totten, M., Wilson, K. L., Haraguchi, T. and Hiraoka, Y. 
(2004). Dynamic interaction between BAF and emerin revealed by FRAP, FLIP, and 
FRET analyses in living HeLa cells. J Struct Biol 147, 31-41. 
Shinagawa, T. and Ishii, S. (2003). Generation of Ski-knockdown mice by expressing a long 
double-strand RNA from an RNA polymerase II promoter. Genes Dev 17, 1340-5. 
Shumaker, D. K., Kuczmarski, E. R. and Goldman, R. D. (2003). The nucleoskeleton: 
lamins and actin are major players in essential nuclear functions. Curr Opin Cell Biol 
15, 358-66. 
Shumaker, D. K., Lee, K. K., Tanhehco, Y. C., Craigie, R. and Wilson, K. L. (2001). 
LAP2 binds to BAF.DNA complexes: requirement for the LEM domain and 
modulation by variable regions. Embo J 20, 1754-64. 
Sijen, T., Fleenor, J., Simmer, F., Thijssen, K. L., Parrish, S., Timmons, L., Plasterk, R. 
H. and Fire, A. (2001). On the role of RNA amplification in dsRNA-triggered gene 
silencing. Cell 107, 465-76. 
Siolas, D., Lerner, C., Burchard, J., Ge, W., Linsley, P. S., Paddison, P. J., Hannon, G. J. 
and Cleary, M. A. (2005). Synthetic shRNAs as potent RNAi triggers. Nat 
Biotechnol 23, 227-31. 
Song, J. J., Smith, S. K., Hannon, G. J. and Joshua-Tor, L. (2004). Crystal structure of 
Argonaute and its implications for RISC slicer activity. Science 305, 1434-7. 
Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H. and Schreiber, R. D. (1998). 
How cells respond to interferons. Annu Rev Biochem 67, 227-64. 
Stein, P., Svoboda, P., Anger, M. and Schultz, R. M. (2003). RNAi: mammalian oocytes do 
it without RNA-dependent RNA polymerase. Rna 9, 187-92. 
References  113 
Stewart, S. A., Dykxhoorn, D. M., Palliser, D., Mizuno, H., Yu, E. Y., An, D. S., Sabatini, 
D. M., Chen, I. S., Hahn, W. C., Sharp, P. A. et al. (2003). Lentivirus-delivered 
stable gene silencing by RNAi in primary cells. Rna 9, 493-501. 
Stuurman, N., Heins, S. and Aebi, U. (1998). Nuclear lamins: their structure, assembly, and 
interactions. J Struct Biol 122, 42-66. 
Sui, G., Soohoo, C., Affar el, B., Gay, F., Shi, Y. and Forrester, W. C. (2002). A DNA 
vector-based RNAi technology to suppress gene expression in mammalian cells. Proc 
Natl Acad Sci U S A 99, 5515-20. 
Tabara, H., Sarkissian, M., Kelly, W. G., Fleenor, J., Grishok, A., Timmons, L., Fire, A. 
and Mello, C. C. (1999). The rde-1 gene, RNA interference, and transposon silencing 
in C. elegans. Cell 99, 123-32. 
Taddei, A., Hediger, F., Neumann, F. R. and Gasser, S. M. (2004). The function of nuclear 
architecture: a genetic approach. Annu Rev Genet 38, 305-45. 
Tahbaz, N., Kolb, F. A., Zhang, H., Jaronczyk, K., Filipowicz, W. and Hobman, T. C. 
(2004). Characterization of the interactions between mammalian PAZ PIWI domain 
proteins and Dicer. EMBO Rep 5, 189-94. 
Tavernarakis, N., Wang, S. L., Dorovkov, M., Ryazanov, A. and Driscoll, M. (2000). 
Heritable and inducible genetic interference by double-stranded RNA encoded by 
transgenes. Nat Genet 24, 180-3. 
Taylor, M. R., Slavov, D., Gajewski, A., Vlcek, S., Ku, L., Fain, P. R., Carniel, E., Di 
Lenarda, A., Sinagra, G., Boucek, M. M., et al. (2005). Thymopoietin (lamina-
associated polypeptide 2) gene mutation associated with dilated cardiomyopathy. Hum 
Mutat 26, 566-574. 
Timmons, L. and Fire, A. (1998). Specific interference by ingested dsRNA. Nature 395, 
854. 
van de Wetering, M., Oving, I., Muncan, V., Pon Fong, M. T., Brantjes, H., van Leenen, 
D., Holstege, F. C., Brummelkamp, T. R., Agami, R. and Clevers, H. (2003). 
Specific inhibition of gene expression using a stably integrated, inducible small-
interfering-RNA vector. EMBO Rep 4, 609-15. 
van der Krol, A. R., Mur, L. A., de Lange, P., Mol, J. N. and Stuitje, A. R. (1990). 
Inhibition of flower pigmentation by antisense CHS genes: promoter and minimal 
sequence requirements for the antisense effect. Plant Mol Biol 14, 457-66. 
114  References 
 Verdel, A., Jia, S., Gerber, S., Sugiyama, T., Gygi, S., Grewal, S. I. and Moazed, D. 
(2004). RNAi-mediated targeting of heterochromatin by the RITS complex. Science 
303, 672-6. 
Vigers, G. P. and Lohka, M. J. (1992). Regulation of nuclear envelope precursor functions 
during cell division. J Cell Sci 102 ( Pt 2), 273-84. 
Vlcek, S., Dechat, T. and Foisner, R. (2001). Nuclear envelope and nuclear matrix: 
interactions and dynamics. Cell Mol Life Sci 58, 1758-65. 
Vlcek, S., Just, H., Dechat, T. and Foisner, R. (1999). Functional diversity of LAP2alpha 
and LAP2beta in postmitotic chromosome association is caused by an alpha-specific 
nuclear targeting domain. Embo J 18, 6370-84. 
Vlcek, S., Korbei, B. and Foisner, R. (2002). Distinct functions of the unique C terminus of 
LAP2alpha in cell proliferation and nuclear assembly. J Biol Chem 277, 18898-907. 
Voinnet, O., Vain, P., Angell, S. and Baulcombe, D. C. (1998). Systemic spread of 
sequence-specific transgene RNA degradation in plants is initiated by localized 
introduction of ectopic promoterless DNA. Cell 95, 177-87. 
Volpe, T. A., Kidner, C., Hall, I. M., Teng, G., Grewal, S. I. and Martienssen, R. A. 
(2002). Regulation of heterochromatic silencing and histone H3 lysine-9 methylation 
by RNAi. Science 297, 1833-7. 
Wassenegger, M., Heimes, S., Riedel, L. and Sanger, H. L. (1994). RNA-directed de novo 
methylation of genomic sequences in plants. Cell 76, 567-76. 
Wilson, K. L. (2000). The nuclear envelope, muscular dystrophy and gene expression. Trends 
Cell Biol 10, 125-9. 
Wilson, K. L., Zastrow, M. S. and Lee, K. K. (2001). Lamins and disease: insights into 
nuclear infrastructure. Cell 104, 647-50. 
Winston, W. M., Molodowitch, C. and Hunter, C. P. (2002). Systemic RNAi in C. elegans 
requires the putative transmembrane protein SID-1. Science 295, 2456-9. 
Wiznerowicz, M. and Trono, D. (2003). Conditional suppression of cellular genes: lentivirus 
vector-mediated drug-inducible RNA interference. J Virol 77, 8957-61. 
Xia, H., Mao, Q., Paulson, H. L. and Davidson, B. L. (2002). siRNA-mediated gene 
silencing in vitro and in vivo. Nat Biotechnol 20, 1006-10. 
Yang, L., Guan, T. and Gerace, L. (1997). Integral membrane proteins of the nuclear 
envelope are dispersed throughout the endoplasmic reticulum during mitosis. J Cell 
Biol 137, 1199-210. 
References  115 
Ye, Q., Barton, R. M. and Worman, H. J. (1998). Nuclear lamin-binding proteins. Subcell 
Biochem 31, 587-610. 
Yi, R., Qin, Y., Macara, I. G. and Cullen, B. R. (2003). Exportin-5 mediates the nuclear 
export of pre-microRNAs and short hairpin RNAs. Genes Dev 17, 3011-6. 
Yu, J. Y., Taylor, J., DeRuiter, S. L., Vojtek, A. B. and Turner, D. L. (2003). 
Simultaneous inhibition of GSK3alpha and GSK3beta using hairpin siRNA expression 
vectors. Mol Ther 7, 228-36. 
Zamore, P. D. (2002). Ancient pathways programmed by small RNAs. Science 296, 1265-9. 
Zamore, P. D., Tuschl, T., Sharp, P. A. and Bartel, D. P. (2000). RNAi: double-stranded 
RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. 
Cell 101, 25-33. 
 
116  References 
 Curriculum vitae  117 
8. Curriculum vitae 
Christian Makolm 
 
Geburtsdatum: 23. April 1976 
Geburtsort:  Hollabrunn, NÖ 
Nationalität:  Österreich 
Adresse:  Piaristengasse 34/12A 
   1080 Wien 
Telefon:  0699/12217548 
e-mail:   Christian.Makolm@gmx.at 
Ausbildung
 
06/2009  voraussichtlicher Studienabschluss Chemie 
10/2002 – 04/2004 Diplomarbeit (New RNAi Vector Application & Functional LAP2α Analysis) 
Abteilung für Molekulare Zellbiologie (Prof. Foisner) 
Department für Medizinische Biochemie, Medizinische Universität Wien 
02/2001 – 06/2001 Projektmitarbeit (organisch-chemische Synthese) 
Université de Provence Aix-Marseille 
seit 09/1994 Studium der Chemie, Universität Wien 
06/1994 Matura am Bundesrealgymnasium Stockerau 
Beruf, (studienbegleitende Tätigkeiten)
 
ab 07/2009  Offiziersausbildung, Berufsfeuerwehr Wien 
11/2008 – 07/2009 Bildungskarenz 
03/2006 – 11/2008 technischer Mitarbeiter in Research & Development 
Bender MedSystems GmbH 
10/2005 – 04/2006 AustroMars (wissenschaftliches Isolationsexperiment) 
für die Crew qualifiziert und ausgebildet, 
CapCom (Kommunikationsschnittstelle) im Kontrollzentrum 
08/2002 Baxter AG (Experimental Virology, Biosafty Level 3) 
07 – 08/2001 Institute of Molecular Pathology 
07 – 09/2000 Baxter AG (Molecular Cell Biology) 
07 – 08/1999 Baxter AG (Lyophilization) 
10/1998 – 05/1999 Sports Experts (Verkäufer) 
08 / 1998 Österreichisches Institut für Hämoderivate (Feinfraktionierung I) 
07/1998 Sports Experts (Verkäufer) 
07 – 08/1997 Immuno AG (Inlandsversand) 
Weitere Qualifikationen
 
Sprachen:  Englisch fließend 
   Französisch Grundkenntnisse 
Software: MS-Office, Adobe Photoshop, Adobe Illustrator, Corel Draw, Clone Manager 
Suite, EndNote, Zeiss LSM, fachspezifische Internet Datenbanken, Unix 
Grundwissen 
Stipendien:  SOKRATES/ERASMUS Mobilitätsstipendium (2001) 
   Top Stipendium des Landes Niederösterreich (2004) 
Sonstiges:  Führerschein B, Ersthelfer (inkl. Frühdefibrillation) 
Publikationen
 
Dorner D., Vlcek S., Foeger N., Gajewski A., Makolm C., Gotzmann J., Hutchison C.J. and Foisner R. 
(2006). Lamina-associated polypeptide 2α regulates cell cycle progression and differentiation via the 
retinoblastoma-E2F pathway. J. Cell Biol., 173, 83-93. 
Posterpräsentation: 
Makolm C., Foisner R., and Gotzmann J. Targeting the Nuclear Envelope by RNA-Interference 
Joint Annual Meeting of ÖGBM/ÖGGGT/ÖGBT/ANGT 2003, (Graz, Austria) 
Poster: 
Dorner D., Makolm C., Gotzmann J., Hutchison C.J. and Foisner R. 
LAP2α regulates pRb-mediated cell cycle exit and differentiation, Fabisch-Symposium 
’Functional Organization of the Nuclear Envelope in Health and Disease’ (Berlin, Deutschland) 
Kongresse, Workshops
 
Joint Annual Meeting of ÖGBM/ÖGGGT/ÖGBT/ANGT 2003, (Graz, Austria) 
Joint Annual Meeting of ÖGBM/ÖGGGT/ÖGBT/ANGT 2004, (Wien, Austria) 
6th International Cytokine Conference (Wien, 2006) 
„Mars 2030 - AustroMars Science Workshop“ (Salzburg, 2006) 
„Introduction to Flow Cytometry“, (OEGFZ, Wien 2007) 
„Joint Annual Meeting of Immunology of the Austrian and German Societies“ (ÖGAI, DGFI, Wien 2008) 
Hobbys
 
Handball Leistungssport (1993 – 2005), Klettern, Bergsteigen, Kochen 
118  Curriculum vitae 
